Stock Code: 603605 Short Name: PROYA



Proya Cosmetics Co., Ltd. 2021 Semi-annual Report

Important Note

- I. The Board of Directors, Board of Supervisors, directors, supervisors and officers of the Company warrant that the contents of the Semi-annual Report are true, accurate and complete without any misrepresentations, misleading statements or material omissions, and that they will be jointly and severally liable therefor.
- II. All directors of the Company have attended the board meeting.
- III. The Semi-annual Report has not been audited.
- IV. HOU Juncheng, the person in charge of the Company, and WANG Li, the chief financial officer and the head of the accounting organization (the person in charge of accounting) warrant that the financial report herein is true, accurate and complete.
- V. Proposals for profit distribution or reserve capitalization during the Reporting Period adopted by the Board of Directors

There is no proposal for profit distribution or reserve capitalization during the Reporting Period.

VI. Risk disclosure on forward-looking statements

 $\sqrt{\text{Applicable}} \square \text{N/A}$

The future plans, development strategies and other forward-looking statements herein shall in no event constitute the Company's substantive commitments to its investors. The investors should keep an eye on investment risks.

VII. Whether there is any non-operational occupation of funds by the controlling shareholders and their affiliates

No

VIII. Whether there is any external guarantee provided in violation of the specified decision-making procedures?

No

IX. Whether there is a majority of the directors that cannot undertake the truthfulness, accuracy and completeness of the Semi-annual Report disclosed by the Company

No

X. Disclosure of material risks

The Company has elaborated the existing risks in this Report. For details, please refer to "(I) Possible Risks" in "V. Other Disclosures" of "Section III Management Discussion and Analysis" herein.

XI. Others

 \square Applicable $\sqrt{N/A}$

Table of Contents

Section I Definit	ions	5
Section II Compa	any Profile and Main Financial Indicators	5
Section III Mana	gement Discussion and Analysis	9
Section IV Corpo	orate Governance	21
Section V Enviro	onmental and Social Responsibilities	23
Section VI Impor	rtant Events	24
Section VII Shar	e Changes and Shareholders	49
Section VIII Pref	Ferred Stock	54
Section IX Bond	S	54
Section X Finance	cial Report	55
Documents for	Financial statements signed and sealed by the legal representative, the officer and the head of the accounting organization	
reference	Originals of all documents and announcements concerning the Cordisclosed in newspapers designated by the CSRC during the Reporting	

Section I Definitions

In this Report, unless the context otherwise requires, the following terms shall be defined as below:

Definitions of frequently-used terms		
PROYA Co., Ltd., PROYA Co., the	means	Proya Cosmetics Co., Ltd.
Company, or We		
CSRC	means	China Securities Regulatory Commission
SSE	means	Shanghai Stock Exchange
Articles of Association	means	Articles of Association of Proya Cosmetics Co.,
		Ltd.
RMB/RMB0,000	means	Renminbi Yuan/Renminbi 10,000 Yuan

Section II Company Profile and Main Financial Indicators

I. Company Information

Chinese name	珀莱雅化妆品股份有限公司
Short name in Chinese	珀莱雅
English name	Proya Cosmetics Co.,Ltd.
Short name in English	Proya
Legal representative	HOU Juncheng

II. Contact Person and Contact Information

	Secretary of the Board	Representative of Security Affairs
Name	ZHANG Yefeng	WANG Xiaoyan
Address	9/F, Proya Building, No. 588 Xixi	9/F, Proya Building, No. 588 Xixi
	Road, Xihu District, Hangzhou City,	Road, Xihu District, Hangzhou City,
	Zhejiang Province	Zhejiang Province
Telephone	0571-87352850	0571-87352850
Fax	0571-87352813	0571-87352813
E-mail	proyazq@proya.com	proyazq@proya.com

III. Basic Information Change

Registered address	No. 588 Xixi Road, Liuxia Street, Xihu District, Hangzhou City,
	Zhejiang Province
Historical changes of the	For details, see the Announcement on the Amendment of the Articles of
registered address	Association and the Registration of Industrial and Commercial
	Change (Announcement No.: 2019-008) disclosed by the Company on
	the designated media for information disclosure on February 27, 2019
Office address	Proya Building, No. 588 Xixi Road, Xihu District, Hangzhou City,
	Zhejiang Province
Postal code of the office address	310023

Website	http://www.proya-group.com
E-mail	proyazq@proya.com
Query index of changes during the Reporting Period	N/A

IV. Information Disclosure and Location Change

Selected newspapers for	Shanghai Securities News and Securities Times
information disclosure	
Website for publication of the	http://www.sse.com.cn
Semi-annual Report	
The Company's Semi-annual	Board Office of Proya Building, No. 588 Xixi Road, Xihu District,
Report is available at	Hangzhou City, Zhejiang Province
Query index of changes during the	N/A
Reporting Period	

V. Company Stock Overview

Stock Type	Stock Exchange	Stock Abbreviation	Stock Code	Stock Abbreviation
				before Change
A Share	Shanghai Stock	Proya	603605	None
	Exchange			

VI. Other Relevant Information

 \square Applicable $\sqrt{N/A}$

VII. Main Accounting Data and Financial Indicators of the Company

(I) Main Accounting Data

Unit: Yuan Currency: RMB

			YOY increase or
	The Reporting	Same period of	decrease in the
Main accounting data	Period	prior year	Reporting Period
	(Jan Jun.)		(%)
Operating income	1,917,718,497.60	1,384,323,848.88	38.53
Net profit attributable to shareholders of	226,101,313.86	178,767,020.76	26.48
the listed company			
Net profit attributable to shareholders of	220,280,393.28	182,466,394.19	20.72
the listed company after deducting			
non-recurring profits or losses			
Net cash flows from operating activities	266,175,578.82	36,564,378.88	627.96
			Increase or
			decrease at the
Main accounting data	End of the		end of the
Walli accounting data	Reporting Period	End of prior year	Reporting Period
	Reporting Leriou		over the end of
			prior year (%)
Net asset attributable to shareholders of	2,481,725,253.59	2,391,535,435.94	3.77
the listed company			

Total assets	3,377,752,471.47	3,636,882,185.29	-7.13
Net profit margin attributable to	11.79%	12.91%	
shareholders of the listed company			
Net profit margin attributable to	11.49%	13.18%	
shareholders of the listed company after			
deducting non-recurring profits or losses			

(II) Main Financial Indicators

Main financial indicators	The Reporting Period (Jan Jun.)	Same period of prior year	YOY increase or decrease in the Reporting Period (%)
Basic earnings per share (RMB/share)	1.13	0.89	26.97
Diluted earnings per share (RMB/share)	1.12	0.89	25.84
Basic earnings per share after deducting non-recurring profits or losses (RMB/share)	1.10	0.91	20.88
Weighted average return on equity (%)	9.10	8.51	Increase by 0.59 percentage points
Weighted average return on equity after deducting non-recurring profits or losses (%)	8.86	8.68	Increase by 0.18 percentage points
Turnover rate of accounts receivable (times/year)	16.71	15.74	6.16
Turnover rate of inventories (times/year)	3.37	3.12	8.01

Description of ☐ Applicable	the main accounting data and financial indicators of the Cor $\sqrt{N/A}$	mpany	
VIII. Differen ☐ Applicable	ices Between Accounting Data under Domestic and Forei $\sqrt{N/A}$	gn Accountir	ng Standards
IX. Items and √ Applicable	Amounts of Non-recurring Profits or Losses \square N/A		
		Unit: Yuan	Currency: RMB

Item of non-recurring profits or	Amount	Note (if applicable)
losses		
Profit or loss from disposal of	-1,416.28	
non-current assets	-1,410.28	
Tax relief with ultra vires		
approval, or without formal		
approval, or on an occasional		
basis		
Governmental grants included in		
the current profit or loss, except		
for those closely related to the		
normal operation of the	9,370,319.81	
Company and gained at a fixed		
amount or quantity according to		
certain standards based on the		

national policies		
Capital occupation fees charged		
to non-financial enterprises		
included in the current profit or		
loss		
Profits from the difference in the		
acquiring subsidiaries, associates		
and joint ventures by the		
enterprise and the fair value of the identifiable net assets of the		
investees at the time of		
investment		
Profit or loss on exchange of		
non-monetary assets		
Profit or loss from entrusting		
others with investment or asset		
management		
Provisions for impairment of		
various assets due to natural		
disasters and other force majeure		
events		
Profit or loss on debt		
restructuring		
Enterprise's reorganization fees,		
such as staffing expenses and		
integration fees		
Profits or losses exceeding the		
fair value arising from		
transactions in which the		
transaction price is obviously		
unfair		
Current net profit or loss of the		
subsidiaries established by		
business combination involving		
enterprises under common		
control from the opening of the		
accounting period to the date of		
consolidation		
Profit or loss from contingencies		
unrelated to the normal operation		
of the Company		
Profit or loss from changes in	-3,545.22	
fair value arising from the	2,2 13.22	
holding of trading financial		
assets, derivative financial		
assets, trading financial		
liabilities and derivative		
financial liabilities, as well as the		
investment income from disposal		
of trading financial assets,		
derivative financial assets,		
trading financial liabilities,		
derivative financial liabilities		
and other debt investments,		
except the effective hedging		
except the effective nedging		

1 1 1 1 1		
business related to the normal		
business of the Company		
Reversal of impairment		
provisions of accounts		
receivable and contract assets		
that have been tested for		
impairment separately		
Profit or loss from external		
entrusted loans		
Profit or loss from changes in the		
fair value of investment		
properties subsequently		
measured at fair value		
Impact from one-time		
adjustment of the current profit		
or loss as required by tax,		
accounting and other laws and		
regulations on the current profit		
or loss		
Entrusted fee income from		
entrusted operation		
Other non-operating incomes		
and expenses besides the above	521,323.29	
items	, in the second of the second	
Other profit or loss items		
conforming to the definition of		
non-recurring profits or losses		
Affected minority interests	-1,842,828.78	
Affected income tax amount	-2,222,932.24	
Total	5,820,920.58	

X. Others

 \square Applicable $\sqrt{N/A}$

Section III Management Discussion and Analysis

I. Description of the Company's Industry and Primary Business during the Reporting Period (I) Primary Business

The Company is committed to building a new domestic cosmetics industry platform, primarily engaged in the R&D, production and sales of cosmetics products, having its main brands that include, among others, "PROYA", "HAPSODE", "TIMAGE", "INSBAHA" and "CORRECTORS". The Company's own brands have covered the consumer delicate skincare products, makeup products, high-efficacy skincare products and other beauty products fields:

1. Popular exquisite skincare products brands

- (1) PROYA, focusing on sci-tech skincare products for young white-collar women, has its general price ranging from RMB100 to RMB300, sold through all channels collaboratively both online and offline.
- (2) HAPSODE, specially customized for young skin aiming at students and young women in lower-tire cities, has its general price ranging from RMB50 to RMB100, sold mainly through online channels.

2. Makeup products brands

(1) TIMAGE, a new Chinese style makeup products brand, has its general price ranging from

RMB150 to 200, sold through online channels.

(2) INSBAHA, a punk-style niche makeup products brand, has its general price ranging from RMB50 to RMB150, sold through online channels.

3. High-efficacy skincare products brand

CORRECTORS, a high-efficacy skincare products brand, has its general price ranging from RMB260 to RMB600, sold through online channels.

(II) Business Models

1. Sales models

Products are mainly sold through online channels, concurrently with offline channels.

Online channels are primarily operated by direct selling and distribution, of which direct selling is carried out mainly via Tmall and JD.com, among other platforms, while expanding to some emerging platforms such as TikTok Shop, and distribution is mainly carried out via Taobao, JD.com and Vipshop, etc..

Offline channels are primarily operated by dealers, including cosmetics specialty stores, supermarkets and single brand stores, etc..

2. Production/R&D models

The Company focuses on independent production, supplemented by OEM processing, and has its own skincare products/other personal care factories and makeup products factories.

The Company mainly commits to independent R&D, supplemented by industry-university-research cooperation, maintaining its R&D cooperation with global industry-leading raw material suppliers such as BASF China, Ashland China and LIPOTRUE S.L. in Spain.

(III) Industry

The Company is in the industry of chemical raw materials and chemicals manufacturing (Classification Code: C26) under the *Guidelines for the Industrial Classification of Listed Companies* promulgated by CSRC; and in the industry of daily chemicals manufacturing (C268), subdivided into cosmetics manufacturing (C2682) under the *Industrial Classification for National Economic Activities* (GB/T4754-2011).

According to the National Bureau of Statistics of China, from January to June 2021, the total retail sales of consumer goods amount to RMB21,190.4 billion, with a YOY increase of 23.0%, including RMB191.7 billion of cosmetics, with a YOY increase of 26.6% (retail sales value from the businesses above certain size).

Based on the analysis of various industry data, the Company has occupied a certain share in the domestic cosmetics market.

II. Analysis of Core Competitiveness During the Reporting Period

 $\sqrt{\text{Applicable}} \square \text{N/A}$

The core competitiveness of the Company is mainly embodied in: creating a self driven organization with efficient coordination among the front, middle and back offices with "product, content and operation" as the mainline, building a consistent operation management system integrating "culture, strategy, mechanism and talent" taking culture as the traction, strategy as the guidance, and mechanism and talent as the two wings, so as to ensure the proper implementation of the strategic objectives.

III. Discussion and Analysis of Business

(I) Financial Analysis

1. YOY growth of operating income

The operating income was RMB1.918 billion, with a YOY increase of 38.53%

Of which: the primary operating income was RMB1.911 billion, with a YOY increase of 38.28% and other operating income was RMB6.438 million

Primary operating income:

(1) By channel

Channel		Amount (RMB100 million)	Increase or decrease in 2021 H1 over the same period (%)	YOY increase or decrease in 2020 (%)	YOY increase or decrease in 2019 (%)	YOY increase or decrease in 2018 (%)	Proportion of 2021H1 (%)	Proportion of 2020 (%)	Proportion of 2019 (%)	Proportion of 2018 (%)
	Direct selling	10.91	135.28	79.63	88.25	90.19	57.08	42.45	28.42	19.94
Online	Distribution	4.54	9.41	34.36	37.95	40.97	23.74	27.56	24.67	23.63
	Sub-total	15.45	75.85	58.59	60.97	59.91	80.82	70.01	53.09	43.57
	Cosmetics stores	2.68	-21.46	-19.28	4.42	7.45	14.02	22.56	33.61	42.52
Offline	Other	0.99	-39.33	-32.81	26.33	59.72	5.16	7.43	13.30	13.91
	Sub-total	3.67	-27.23	-23.12	9.82	16.88	19.18	29.99	46.91	56.43
	Total	19.11	38.28	20.26	32.11	32.41	100.00	100.00	100.00	100.00

Note: The proportion of each sub-channel is the proportion of the main business income. The mantissa of partial totals may be inconsistent with the sum of individual data due to rounding, the same below.

(2) By brand

]	Brand	Amount (RMB100 million)	Increase or decrease in 2021 H1 over the same period (%)	YOY increase or decrease in 2020 (%)	YOY increase or decrease in 2019 (%)	YOY increase or decrease in 2018 (%)	Proportion of 2021H1 (%)	Proportion of 2020 (%)	Proportion of 2019 (%)	Proportion of 2018 (%)
	PROYA	14.87	31.44	12.43	26.81	32.38	77.81	79.66	85.21	88.77
Own brands	Other brands	3.67	169.36	75.08	19.74	32.65	19.17	14.82	10.18	11.23
branus	Sub-total	18.54	46.24	19.11	26.02	32.41	96.98	94.48	95.39	100.00
Agent brands	Cross-border agent brands	0.58	-49.68	44.09	-	1	3.02	5.52	4.61	-
,	Total	19.11	38.28	20.26	32.11	32.41	100.00	100.00	100.00	100.00

Note: Among which, the operating income from TIMAGE was RMB111 million.

(3) By category

		Increase or	YOY	YOY	YOY				
	Amount	decrease in	increase	increase	increase	Proportion	Proportion	Proportion	Proportion
Category	(RMB100	2021 H1	or	or	or	of	of 2020	of 2019	of 2018
Category	million)	over the	decrease	decrease	decrease	2021H1	(%)	(%)	(%)
	minion)	same period	in 2020	in 2019	in 2018	(%)	(70)	(70)	(70)
		(%)	(%)	(%)	(%)				
Skincare	16.30	33.91	11.38	24.89	32.29	85.27	86.50	93.40	98.80
(including cleansing)	10.30	33.91	11.36	24.69	32.29	63.27	80.30	93.40	96.60
Make-up	2.71	97.45	181.91	482.43	42.59	14.17	12.41	5.29	1.20
Others	0.11	-61.56	0.47	1	-	0.56	1.09	1.31	-
Total	19.11	38.28	20.26	32.11	32.41	100.00	100.00	100.00	100.00

2. YOY growth in net profit

The net profit attributable to shareholders of the listed company was RMB226 million, with a YOY increase of 26.48%

The net profit attributable to shareholders of the listed company after deducting non-recurring profits or losses was RMB220 million, with a YOY increase of 20.72%

Indicators	2021 H1	2021 Q1	2020	2020H1	2019	2018
1. Net profit margin on sales	10.88%	11.80%	12.04%	12.55%	11.73%	12.14%
2. Gross profit margin on sales	63.73%	64.41%	63.55%	59.90%	63.96%	64.03%
3. Sales expense ratio	42.09%	41.72%	39.90%	33.04%	39.16%	37.52%
Including: Image promotion fee ratio	33.95%	33.06%	32.68%	24.18%	26.86%	21.19%
4. General and administrative expense ratio	6.06%	5.78%	5.44%	7.24%	6.25%	7.26%
5. R&D expense ratio	1.64%	1.95%	1.92%	2.30%	2.39%	2.17%
6. Turnover rate of accounts receivable (times)	16.71	14.75	15.53	15.74	21.74	36.04
7. Turnover interval of accounts receivable (days)	21.54	24.41	23.18	22.87	16.56	9.99
8. Turnover rate of inventories (times)	3.37	2.92	3.50	3.12	4.12	4.04
9. Turnover interval of inventories (days)	106.82	123.40	102.86	115.55	87.38	89.11

(II) Business Analysis

1. New product strategy

During the Reporting Period, the Company upgraded the product-driven strategy and continued to implement the "hero product strategy".

- (1) Based on the increasingly mature digital management of product lifecycle, the Double Anti-Aging Essence and Ruby Essence were upgraded as to the composition, formula and package design for the brand of PROYA, with a more perfect Version 2.0 formed for PROYA to further promote the shaping of the sense of technology and youth.
- (2) The hero products portfolio has been perfected by extending the categories from essences to face and eye creams and the effect from age defying to repair, to attract users, thereby improving the per customer transaction and repeat purchases, and enhancing the brand adherence. A series of new hero products skincare products, such as the Ruby Face Cream, Advanced Original Repair Essence and Ruby Eye Cream of PROYA.
- (3) Further efforts have been made on improving the promotion efficiency of hero products, for full-link optimization intervention from consumer experience, attraction and trust building to final transaction. With a cost-effective and efficient launching model and excellent products that meet the needs of consumers, the Company changed the customers' feeling about PROYA from "Proya is really different now" last year to "Proya is a brand that can represent China and compete internationally", whiling continuing to step into a higher level.

2. New marketing strategy

During the Reporting Period, PROYA has always put focus on the current life and state of young people with the spirit of discovery, and encouraged consumers to be brave, courageous and optimistic from their respective story, to convey the brand spirit of "discovering while young". Marketing events for the brand are as follows:

(1) In January, with "come to the new world in the first year of graduation", PROYA kept a close eye on the living conditions of new employees in the workplace and gave understanding, encouragement and care to the young groups.

- (2) On the Women's Day in March, with "prejudice rather than gender the boundary line", PROYA work with *China Women's News* to actively speak up for women with the brand power based on its detailed insight into "gender bias" and deep thought about "gender equality".
- (3) In May, PROYA officially announced its cooperation with China Aerospace IP to pay tribute to the 65th anniversary of China Aerospace by "flying from China to the universe". The joint products were widely loved and praised by consumers.

In the same month, on May 20, a special day to express love among lovers, PROYA launched a discussion on love with OWSPACE and Shanghai Translation proposing "Dare to love, and dare to be single". The brand not only output the love proposition with emotional resonance, but also created a warm and healing brand image.

(4) In June, PROYA launched a concentrated film clip of "paying tribute to everyone who goes to discover", inviting HAO Jingfang, a well-known writer, and people. cn to pay tribute to the discoverers of each era. The short film stimulated the national pride of the audience, while conveying the "spirit of discovery", the core of the brand.

3. New channel strategy

Online:

(1) Tmall Flagship Store:

During the Reporting Period, we have continued the "branding + fine operation" reform by adjusting the category structure, optimizing the product content, relying on the big data marketing strategy, and strengthening the prominent KOL cooperation, thus greatly improving the launching efficiency, so as to give effect to the objectives of "vast customer orders, high gross profit and mass repurchases", and render a sustainable and quality business development.

(2) TikTok Shop & Kwai Shop:

During the Reporting Period, we have seized the popularity of live streaming, combining self broadcasting with talent broadcasting. Attention has been paid to the operation through self broadcasting by improving the proportion thereof, and annual frame cooperation has been improved with high-quality streamers covering both general streamers and non-vertical streamers, to optimize the commodity structure and improve the gross and net profit.

(3) JD.com, Vipshop and Tmall Supermarket:

We have further optimized the platform operation, strengthened the member marketing, adjusted the product structure, optimized the rhythm of launching expenses, and strengthened the sales of hero products and new products.

Offline:

- (1) Cosmetics stores: We have adjusted and upgraded the existing outlets, modified the product structure, optimized the training system and improved the terminal service awareness.
- (2) Supermarkets: Focusing on building department store systems such as Intime, Chongqing and Rainbow, while expanding to other high-quality department stores, we have strengthened inventory management, customized product portfolio suitable for supermarket channels, and enhanced BA's initiative.

4. New organizational strategy

- (1) Organization: We have focused on the building of digital middle office by deepening the strategy relating to hero products and popular products, and the strategy concerning precise launch with middle office to improve ROI. The virtual project organization form was adopted with products and launching as the mainline to create an end-to-end, efficient and self-driven process-oriented organization.
- (2) Talent: We have further promoted the talent supply chain mechanism matching with business, to select, identify and use talents in an accurate, quick and efficient manner, thereby to gradually build a young team with strong combat effectiveness, learning ability, self drive and entrepreneurial passion.
- (3) Mechanism: By advocating the "three heights" performance culture of "high investment, high performance and high return", we have established a performance management system of "setting goals and attaching importance to the process for achievement". Around the business strategy, every effort was made to build a diversified business incentive system covering a short term (for quarterly performance and project incentive), a medium term (for annual additional dividend) and a long term (for

equity incentive and partners).

Material changes in the Company's business during the Reporting Period, as well as events that have a significant impact on the Company's business during such period and are expected to have a significant impact thereon in the future

 \square Applicable $\sqrt{N/A}$

IV. Main Business Conditions during the Reporting Period

(I) Primary Business Analysis

1 Analysis of changes in related items in financial statements

Unit: Yuan Currency: RMB

Item	Current period	Same period of prior year	Change ratio (%)
Operating income	1,917,718,497.60	1,384,323,848.88	38.53
Operating cost	695,558,289.19	555,120,455.16	25.30
Selling expense	807,204,631.76	457,414,432.20	76.47
General and administrative	116,191,173.05	100,182,355.15	15.98
expense			
Financial expense	-1,864,128.79	-7,374,480.76	N/A
R&D expense	31,371,344.46	31,865,144.96	-1.55
Net cash flow from operating	266,175,578.82	36,564,378.88	627.96
activities			
Net cash flow from investing	-190,628,459.71	104,618,006.73	-282.21
activities			
Net cash flow from financing activities	-248,631,053.62	-31,140,550.44	N/A

Reasons for changes in operating income: Mainly due to the growth of operating income from online sales.

Reasons for changes in operating cost: Mainly due to the growth of operating income driving the corresponding growth of operating cost.

Reasons for changes in selling expense:

In the first half of 2021, the selling expense amounted to RMB807 million, accounting for 42.09% of the operating income (33.04% in the same period of prior year), representing a YOY increase by RMB350 million or 76.47%, mainly due to the YOY increase by RMB316 million or 94.47% in the image publicity and promotion expense in the current period, including: 1. the YOY increase of promotion expense for the new brands (such as TIMAGE); 2. the YOY increase of online sales and image publicity and promotion expense.

Reasons for changes in general and administrative expense:

In the first half of 2021, the general and administrative expense amounted to RMB116 million, accounting for 6.06% of the operating income (7.24% in the same period of prior year), representing a YOY increase by RMB16.01 million or 15.98%, mainly due to the YOY increase in employee benefits and labor costs.

Reasons for changes in financial expense: Mainly due to the YOY increase in exchange gains and losses in the current period.

Reasons for changes in R&D expense:

In the first half of 2021, the R&D expense amounted to RMB31.37 million, accounting for 1.64% of the operating income (2.30% in the same period of prior year), which was basically the same as that in the same period of prior year. The parent company's R&D expense ratio in the first half of 2021 was 3.76% (4.31% in the same period of prior year).

Reasons for changes in net cash flow from operating activities:

The net cash flow from operating increased by RMB230 million on a YOY basis, mainly due to:

- 1. Factors relating to increase in cash: the sales receipts increased by RMB740 million YOY (corresponding to YOY increase in sales and decrease in accounts receivable);
- 2. Factors relating to decrease in cash: the payment for goods increased by RMB71 million YOY, and the cash paid for other operating activities increased by RMB378 million (mainly due to the YOY increase in image publicity and promotion expense).

Reasons for changes in net cash flow from investing activities:

The net cash flow from investment decreased by RMB295 million on a YOY basis, mainly due to:

- 1. Factors relating to increase in cash: the cash paid for investing in associates and other equities during the period had an amount of RMB31 million, with a YOY decrease by RMB35 million from RMB67 million in the same period of prior year;
- 2. Factors relating to decrease in cash: the cash inflow from recovering the principal and income of wealth management products in the same period prior year had an amount of RMB216 million; the cash paid for acquisition of fixed assets, construction in progress and other investing activities increased YOY during the current period.

Reasons for changes in net cash flow from financing activities:

The net cash flow from financing decreased by RMB217 million on a YOY basis, mainly due to:

- 1. The short-term loans received from banks decreased by RMB99 million, and the debt repayment expenditure increased by RMB87 million YOY, with the total net cash outflow from both items increased by RMB186 million YOY;
 - 2. The dividend distribution and interest expenses increased by RMB31 million YOY.

2 Detailed descriptions of significant changes in business type, profit composition or prof source of the Company in the current period	it
\square Applicable $\sqrt{N/A}$	
(II) Descriptions of significant changes in profits caused by non-primary business	
\square Applicable $\sqrt{N/A}$	
(III) Analysis of Assets and Liabilities	
$\sqrt{\text{Applicable}} \square \text{ N/A}$	

1. Assets and liabilities

Unit: Yuan Currency: RMB

Item	Closing balance of current period	Proportio n of closing balance of current period to total assets (%)	Closing balance of prior year	Proportio n of closing balance of prior year to total assets (%)	Proportion of changes in the closing balance of current period over the closing balance of prior year (%)	Description
------	-----------------------------------	---	----------------------------------	--	---	-------------

	1		1			1
Currency funds	1,236,337,706.75	36.60	1,416,654,640.93	38.95	-12.73	
Accounts receivable	174,316,681.46	5.16	284,878,419.58	7.83	-38.81	Mainly due to the collection of accounts receivable upon the maturity of credit for some customers
Inventories	356,282,644.43	10.55	468,641,017.75	12.89	-23.98	
Contract assets		0.00		0.00	N/A	
Investment properties	71,819,415.95	2.13	72,237,610.10	1.99	-0.58	
Long-term equity investment	186,592,634.00	5.52	58,220,059.60	1.60	220.50	Mainly due to: 1. see the note below for details; 2. the additional investment of RMB28.21 million made to Jiaxing Woyong
Fixed assets	553,956,322.47	16.40	565,864,152.62	15.56	-2.10	woyong
Construction in progress	115,081,293.14	3.41	47,324,523.36	1.30	143.17	Mainly due to the investment in construction in progress for Huzhou expanded production base construction project (phase I) and Longwu R&D center construction project during this period
Right-of-use assets		0.00		0.00	N/A	
Short-term borrowings	200,000,000.00	5.92	299,280,435.09	8.23	-33.17	Mainly due to the net repayment

Contract liabilities	52,820,185.37	1.56	30,618,778.99	0.84	72.51	of bank loans of RMB99 million during this period Mainly due to the increase of more than RMB18 million in receipts in advance
Long-term borrowings		0.00		0.00	N/A	
Lease liabilities		0.00		0.00	N/A	~ .
Goodwill	0.00	0.00	31,034,161.20	0.85	-100.00	See the note below for details
Other non-current assets	5,731,163.01	0.17	87,322,780.03	2.40	-93.44	Mainly due to the payment for purchasing the plot in Longwu, Hangzhou at the beginning of the year; the closing procedures for the plot and the properties thereon had been completed with obtainment of relevant title certificate during this period, which was included into the intangible assets and construction in progress accordingly
Accounts payable	346,738,059.11	10.27	515,832,031.27	14.18	-32.78	Mainly due to the maturity of the accounts payable in this period

Other current liabilities	2,149,196.85	0.06	1,439,262.02	0.04	49.33	Mainly due to the increase of advance payment for goods in contract liabilities and the corresponding increase of pending output VAT
Estimated liabilities	6,052,681.88	0.18	10,190,099.22	0.28	-40.60	Mainly due to the estimated decrease in returns sales revenue

Note:

In April 2021, the Company entered into a capital increase and share exchange agreement with Zhuhai Healthlong Biotechnology Co., Ltd., among other parties, under which the Company increased its capital to Zhuhai Healthlong Biotechnology Co., Ltd. with its 52% equity in Shanghai Healthlong Biochemical Technology Co., Ltd.. After the capital increase and share exchange, Shanghai Healthlong Biochemical Technology Co., Ltd., the former majority-owned subsidiary of the Company, became a wholly-owned subsidiary of Zhuhai Healthlong Biotechnology Co., Ltd. and was excluded from the consolidation scope of the Company. The Company holds 10% equity of, and appoints a director to, Zhuhai Healthlong Biotechnology Co., Ltd..

For the above reasons, the Company's investment in Zhuhai Healthlong Biotechnology Co., Ltd. was accounted for as "long-term equity investment", which had a carrying amount of RMB97.19 million by the end of June. The originally recognized goodwill was reduced simultaneously (that is, the part by which the investment made by the Company in Shanghai Healthlong in the early stage exceeded the fair value of identifiable net assets calculated according to the shareholding ratio).

Other descriptions None

2. Overseas assets

 \square Applicable $\sqrt{N/A}$

3. Restrictions on major assets by the end of the Reporting Period

 $\sqrt{\text{Applicable}} \square \text{N/A}$

Unit: Yuan

		Cint. Tuan			
Item	Closing carrying amount	Reasons for restriction			
Cash and bank balances	7,967,481.72	Transformer margin, letter of			
Cash and bank balances	7,907,481.72	credit deposit, Tmall deposit and			

		Alipay deposit, etc.
Total	7,967,481.72	

4. Other descriptions

 \square Applicable $\sqrt{N/A}$

(IV) Investment Analysis

1. Overall analysis of external equity investment

 $\sqrt{\text{Applicable}} \quad \square \text{ N/A}$

Unit: Yuan

	(Closing balanc	e	Opening balance			
Item	Gross carrying amount	Provision for impairment	Carrying amount	Gross carrying amount	Provision for impairment	Carrying amount	
Investment in associates	183,291,583.06		183,291,583.06	54,913,429.03		54,913,429.03	
Investment in joint ventures	3,301,050.94		3,301,050.94	3,306,630.57		3,306,630.57	
Total	186,592,634.00		186,592,634.00	58,220,059.60		58,220,059.60	

See "VII. 17 Long-term equity investment" in "Section X Financial Report" hereof for details.

(1) Significant equity investment

 \square Applicable $\sqrt{N/A}$

(2) Significant non-equity investment

 \square Applicable $\sqrt{N/A}$

(3) Financial assets measured at fair value

 \square Applicable $\sqrt{N/A}$

(V) Disposal of major assets and equities

 \square Applicable $\sqrt{N/A}$

(VI) Analysis of major majority-owned and non-majority-owned companies

 $\sqrt{\text{Applicable } \square \text{ N/A}}$

Unit: RMB0'000 Currency: RMB

Primary subsidiary	Business nature	Major products or services	Register ed capital	Total assets	Net assets	Net profit	Majority- owned or non-majo rity-owne d
Zhejiang Meili Valley E-commerce Co., Ltd.	Cosmetics sales	Cosmetics	1,000.00	34,208.50	17,051.83	7,470.13	Majority- owned
Hangzhou Proya Trade Co., Ltd.	Cosmetics sales	Cosmetics	5,000.00	45,346.96	9,794.36	-3,271.18	Majority- owned
Hapsode (Hangzhou) Cosmetics Co., Ltd.	Cosmetics sales	Cosmetics	5,000.00	11,830.14	-20,560.50	-711.84	Majority- owned

(VII) Structured entities controlled by the Company

 \square Applicable $\sqrt{N/A}$

V. Other Disclosures

(I) Possible Risks

 $\sqrt{\text{Applicable } \square \text{ N/A}}$

- 1. Industry competition risk
- (1) Given the intensified competition among brands in the industry, the Company's brand upgrading strategy and hero product strategy may fail to reach the expected goal;
- (2) Given the intensified competition for marketing investment, the control of digital and refined investment costs may fail to reach the expected goal.
- 2. Project incubation risk
- (1) Risk of new brand incubation: the performance may fail to reach the expected goal after heavy marketing investment;
- (2) Risk of new category development: as the operation modes for different categories differ greatly, the team may be unable to meet the requirements and the performance may fail to meet the expected goal.
- 3. The COVID-19 outbreak may have an uncertain impact on the operation.

(II) Other Disclosures

 \square Applicable $\sqrt{N/A}$

Section IV Corporate Governance

I. Brief Introduction to the General Meeting of Shareholders

Session	Date of convening	Query index of the designated website where the resolution is published	Disclosure date of resolution	Resolution	
2020 annual general meeting	May 13, 2021	Announcement No. 2021-029 on the website of SSE (www.sse. com. cn)	May 14, 2021	The meeting reviewed and approved the Company's 2020 Annual Report and its Summary, the Company's 2020 Annual Profit Distribution Plan and other proposals. For details, please see the Announcement on Resolution of the Company's 2020 Annual General Meeting (Announcement No.: 2021-029) disclosed by the Company on the website of SSE (http://www.sse.com.cn) and relevant information disclosure media on May 14, 2021.	

Extraordinary general meetings of shareholders required by preferred shareholders with	voting
rights	

 \square Applicable $\sqrt{N/A}$

Description of general meetings of \square Applicable $\sqrt{N/A}$	of shareholders		
II. Changes in directors, superv √ Applicable □ N/A	isors and officers	of the Company	
Name	Pos	ition	Changes
CHEN Yan	Independent direc		Left office
MA Dongming	Independent direc		Elected
Description of changes in director ☐ Applicable √N/A III. Profit Distribution or Capit Semi-annual profit distribution	al Reserve Capita	lization Plans	
Whether there is any profit distr reserve capitalization	ribution or capital	No	
Number of bonus shares distribu	ited per 10 shares		0
(share) Amount of dividends paid per	10 charac (DMR)		0
(including tax)	10 shares (KMD)		O
Number of shares converted from	n capital reserves		0
per 10 shares (share)	ir cupitur reserves		
	rofit distribution or	capital reserve ca	pitalization plans
N/A			
incentives and their impact	t s that have been	disclosed in the	ership plans or other employee
(II) Incentives not disclosed in	the interim annou	ncement or with	follow-up progress
Equity incentives \square Applicable $\sqrt{N/A}$			
Other descriptions \square Applicable $\sqrt{N/A}$			
Employee stock ownership plans \square Applicable $\sqrt{N/A}$			
Other incentives \square Applicable $\sqrt{N/A}$			

Section V Environmental and Social Responsibilities

I. Environmental Information

(I) Description on environmental protection of the company and its primary subsidiaries which are in high pollution industries regulated by the environmental protection authority $\hfill\Box$ Applicable $\hfill \sqrt{N/A}$
☐ Applicable V N/A
(II) Description on environmental protection of the company not in high pollution industries \Box Applicable $~\sqrt{N/A}$
(III) Description of follow-up progress or changes in the contents of the environmental information disclosed during the Reporting Period $\square \ \text{Applicable} \sqrt{N/A}$
(IV) Relevant information conducive to protecting ecology, preventing pollution and fulfilling environmental responsibilities
$\sqrt{\mbox{Applicable}}$ \square N/A 1. During the Reporting Period, the Company actively responded to the call of the nation by conducting macro management of solid waste. Having applied to register in the National Solid Waste and Chemical Management Information System Platform, Huzhou Plant made an annual pre-declaration of the amount of hazardous waste generated, conducted a public bidding for hazardous waste disposal units through the platform, and applied for treatment of hazardous waste on the platform, being able to track data of solid waste and anticipate risks thereof in the whole process.
2. During the Reporting Period, Huzhou Plant continued to carry out reasonable energy conservation and emission reduction as suggested, and to practice as a resource-saving and environment-friendly green factory.
(V) Measures taken to reduce carbon emissions during the Reporting Period and the effect thereof
\square Applicable $\sqrt{N/A}$
 II. Efforts to Consolidate and Expand the Achievements in Poverty Alleviation and Rural Revitalization □ Applicable √N/A

Section VI Important Events

I. Performance of Commitments

(I) Commitments of the Company and Its De Facto Controllers, Shareholders, Related Parties and Acquirers, etc., During or as of the Reporting Period $\sqrt{\text{Applicable} \,\square\, \text{N/A}}$

Background	Туре	Promiser	Content	Date and Term	Is there a term for performance	Whether it is performed timely and strictly	Reasons for failure of timely performance (if applicable)	Next step in case of failure of timely performance (if applicable)
------------	------	----------	---------	------------------	---------------------------------	--	--	--

	Restricted	Controlling	(1) Within 36 months from the date of listing	Made on:	Yes	Yes	N/A	N/A
	sale of	shareholders	of the Company's shares, I will not transfer or	November				
	shares	and de facto	entrust others with management of the shares	15, 2017;				
		controllers:	in the Company directly or indirectly held by	Term:				
		HOU	me, nor will I have such shares repurchased	November				
		Juncheng	by the Company; (2) If the closing price of	15, 2017				
		and FANG	the Company's shares has been lower than	to				
		Aiqin (a	the offering price for 20 consecutive trading	November				
		couple)	days within 6 months after the listing of the	14, 2020				
			Company, or the closing price at the end of 6					
			months after the listing is lower than the					
			offering price, the lock-up period of the					
			Company's shares held by me shall be					
			automatically extended for 6 months; (3) If					
			the Company's shares held by me are reduced					
			within two years after the expiration of the					
Commitments			lock-up period, the reduction price shall not					
on the IPO			be lower than the offering price; (4) The					
			lock-up period of the Company's shares held					
			by me/us shall be automatically extended for					
			6 months in case I/we violate the above					
			commitments on share locking.					
	Restricted	Director and	(1) Within 36 months from the date of listing	Made on:	Yes	Yes	N/A	N/A
	sale of	general	of the Company's shares, I will not transfer or	November				
	shares	manager:	entrust others with management of the shares	15, 2017;				
		FANG	in the Company directly or indirectly held by	Term:				
		Yuyou	me, nor will I have such shares repurchased	November				
			by the Company; (2) If the closing price of	15, 2017				
			the Company's shares has been lower than	to				
			the offering price for 20 consecutive trading	November				
			days within 6 months after the listing of the	14, 2020				
			Company, or the closing price at the end of 6					
			months after the listing is lower than the					
			offering price, the lock-up period of the					
			Company's shares held by me shall be					

					ı		
		automatically extended for 6 months; (3) If					
		the Company's shares held by me are reduced					
		within two years after the expiration of the					
		lock-up period, the reduction price shall not					
		be lower than the offering price; (4) The					
		lock-up period of the Company's shares held					
		by me/us shall be automatically extended for					
		6 months in case I/we violate the above					
		commitments on share locking.					
Restricted	12 natural	(1) Within 36 months from the date of listing	Made on:	Yes	Yes	N/A	N/A
sale of	person	of the Company's shares, I will not transfer or	November				
shares	shareholders:	entrust others with management of the shares	15, 2017;				
	LI Xiaolin,	in the Company directly or indirectly held by	Term:				
	XU Junqing,	me, nor will I have such shares repurchased	November				
	FANG	by the Company; (2) If the closing price of	15, 2017				
	Aifen, YE	the Company's shares has been lower than	to				
	Caifu, LI	the offering price for 20 consecutive trading	November				
	Jianqing,	days within 6 months after the listing of the	14, 2020				
	CHEN	Company, or the closing price at the end of 6					
	Dongfang,	months after the listing is lower than the					
	LI Wenqing,	offering price, the lock-up period of the					
	XU	Company's shares held by me shall be					
	Dongkui,	automatically extended for 6 months; (3) If					
	BAO	the Company's shares held by me are reduced					
	Qingfang,	within two years after the expiration of the					
	FANG	lock-up period, the reduction price shall not					
	Jiaqin,	be lower than the offering price; (4) The					
	FANG	lock-up period of the Company's shares held					
	Shanming,	by me/us shall be automatically extended for					
	YE Hong	6 months in case I/we violate the above					
		commitments on share locking.					

Restricted	Directors	(1) During my tenure as a director/officer of	Made on:	No	Yes	N/A	N/A
sale of	and officers:	the Company, the shares transferred each year	November				
shares	HOU	shall not exceed 25% of the total shares in the	15, 2017;				
	Juncheng,	Company held directly or indirectly by me;	Term:				
	FANG	Within six months after my leaving office, I	Indefinite				
	Yuyou,	will not transfer the shares of the Company	term from				
	CAO	directly or indirectly held by me; (2) If the	November				
	Liangguo	Company's shares held by me are reduced	15, 2017				
		within two years after the expiration of the					
		lock-up period, the reduction price shall not					
		be lower than the offering price; If the closing					
		price of the Company's shares has been lower					
		than the offering price for 20 consecutive					
		trading days within 6 months after the listing					
		of the Company, or the closing price at the					
		end of 6 months after the listing is lower than					
		the offering price, the lock-up period of the					
		Company's shares held by me shall be					
		automatically extended for 6 months, which					
		shall not be terminated due to my job change,					
		resignation, etc.; (3) The lock-up period of					
		the Company's shares held by me/us shall be					
		automatically extended for 6 months in case					
		I/we violate the above commitments on share					
		locking.					
Restricted	Officers:	(1) Within 12 months from the date of listing	Made on:	No	Yes	N/A	N/A
sale of	ZHANG	of the Company's shares, I will not transfer or	November				
shares	Yefeng and	entrust others with management of the shares	15, 2017;				
	ZHANG	in the Company directly or indirectly held by	Term:				
	Minhua	me, nor will I have such shares repurchased	Indefinite				
		by the Company; (2) During my tenure as an	term from				
		officer of the Company, the shares transferred	November				
		each year shall not exceed 25% of the total	15, 2017				
		shares in the Company held directly or					
		indirectly by me; Within six months after my					

		1 1 00 Y 111 0 1 1 2					
		leaving office, I will not transfer the shares of					
		the Company directly or indirectly held by					
		me; (3) If the Company's shares held by me					
		are reduced within two years after the					
		expiration of the lock-up period, the reduction					
		price shall not be lower than the offering					
		price; If the closing price of the Company's					
		shares has been lower than the offering price					
		for 20 consecutive trading days within 6					
		months after the listing of the Company, or					
		the closing price at the end of 6 months after					
		the listing is lower than the offering price, the					
		lock-up period of the Company's shares held					
		by me shall be automatically extended for 6					
		months, which shall not be terminated due to					
		my job change, resignation, etc.; (4) The					
		lock-up period of the Company's shares held					
		by me/us shall be automatically extended for					
		6 months in case I/we violate the above					
		commitments on share locking.					
Restricted	Officer: JIN	(1) Within 12 months from the date of listing	Made on:	No	Yes	N/A	N/A
sale of	Yanhua	of the Company's shares, I will not transfer or	April 16,				- "
shares		entrust others with management of the shares	2018;				
5110105		in the Company directly or indirectly held by	Term:				
		me, nor will I have such shares repurchased	Indefinite				
		by the Company; (2) During my tenure as an	term from				
		officer of the Company, the shares transferred	April 16,				
		each year shall not exceed 25% of the total	2018				
		shares in the Company held directly or	2010				
		indirectly by me; Within six months after my					
		leaving office, I will not transfer the shares of					
		the Company directly or indirectly held by					
		me; (3) If the Company's shares held by me					
		are reduced within two years after the					
		expiration of the lock-up period, the reduction					
		expiration of the lock-up period, the reduction					

		mine shall not be levered than the effective					
		price shall not be lower than the offering					
		price; If the closing price of the Company's					
		shares has been lower than the offering price					
		for 20 consecutive trading days within 6					
		months after the listing of the Company, or					
		the closing price at the end of 6 months after					
		the listing is lower than the offering price, the					
		lock-up period of the Company's shares held					
		by me shall be automatically extended for 6					
		months, which shall not be terminated due to					
		my job change, resignation, etc.; (4) The					
		lock-up period of the Company's shares held					
		by me/us shall be automatically extended for					
		6 months in case I/we violate the above					
		commitments on share locking.					
Restricted	Officer:	(1) Within 12 months from the date of listing	Made on:	No	Yes	N/A	N/A
sale of	WANG Li	of the Company's shares, I will not transfer or	September				
shares		entrust others with management of the shares	3, 2018;				
		in the Company directly or indirectly held by	Term:				
		me, nor will I have such shares repurchased	Indefinite				
		by the Company; (2) During my tenure as an	term from				
		officer of the Company, the shares transferred	September				
		each year shall not exceed 25% of the total	3, 2018				
		shares in the Company held directly or					
		indirectly by me; Within six months after my					
		leaving office, I will not transfer the shares of					
		the Company directly or indirectly held by					
		me; (3) If the Company's shares held by me					
		are reduced within two years after the					
		expiration of the lock-up period, the reduction					
		price shall not be lower than the offering					
		price; If the closing price of the Company's					
		shares has been lower than the offering price					
		for 20 consecutive trading days within 6					
		months after the listing of the Company, or					

1	1				ı		
		the closing price at the end of 6 months after					
		the listing is lower than the offering price, the					
		lock-up period of the Company's shares held					
		by me shall be automatically extended for 6					
		months, which shall not be terminated due to					
		my job change, resignation, etc.; (4) The					
		lock-up period of the Company's shares held					
		by me/us shall be automatically extended for					
		6 months in case I/we violate the above					
		commitments on share locking.					
Restricted	Controlling	(1) The number of shares in the Issuer	Made on:	No	Yes	N/A	N/A
sale of	shareholders	directly or indirectly reduced by me within 24	November				
shares	and de facto	months after the expiration of the lock-up	15, 2017;				
	controllers:	period shall not exceed 6% of the total	Term:				
	HOU	number of shares therein before this Offering;	Indefinite				
	Juncheng	(2) My reduction of shareholding in the	term from				
	and FANG	Company shall be conducted through	November				
	Aiqin	centralized bidding at a stock exchange, block	15, 2017				
	1	trading or transfer by agreement, among other	•				
		ways, in compliance with the provisions of					
		relevant laws, regulations and rules; (3) I will,					
		before reducing the Company's shares, make					
		an announcement three trading days in					
		advance, and perform the obligation of					
		information disclosure in a timely and					
		accurate manner pursuant to the rules of the					
		stock exchange, unless my shareholding in					
		the Company falls below 5%; (4) I will, in					
		case of failing to fulfill the above					
		commitments on shareholding reduction,					
		publicly explain the specific reasons for my					
		non-fulfillment at the Company's general					
		meeting of shareholders and the media for					
		disclosure designated by the CSRC, while					
		apologizing to the Company's shareholders					

		and public investors.					
Restricted	Shareholders	(1) I will, in case of an intention to reduce my	Made on:	No	Yes	N/A	N/A
sale of	with direct	shareholding after the expiration of the	November				
shares	shareholding	lock-up period, carefully abide by relevant	15, 2017;				
	of more than	provisions of the CSRC and the stock	Term:				
	5%: FANG	exchange on reduction by shareholders,	Indefinite				
	Yuyou and	prudently formulate the shareholding	term from				
	LI Xiaolin	reduction plan in light of the needs for the	November				
		Company with respect to share price	15, 2017				
		stabilization, operation and capital					
		management, and gradually reduce my shares					
		after the expiration of the lock-up period; (2)					
		My reduction of shareholding in the					
		Company shall be conducted through					
		centralized bidding at a stock exchange, block					
		trading or transfer by agreement, among other					
		ways, in compliance with the provisions of					
		relevant laws, regulations and rules; (3) I will,					
		before reducing the Company's shares, make					
		an announcement three trading days in					
		advance, and perform the obligation of					
		information disclosure in a timely and					
		accurate manner pursuant to the rules of the					
		stock exchange, unless my shareholding in					
		the Company falls below 5%; (4) I will, in					
		case of failing to fulfill the above					
		commitments on shareholding reduction,					
		publicly explain the specific reasons for my					
		non-fulfillment at the Company's general					
		meeting of shareholders and the media for					
		disclosure designated by CSRC, while					
		apologizing to the Company's shareholders					
		and public investors.					22/1
Other	The	We will, in case of failure to take specific	Made on:	No	Yes	N/A	N/A
	Company	measures to stabilize the share price when the	November				

 1	T	T	1		1	ı	
		preconditions for initiating the share price	15, 2017;				
		stabilization plan are met, publicly explain	Term:				
		the specific reasons for the failure to take	Indefinite				
		such measures at the general meeting of	term from				
		shareholders and the media for disclosure	November				
		designated by the CSRC, while apologizing	15, 2017				
		to the shareholders and public investors. If					
		losses are caused to investors for reasons					
		other than force majeure, we will be liable for					
		compensation to the investors according to					
		law and bear corresponding responsibilities in					
		accordance with laws, regulations and					
		requirements of relevant regulatory					
		authorities; If the losses are caused by force					
		majeure, a treatment scheme to minimize the					
		damages to the investors' interests shall be					
		studied as soon as possible and submitted to					
		the general meeting of shareholders for					
		deliberation, so as to best protect our					
		investors' interests. If we newly appoints					
		directors and officers within three years from					
		the date of listing of our shares, we will					
		require the newly appointed directors and					
		1 -					
		officers to fulfill the corresponding commitments made by the directors and					
		officers when we are listed.					
Othor	Controllin -		Mada	No	Vac	N/A	NT/A
Other	Controlling	If I fail to take specific measures to stabilize	Made on:	NO	Yes	IN/A	N/A
	shareholders	the price price in accordance with the share	November				
	and de facto	price stabilization plan when the	15, 2017;				
	controllers	preconditions for initiating such plan are met,	Term:				
	of the	I will publicly explain the specific reasons for	Indefinite				
	Company	the failure at the Issuer's general meeting of	term from				
		shareholders and the media for disclosure	November				
		designated by the CSRC, while apologizing	15, 2017				
		to the Issuer's shareholders and public					

		investors; To the extent of non-fulfillment of the above commitments, I will stop receiving shareholder dividends from the Issuer within 5 working days from the date of the above event, and my shares in the Issuer will not be transferred until I take corresponding measures to stabilize the share price and the implementation thereof is completed in accordance with the provisions of the above plan.					
Other	Directors (excluding independent directors) and officers of the Company	If I fail to take specific measures to stabilize the price price in accordance with the share price stabilization plan when the preconditions for initiating such plan are met, I will publicly explain the specific reasons for the failure at the Issuer's general meeting of shareholders and the media for disclosure designated by the CSRC, while apologizing to the Issuer's shareholders and public investors; To the extent of non-fulfillment of the above commitments, I will stop receiving remunerations and shareholder dividends (if any) from the Issuer within 5 working days from the date of the above event, and my shares in the Issuer (if any) will not be transferred until I take corresponding measures to stabilize the share price and the implementation thereof is completed in accordance with the provisions of the above plan.	Made on: November 15, 2017; Term: Indefinite term from November 15, 2017	No	Yes	N/A	N/A
Other	The Company	If our Prospectus contains any misrepresentation, misleading statement or major omission, resulting in losses to investors in the securities trading, we will compensate the investors for the losses	Made on: November 15, 2017; Term: Indefinite	No	Yes	N/A	N/A

ı							
		according to law. After such act is held by the	term from				
		CSRC, the stock exchange where we are	November				
		listed or the judicial authority to be illegal, we	15, 2017				
		will, based on the principles of simplifying					
		procedures, active negotiation, compensation					
		in advance and effectively protecting the					
		interests of investors, especially minority					
		investors, and according to the measurable					
		economic losses directly suffered by the					
		investors, actively compensate the investors					
		for their direct economic losses through					
		settlement, mediation by a third party and					
		establishment of Investor Compensation					
		Fund, etc Insofar as we violate the above					
		commitments, we will publicly apologize to					
		the shareholders and public investors for					
		failing to perform the above compensation					
		measures at the general meeting of					
		shareholders and the media for disclosure					
		designated by the CSRC, and compensate the					
		investors according to such actual losses as					
		recognized by the CSRC and relevant judicial					
		authorities.					
Other	Controlling	If the Issuer's Prospectus contains any	Made on:	No	Yes	N/A	N/A
Oulei	shareholders	misrepresentation, misleading statement or	November	NO	168	IN/A	IN/A
	and de facto	major omission, resulting in losses to	15, 2017;				
	controllers	investors in the securities trading, I will	Term:				
	of the Issuer	compensate the investors for the losses	Indefinite				
		according to law. After such act is held by the	term from				
		CSRC, the stock exchange where the	November				
		Company is listed or the judicial authority to	15, 2017				
		be illegal, I will, based on the principles of					
		simplifying procedures, active negotiation,					
		compensation in advance and effectively					
		protecting the interests of investors,					

						1	
		especially minority investors, and according					
		to the measurable economic losses directly					
		suffered by the investors, actively compensate					
		the investors for their direct economic losses					
		through settlement, mediation by a third party					
		and establishment of Investor Compensation					
		Fund, etc Insofar as I violate the above					
		commitments, I will publicly apologize to the					
		shareholders and public investors for failing					
		to perform the above compensation measures					
		at the general meeting of shareholders and the					
		media for disclosure designated by the CSRC,					
		stop receiving shareholder dividends from the					
		Issuer within 5 working days from the date of					
		violation of the above commitments, and					
		meanwhile, my shares in the Issuer shall not					
		be transferred until I take corresponding					
		compensation measures as per the above					
		commitments and the implementation thereof					
		is completed.					
Di	irectors,	If the Issuer's Prospectus contains any	Made on:	No	Yes	N/A	N/A
su	pervisors	misrepresentation, misleading statement or	November				
and	nd officers	major omission, resulting in losses to	15, 2017;				
		investors in the securities trading, I will	Term:				
		compensate the investors for the losses	Indefinite				
		according to law. After such act is held by the	term from				
		CSRC, the stock exchange where the	November				
		Company is listed or the judicial authority to	15, 2017				
		be illegal, I will, based on the principles of					
		simplifying procedures, active negotiation,					
		compensation in advance and effectively					
		protecting the interests of investors,					
		especially minority investors, and according					
		to the measurable economic losses directly					
1		•					

1	T			1			
		the investors for their direct economic losses					
		through settlement, mediation by a third party					
		and establishment of Investor Compensation					
		Fund, etc Insofar as I violate the above					
		commitments, I will publicly apologize to the					
		shareholders and public investors for failing					
		to perform the above compensation measures					
		at the general meeting of shareholders and the					
		media for disclosure designated by the CSRC,					
		stop receiving remunerations (or allowances)					
		and shareholder dividends (if any) from the					
		Issuer within 5 working days from the date of					
		violation of the above commitments, and					
		meanwhile, my shares in the Issuer (if any)					
		shall not be transferred until I take					
		corresponding compensation measures as per					
		the above commitments and the					
		implementation thereof is completed.					
Other	The	In order to ensure the effective use of the	Made on:	No	Yes	N/A	N/A
	Company	proceeds from this Offering, effectively	November				
		prevent the risk of dilution on immediate	15, 2017;				
		return and improve the ability of future	Term:				
		return, we plan to improve the quality of	Indefinite				
		assets, as well as increase the operating	term from				
		income and future income for sustainable	November				
		development by strengthening the operation	15, 2017				
		management and internal control,					
		accelerating the construction progress of					
		investment projects and improving the					
		investor return mechanism, to recover the					
		diluted immediate return. We undertake to					
		continuously improve various recovery					
		measures against dilution on immediate					
		return in accordance with the implementation					
		rules subsequently issued by the CSRC and					

		ı						
			the SSE. In case of violating the above					
			commitments, we will promptly announce the					
			facts and reasons for the violation, and will,					
			unless the violation is caused by force					
			majeure or other reasons not attributable to					
			us, apologize to our shareholders and public					
			investors, while making supplementary or					
			alternative commitments to the investors for					
			the purposes of protecting their interests as					
			much as possible, and implementing such					
			supplementary or alternative commitments					
			after the same being reviewed and approved					
			by our general meeting of shareholders.					
	Other	Controlling	In order to give effect to the Company's		No	Yes	N/A	N/A
		shareholders	recovery measures against dilution on	November				
		and de facto	immediate return, as the controlling	15, 2017;				
		controllers:	shareholder and de facto controller of the	Term:				
		HOU	Company, I undertake that: (1) in no event	Indefinite				
		Juncheng	will I abuse my position as a controlling	term from				
		and FANG	shareholder and <i>de facto</i> controller, or	November				
		Aiqin	interfere with the operation and management	15, 2017				
			activities of the Company beyond my					
			authority, or encroach on the interests of the					
			Company; (2) I will, in case relevant					
			provisions of the Company and my					
			commitments are inconsistent with relevant					
			opinions and implementation rules on					
			recovery measures against dilution on					
			immediate return separately issued by the					
			CSRC and the SSE, make supplementary					
			commitments promptly in accordance with					
			the provisions of the CSRC and the SSE, and					
			actively procure the Company to make new					
			commitments or adopt new measures as					
			required thereby; (3) I will fully, completely					

and timely fulfill the recovery measures against dilution on immediate return formulated by the Company and any of my commitments on this regard. If I violate such commitments, thereby causing losses to the Company or its shareholders, I will be willing to: ① make a public explanation and apology at the general meeting of shareholders and the media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers Other Directors In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company, and refrain from incur any post-related consumption unless it is necessary to perform my duties, and strictly accept the supervision			1 1 (1011 1					
formulated by the Company and any of my commitments on this regard. If I violate such commitments, thereby causing losses to the Company or its shareholders, I will be willing to: ① make a public explanation and apology at the general meeting of shareholders and the media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's future profits. In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company, [2] I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
commitments on this regard. If I violate such commitments, thereby causing losses to the Company or its shareholders, I will be willing to: ① make a public explanation and apology at the general meeting of shareholders and the media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers and officers for the Company, I undertake that: (I) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
commitments, thereby causing losses to the Company or its shareholders, I will be willing to: ① make a public explanation and apology at the general meeting of shareholders and the media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's future profits. In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (I) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide to rindividuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide to the company and refrain from incur any post-related consumption unless it is necessary to perform								
Company or its shareholders, I will be willing to: ① make a public explanation and apology at the general meeting of shareholders and the media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers and officers and officers of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
to: ① make a public explanation and apology at the general meeting of shareholders and the media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			, ,					
at the general meeting of shareholders and the media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company, (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (i) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
Qundertake the liability for compensation to the Company and/or the shareholders according to law; (3) unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			at the general meeting of shareholders and the					
the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers and officers (Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			media for disclosure designated by the CSRC;					
according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers and officers and officers and officers and officers interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			② undertake the liability for compensation to					
the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			the Company and/or the shareholders					
measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			according to law; 3 unconditionally accept					
regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			the punishment or relevant regulatory					
and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			measures imposed on me by the securities					
and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			regulatory authorities such as the CSRC					
promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform Directors In order to give effect to the Company's Made on: No November 15, 2017; Term: Indefinite term from November 15, 2017								
promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors In order to give effect to the Company's and officers recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			relevant regulations and rules formulated or					
shall the above recovery measures be construed as a guarantee as to the Company's future profits. Other Directors In order to give effect to the Company's and officers recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
Construed as a guarantee as to the Company's future profits. Other Directors and officers In order to give effect to the Company's recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform Made on: No Yes N/A N/A Term: Indefinite term from November 15, 2017								
Other Directors and officers In order to give effect to the Company's and officers In order to give effect to the Company's measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			<u> </u>					
Other Directors and officers In order to give effect to the Company's and officers Individuals recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
and officers recovery measures against dilution on immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform	Other	Directors	*	Made on:	No	Yes	N/A	N/A
immediate return, as a director/officer of the Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
Company, I undertake that: (1) I will not transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			, ,					
transfer interests to other entities or individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
individuals free of charge or on unfair conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			1					
conditions, or otherwise damage the interests of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform								
of the Company; (2) I will strictly abide by the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			g .					
the budget management of the Company, and refrain from incur any post-related consumption unless it is necessary to perform			9					
refrain from incur any post-related consumption unless it is necessary to perform				15, 2017				
consumption unless it is necessary to perform								
waste or excessive consumption; (3) I will not								
and management of the Company to avoid			and management of the Company to avoid					

use the Company's assets to engage in			
investment and consumption activities			
unrelated to my performance of duties; (4) I			
will actively promote the improvement of the			
Company's remuneration system to make it			
consistent with the recovery requirements on			
diluted immediate return; support the			
Company's Board of Directors or			
remuneration committee to link the			
formulation, modification and supplement of			
the Company's remuneration system with the			
implementation of the Company's recovery			
measures against dilution on immediate			
return; and commit to link the exercise			
conditions of the Company's equity			
incentives to be announced with the			
implementation of the Company's recovery			
measures; (5) I will, in case relevant			
provisions of the Company and my			
commitments are inconsistent with relevant			
opinions and implementation rules on			
recovery measures against dilution on			
immediate return separately issued by the			
CSRC and the SSE, make supplementary			
commitments promptly in accordance with			
the provisions of the CSRC and the SSE, and			
actively procure the Company to make new			
commitments or adopt new measures as			
required thereby; (6) I will fully, completely			
and timely fulfill the recovery measures			
against dilution on immediate return			
formulated by the Company and any of my			
commitments on this regard. If I violate such			
commitments, thereby causing losses to the			
Company or its shareholders, I will be willing			

		to: ① make a public explanation and apology at the general meeting of shareholders and the media for disclosure designated by the CSRC; ② undertake the liability for compensation to the Company and/or the shareholders according to law; ③ unconditionally accept the punishment or relevant regulatory measures imposed on me by the securities regulatory authorities such as the CSRC and/or the SSE in accordance with the relevant regulations and rules formulated or promulgated thereby. Nevertheless, in no way shall the above recovery measures be construed as a guarantee as to the Issuer's				
Avoiding horizontal competition	Controlling shareholders and de facto controller: HOU Juncheng and FANG Aiqin	future profits. 1. I do not, and will not, directly or indirectly engage in any activities that constitute horizontal competition with the existing and future businesses of the Company and its majority-owned subsidiaries, including but not limited to the research and development, production and sales of any products that are the same as or similar to the products developed, produced and sold by the Company and its majority-owned subsidiaries, and am willing to be liable for the economic losses caused by violating the above commitments to the Company; 2. For the enterprises under my control, I will perform my obligations under these commitments through my local offices and personnel (including but not limited to directors and managers) in such enterprises, and am willing to bear the liability for compensation for the economic losses caused	No	Yes	N/A	N/A

			T					,
			to the Company due to the violation of the					
			above commitments; 3. From the date of					
			signing this letter of commitment, if the					
			Company further expands its products and					
			business scope, I and the enterprises under					
			my control will refrain from competing with					
			the expanded products or business of the					
			Company, or will, in case of competing with					
			the same, withdraw from the competition by					
			(1) stopping producing products that					
			constitute or may constitute the competition,					
			(2) ceasing to operate such business as					
			constitutes or may constitute the competition,					
			(3) incorporating the competitive business					
			into the Company for operation, or (4)					
			transferring the competitive business to					
			unrelated third parties; 4. Hangzhou					
			Huazhuang Industrial Investment Co., Ltd.,					
			Huzhou Mogan Wangshu Cosmetics Industry					
			Phase I Venture Capital Partnership (L.P.)					
			and their investees engage in no cosmetics					
			business or upstream and downstream					
			business thereof, and if they engage in such					
			businesses in the future, I undertake that I					
			will withdraw my investment in them through					
			equity transfer and other means, and that the					
			Company will be given priority to decide					
			whether to invest in the said enterprises					
			subject to the legal provisions and the consent					
			of other shareholders of such enterprises.					
	Other	Controlling	In order to give effect to the Company's	Made on:	No	Yes	N/A	N/A
Commitments		shareholders	recovery measures against dilution on	April 21,				
on		and de facto	immediate return, I undertake that: 1. I will	2021;				
refinancing		controllers:	not interfere with the Company's operation	Term:				
		HOU	and management activities beyond my	Indefinite				

	Juncheng	authority or encroach on the interests of the	term from				
	and FANG	Company; 2. From the date of making these	April 21,				
	Aiqin	commitments to the completion of the	2021				
	1	implementation of this public offering by the					
		Company of A-share convertible corporate					
		bonds, to the extent the CSRC makes new					
		regulatory provisions concerning the recovery					
		measures against dilution on immediate					
		return, etc., rendering the above commitments					
		non-conforming to the provisions, I will make					
		supplementary commitments in accordance					
		with the latest provisions of the CSRC at that					
		time; 3. I will earnestly fulfill the Company's					
		relevant recovery measures against dilution					
		on immediate return and any of my					
		commitments on this regard, or, will, in case					
		of violating the said commitments thus					
		causing losses to the Company or its					
		investors, be willing to bear the liability for					
		compensation to the Company or the					
		investors according to law. As one of the					
		parties responsible for the recovery measures,					
		I will, to the extent I violate or refuse to fulfil					
		the above commitments, accept the					
		punishment or relevant regulatory measures					
		imposed on me by the securities regulatory					
		authorities such as the CSRC and the SSE in					
		accordance with the relevant regulations and					
		rules formulated or promulgated thereby.					
Other	Directors	In order to give effect to the Company's	Made on:	No	Yes	N/A	N/A
	and officers	recovery measures against dilution on	April 21,				
		immediate return, I undertake that: 1. I will	2021;				
		not transfer interests to other entities or	Term:				
		individuals free of charge or on unfair	Indefinite				
		conditions, or otherwise damage the interests	term from				

of the Company; 2. I will restrict my	April	21,		
post-related consumption behavior; 3. I will	2021			
not use the Company's assets to engage in				
investment and consumption activities				
unrelated to my performance of duties; 4. The				
remuneration system formulated by the Board				
of Directors or the remuneration and				
assessment committee will be linked to the				
implementation of the Company's recovery				
measures on return; 5. The exercise				
conditions of the Company's equity incentive,				
if the same is implemented in the future, to be				
announced will be linked to the				
implementation of the Company's recovery				
measures on return; 6. From the date of				
making these commitments to the completion				
of the implementation of this public offering				
by the Company of A-share convertible				
corporate bonds, to the extent the CSRC				
makes new regulatory provisions concerning				
the recovery measures against dilution on				
immediate return, etc., rendering the above				
commitments non-conforming to the				
provisions, I will make supplementary				
commitments in accordance with the latest				
provisions of the CSRC at that time. As one				
of the parties responsible for the recovery				
measures, I will, to the extent I violate or				
refuse to fulfil the above commitments,				
accept the punishment or relevant regulatory				
measures imposed on me by the securities				
regulatory authorities such as the CSRC and				
the SSE in accordance with the relevant				
regulations and rules formulated or				
promulgated thereby.				

II. Non-operational Occupation of Funds by the Co	ontrolling Shareholders and O	ther Related Parties during the	e Reporting Period
\square Applicable $\sqrt{N/A}$			
III. Illegal Guarantee			
iii. megai Guaramee			
☐ Applicable √N/A			

IV A 124 . C.C	I D 4		
IV. Audit of Semi \square Applicable $\sqrt{}$	_		
□ Applicable V	IV/A		
V. Changes and Tool of Prior Year	Treatment of Matters Invol	ved in Modified Audit Opinion	ns in the Annual Report
\square Applicable $\sqrt{}$	N/A		
VI. Matters Rela	ted to Bankruptcy and Reo	rganization	
□ Applicable √		8	
VII. Material Lit	igation and Arbitration		
☐ There are mat		on during the Reporting Period Period	There are no material
-		Rectifications of the Listed Com areholders and De Facto Cont	
\square Applicable $\sqrt{}$	N/A		
IX. Integrity of a Reporting P		ng Shareholders and De Facto	Controllers during the
√ Applicable □ During the Report good faith.		controlling shareholders and de	facto controllers were in
X. Significant Re	lated-party Transactions		
(I) Related-party	Transactions Pertaining to	Daily Operation	
1. Matters that the follow-up imp		interim announcement withou	ut progress or change in
\square Applicable $\sqrt{}$	N/A		
2. Matters that follow-up implen		interim announcement with pr	rogress or changes in the
,	N/A		
shareholders were <i>Proposal on the</i> approved. For deta <i>Transactions in 2</i> com. cn) on April	held by the Company on Ap Estimated Amount of Daily ails, please refer to the Annou 021 (Announcement No.: 20	of Directors and the 2020 and pril 21, 2021 and May 13, 2021 and Related-party Transactions in uncement on the Estimated Amor (21-018) disclosed on the websit 2021, the daily related-party transing of the year.	respectively, at which the 2021 was reviewed and ant of Daily Related-party at the of the SSE (www.sse.
The estimate	d and actual amounts of the	Company's daily related-party to	ransactions in 2021 are as
follows:			
Category of			Actual amount in 2021

related-party transaction	Related party	Estimated amount in 2021	Actual amount in 2021 H1

Deposits in bank accounts opened with the related party	Zhejiang Leqing Rural Commercial Bank Co., Ltd.	No more than RMB150 million for daily amount	RMB149.2961 million
Related lease	Huzhou Beauty Town Technology Incubation Park Co., Ltd.	RMB800,000	RMB484,000

Note: The "actual amount in 2021" of Zhejiang Leqing Rural Commercial Bank Co., Ltd. represents the balance in the accounts as of June 30, 2021. In the first half of 2021, the Company obtained deposit interest of RMB3.1784 million from Zhejiang Leqing Rural Commercial Bank Co., Ltd..

interest of RMB3.1784 million from Zhejiang Leqing Rurai Commercial Bank Co., Ltd
3. Matters not disclosed in the interim announcement $\hfill\Box$ Applicable $\hfill \sqrt{N/A}$
(II) Related-party Transactions Arising from Acquisition or Disposal of Assets or Equities 1. Matters that have been disclosed in the interim announcement without progress or change in the follow-up implementation $\square \ \text{Applicable} \sqrt{N/A}$
2. Matters that have been disclosed in the interim announcement with progress or change in the follow-up implementation $\hfill\Box$ Applicable $\hfill \sqrt{N/A}$
3. Matters not disclosed in the interim announcement $\hfill\Box$ Applicable $\hfill \hfill \hf$
4. The performance realization during the Reporting Period where the performance agreement is involved $\hfill\Box$ Applicable $\hfill \sqrt{N/A}$
(III) Significant related-party transactions pertaining to joint external investment
1. Matters that have been disclosed in the interim announcement without progress or change in the follow-up implementation $\hfill\Box$ Applicable $\hfill \sqrt{N/A}$
2. Matters that have been disclosed in the interim announcement with progress or change in the follow-up implementation $\hfill\Box$ Applicable $\hfill \hfill \hfill$
3. Matters not disclosed in the interim announcement $\hfill\Box$ Applicable $\hfill \sqrt{N/A}$
(IV) Credits and Debits with Related Parties
1. Matters that have been disclosed in the interim announcement without progress or change in the follow-up implementation $\hfill\Box$ Applicable $\hfill \sqrt{N/A}$

2. Matters that have been disclosed in the interim announcement with progress or change in the follow-up implementation
\square Applicable $\sqrt{N/A}$
3. Matters not disclosed in the interim announcement \Box Applicable $\sqrt{N/A}$
(V) Financial Businesses between the Company and Its Related Financial Companies Majority-owned Financial Companies and Related Parties $\square \ \text{Applicable} \ \sqrt{N/A}$
(VI) Other Significant Related-party Transactions \square Applicable $\sqrt{N/A}$
(VII) Others $\Box \text{ Applicable } \sqrt{N/A}$
XI. Significant Contracts and Performances Thereof
1 Trusteeship, contracting and leasing
\square Applicable $\sqrt{N/A}$

2 Significant guarantees performed and outstanding during the Reporting Period

 $\sqrt{\text{Applicable}} \quad \square \text{ N/A}$

Unit: RMB0'000 Currency: RMB

External guarantees of the	Company (excluding	guarante	es for sub	sidiaries)				
Guarantor Guarantor and listed company Guaranteed Guarantee Guarantee amount Guarantee	type	Main debt	Collateral (if any)	Has the guarantee been fulfilled	Is the guarantee overdue	Overdue amount under guarantee	Counter guarantee	Related-party guarantee or not	Association relationship
Total amount of guarantee during the Reporting Period (excluding guarantee for subsidiaries)	U								
Total guarantee balance at the end of the Reporting Period (A) (excluding guarantee for subsidiaries)	9 0								
Guarantees	of the Comp	oany for it	s subsidia	ries					
Total amount of guarantee for subsidiaries during the Reporting Period	9,900								
Total guarantee balance to subsidiaries at the end of the Reporting Period (B)	0								
Total amount of the Company's guarantee (including guarantee for subsidiaries)									
Total guarantee amount (A + B)	0								
Proportion of total guarantee amount to the Company's net assets (%)	0								
Of which:									
Amount of guarantee provided for shareholders, de facto controllers and their related parties (C)	U								
Amount of debt-related guarantee provided directly or indirectly for th guaranteed parties with asset-liability ratio exceeding 70% (D)	0								
Amount of total guarantee exceeding 50% of net assets (E)	0								
Total amount of guarantees in the above three items $(C + D + E)$	0								
Descriptions of possible joint and several liability for repayment under ongoing guarantee	N/A								
Descriptions of guarantee	N/A								

3 Other significant contracts

 \square Applicable $\sqrt{N/A}$

XII. Description of Other Significant Events

 \square Applicable $\sqrt{N/A}$

Section VII Share Changes and Shareholders

I. Changes in Share Capital

- (I) Statement of Changes in Shares
- 1. Statement of changes in shares

Unit: share

	Before		In	crease	or decreas	se this time	e (+,-)	After this	change
	Quantity	Ratio (%)	New shares	Bon us shar es	Capitali zation of capital reserve	Others	Sub-total	Quantity	Ratio (%)
I. Restricted share	747,425	0.37				-293,2 65	-293,265	454,160	0.23
1. Shareholdings by the State									
2. Shareholdings by the State-owned legal persons									
3. Other shareholdings by domestic investors	747,425	0.37				-293,2 65	-293,265	454,160	0.23
Including: shareholdings by domestic legal persons									
Shareholdings by domestic natural persons	747,425	0.37				-293,2 65	-293,265	454,160	0.23
4. Shareholdings by foreign investors									
Including: Shareholdings by overseas legal persons									
Shareholdings by overseas natural persons II. Unrestricted	200,369,	99.63				+293,2	+293,26	200,662,	99.77

outstanding	500			65	5	765	
share							
1. RMB	200,369,	99.63		+293,2	+293,26	200,662,	99.77
common stock	500	99.03		65	5	765	99.77
2. Domestic							
listed foreign							
share							
3. Overseas							
listed foreign							
share							
4. Others							
III. Total	201,116,	100.0		0	0	201,116,	100.00
III. Total	925	0				925	100.00

2. Description of changes in shares

 $\sqrt{\text{Applicable}} \square \text{N/A}$

On January 5, 2021, the Company held the 18th meeting of the second Board of Directors and the 17th meeting of the second Board of Supervisors, deliberating and approving the *Proposal on the Satisfaction of Restrictions Release Conditions for the Second Release Period of the Restricted Shares Granted Initially and with Reserve under the 2018 Restricted Share Incentive Plan*, and agreeing to handle the release procedures for the grantees who meet the conditions for releasing the restrictions. A total of 293,265 restricted shares were released, which were allowed to be listed and circulated on January 14, 2021. The number of the unrestricted outstanding shares in the Company increased from 200,369,500 before the Listing to 200,662,765, while that of the restricted outstanding shares decreased from 747,425 before the Listing to 454,160.

3. Impact of share changes on financial indicators such as earnings per share and net assets per share during the period after the Reporting Period to the disclosure date of the Semi-annual Report (if any)

	App	lical	ole	V	N/A
_	T IPP	nout	,10	•	1 1/1 1

4. Other contents deemed necessary by the Company for disclosure or required to be disclosed by the securities regulatory authority

L	l App	licab	le	V	N/A
---	-------	-------	----	---	-----

(II) Changes in Restricted Shares

 $\sqrt{\text{Applicable } \square \text{ N/A}}$

Unit: share

Name of shareholder	Number of restricted shares at the opening of the period	Number of restricted shares released during the Reporting Period	Increase in the number of restricted shares in the Reporting Period	Number of restricted shares at the end of the Reporting Period	Reasons for restriction	Release date
JIN Yanhua	68,810	29,490	0	39,320	Initial grant under the 2018 Restricted Share Incentive Plan	January 14, 2021

ZHANG Yefeng	34,020	14,580	0	19,440	Initial grant under the 2018 Restricted Share Incentive Plan	January 14, 2021
WANG Li	41,230	17,670	0	23,560	Grant with reserve under the 2018 Restricted Share Incentive Plan	January 14, 2021
18 grantees being granted initially under the 2018 Restricted Share Incentive Plan	461,645	172,685	0	288,960	Initial grant under the 2018 Restricted Share Incentive Plan	January 14, 2021
10 grantees being granted with reserve under the 2018 Restricted Share Incentive Plan	141,720	58,840	0	82,880	Grant with reserve under the 2018 Restricted Share Incentive Plan	January 14, 2021
Total	747,425	293,265	0	454,160	/	/

II. Shareholders

(I) Total Number of Shareholders:

Total number of common shareholders by the end of the	17,050
Reporting Period (person)	
Total number of preferred shareholders with voting rights	0
by the end of the Reporting Period (person)	

(II) Shareholding of Top Ten Shareholders and Top Ten Outstanding Shareholders (or Unrestricted Shareholders) by the End of the Reporting Period

Unit: share

Shareholding of top ten shareholders							
Name of	Increase or decrease during	Number of shares held	Ratio	Number	Pledge, a	_	Nature of
shareholder (full name)	the Reporting Period	at the closing of the period	(%)	restricted shares	Share status	Number	shareholder

HOU Juncheng	-764,869	71,875,631	35.74	0	/		Domestic natural person
FANG Yuyou	-2,607,427	42,211,691	20.99	0	Pledged	11,920 ,000	Domestic natural person
Hong Kong Securities Clearing Company Limited	13,759,263	30,518,946	15.17	0	/		Other
CAO Liangguo	-81,000	4,043,938	2.01	0	/		Domestic natural person
XU Junqing	-2,111,591	3,832,210	1.91	0	/		Domestic natural person
LI Xiaolin	-2,741,312	3,502,910	1.74	0	/		Domestic natural person
Industrial and Commercial Bank of China Limited - Jingshun Changcheng Emerging Growth Hybrid Securities Investment Fund	-799,766	1,700,000	0.85	0	/		Other
Aberdeen Standard Investment Management (Asia) Co., Ltd Aberdeen Standard - China A-share Equity Fund	1,069,326	1,069,326	0.53	0	/		Other
Abu Dhabi Investment Authority		997,598	0.50	0	/		Other
China CITIC Bank Co., Ltd ABC Huili Strategy Selected Hybrid Securities Investment Fund	-93,400	935,541	0.47	0	/		Other
	Shareho	olding of top te					
Nam		Number of unrestricted shares held		Type and number		or of shares Number	
HOU Juncheng			RMR common			71,875,631	

FANG Yuyou	42,211,691	RMB common stock	42,211,691		
Hong Kong Securities Clearing Company Limited	30,518,946	RMB common stock	30,518,946		
CAO Liangguo	4,043,938	RMB common stock	4,043,938		
XU Junqing	3,832,210	RMB common stock	3,832,210		
LI Xiaolin	3,502,910	RMB common stock	3,502,910		
Industrial and Commercial Bank of China Limited - Jingshun Changcheng Emerging Growth Hybrid Securities Investment Fund	1,700,000	RMB common stock	1,700,000		
Aberdeen Standard Investment Management (Asia) Co., Ltd Aberdeen Standard - China A-share Equity Fund	1,069,326	RMB common stock	1,069,326		
Abu Dhabi Investment Authority	997,598	RMB common stock	997,598		
China CITIC Bank Co., Ltd ABC Huili Strategy Selected Hybrid Securities Investment Fund	935,541	RMB common stock	935,541		
Description of special accounts for repurchase among top ten shareholders	None				
Description of the above shareholders delegating, being delegated and waiving voting rights	None				
Description of the association relationship or concerted action of the above shareholders	FANG Yuyou is the younger brother of HOU Juncheng's spouse FANG Aiqin, so HOU Juncheng and FANG Yuyou are related.				
Description of preferred shareholders with voting rights and the number of shares held thereby	None				

Number of shares held by the top ten restricted shareholders and the restrictions $\sqrt{\text{Applicable}\;\square\;N/A}$

Unit: share

	Name of rectricted about alder	Number of restr	and trading of cted shares	D	
S/N	Name of restricted shareholder	restricted shares held	Tradable time	Number of new tradable shares	Restrictions
1	Grantees of equity incentives	454,160			See the note for details
Description of the association					
relationship or concerted action of the above shareholders		None			

Note: The restricted shares held by the grantees of equity incentives refer to the shares granted initially and with reserve under the Company's 2018 Restricted Share Incentive Plan, of which, the shares initially granted shall be subject to a restriction period of 36 months from completion of the registration of such shares in Shanghai Branch of China Securities Depository and Clearing Corporation Limited (September 10, 2018), and the shares granted with reserve shall be subject to a restriction period of 37 months from completion the registration thereof in Shanghai Branch of China Securities Depository and Clearing Corporation Limited (September 10, 2018).

(III) Strategic Investors or General Legal Persons Becoming the Top Ten Shareholders due to Placement of New Shares

 \square Applicable $\sqrt{N/A}$

III. Directors, Supervisors and Officers

(I) Changes in Shareholding of Current Directors, Supervisors and Officers, Including Those Leaving Office, During the Reporting Period

 $\sqrt{\text{Applicable}} \square \text{N/A}$

Unit: share

Name	Position	Number of shares held at the opening of the period	Number of shares held at the closing of the period	Increase and decrease of shares during the Reporting Period	Reasons for increase or decrease
HOU Juncheng	Director	72,640,500	71,875,631	-764,869	Reduction in response to personal capital demand
FANG Yuyou	Director	44,819,118	42,211,691	-2,607,427	Reduction in response to personal capital demand
CAO Liangguo	Director	4,124,938	4,043,938	-81,000	Reduction in response to personal capital demand

Other description Discription Applicable	
(II) Equity Inc ☐ Applicable	entives Granted to Directors, Supervisors and Officers during the Reporting Period $\sqrt{N/A}$
(III) Other Dea	
IV. Changes in ☐ Applicable	Controlling Shareholders or De Facto Controllers $\sqrt{N/A}$
	Section VIII Preferred Stock
☐ Applicable	$\sqrt{N/A}$

Section IX Bonds

I. Debentures, Corporate Bonds and Non-financial Business Debt Financing Instruments
\square Applicable $\sqrt{N/A}$
II. Convertible Corporate Bonds

Section X Financial Report

I. Auditor's Report

 \square Applicable $\sqrt{N/A}$

II. Financial Statements

Consolidated Balance Sheet

June 30, 2021

Prepared by: Proya Cosmetics Co., Ltd

Item	Note	June 30, 2021	December 31, 2020
Current assets:		,	,
Cash and bank balances	VII.1	1,236,337,706.75	1,416,654,640.93
Balances with clearing			
agencies			
Placements with banks and			
other financial institutions			
Held-for-trading financial			
assets			
Derivative financial assets			
Notes receivable			
Accounts receivable	VII.5	174,316,681.46	284,878,419.58
Receivable financing	VII.6	5,263,729.60	5,531,997.32
Prepayments	VII.7	89,183,962.68	82,742,815.92
Premiums receivable			
Amounts receivable under			
reinsurance contracts			
Reinsurer's share of			
insurance contract reserves			
Other receivables	VII.8	47,275,902.55	48,733,527.35
Including: Interest			
receivable			
Dividends receivable			
Financial assets purchased			
under resale agreements			
Inventories	VII.9	356,282,644.43	468,641,017.75
Contract assets			
Held-for-sale assets			
Non-current assets due			
within one year			
Other current assets	VII.13	45,267,333.55	35,235,811.27
Total current assets		1,953,927,961.02	2,342,418,230.12
Non-current assets:			
Loans and advances to			
customers			
Debt investments			
Other debt investments			

Long-term receivables			
Long-term equity	VII.17	186,592,634.00	58,220,059.60
investments			, -,
Other investments in	VII.18	20,580,000.00	20,580,000.00
equity instruments			
Other non-current financial			
assets			
Investment properties	VII.20	71,819,415.95	72,237,610.10
Fixed assets	VII.21	553,956,322.47	565,864,152.62
Construction in progress	VII.22	115,081,293.14	47,324,523.36
Bearer biological assets			
Oil and gas assets			
Right of use assets			
Intangible assets	VII.26	380,925,301.67	314,643,323.97
Development expenditure			
Goodwill			31,034,161.20
Long-term prepaid	VII.29	38,161,082.81	50,576,793.53
expenses			
Deferred income tax assets	VII.30	50,977,297.40	46,660,550.76
Other non-current Assets	VII.31	5,731,163.01	87,322,780.03
Total non-current assets		1,423,824,510.45	1,294,463,955.17
Total assets		3,377,752,471.47	3,636,882,185.29
Current liabilities:			
Short-term borrowings	VII.32	200,000,000.00	299,280,435.09
Loans from the central			
bank			
Taking from banks and			
other financial institutions			
Held-for-trading financial			
liabilities			
Derivative financial			
liabilities			
Notes payable	VII.35	63,672,739.08	64,580,000.00
Accounts payable	VII.36	346,738,059.11	515,832,031.27
Receipts in advance			
Contract liabilities	VII.38	52,820,185.37	30,618,778.99
Financial assets sold under			
repurchase agreements			
Customer deposits and			
deposits from banks and other			
financial institutions			
Funds from securities			
trading agency			
Funds from underwriting			
securities agency Employee benefits payable	VII.39	52 000 015 47	70 000 020 70
		52,909,015.47	70,828,239.70
Taxes payable Other payables	VII.40 VII.41	73,837,489.98 73,609,323.68	71,335,290.77 75,546,323.32
- · ·	V 11.41	73,009,323.00	13,340,343.34
Including: Interest payable			
Dividends payable	+		
Fees and commissions	+		
payable			
Amounts payable under	 		
ranounts payable under			

reinsurance contracts			
Held-for-sale liabilities			
Non-current liabilities due			
within one years			
Other current liabilities	VII.44	2,149,196.85	1,439,262.02
Total current liabilities	, ==, :	865,736,009.54	1,129,460,361.16
Non-current liabilities:			-,,,,
Insurance contract reserves			
Long-term borrowings			
Bonds payable			
Including: Preferred			
stock			
Perpetual bonds			
Lease liabilities			
Long-term payables			
Long-term employee			
benefits payable			
Provisions	VII.50	6,052,681.88	10,190,099.22
Deferred income	VII.51	7,455,808.33	8,495,353.33
Deferred income tax	VII.30	6,141,332.95	6,874,105.45
liabilities	, 11.00	0,1 .1,652.56	3,371,1321.12
Other non-current			
liabilities			
Total non-current liabilities		19,649,823.16	25,559,558.00
Total liabilities		885,385,832.70	1,155,019,919.16
Owner's equity (or		, ,	, , ,
shareholders' equity):			
Paid-in capital (or share	VII.53	201,116,925.00	201,116,925.00
capital)			
Other equity instruments			
Including: Preferred			
stock			
Perpetual bonds			
Capital reserve	VII.55	841,032,150.17	837,034,836.69
Less: Treasury shares	VII.56	7,361,933.60	12,653,905.25
Other comprehensive	VII.57	-665,661.47	-269,066.13
income			
Special reserve			
Surplus reserve	VII.59	100,634,780.00	100,634,780.00
General risk reserve			
Retained profits	VII.60	1,346,968,993.49	1,265,671,865.63
Total owners' equity (or		2,481,725,253.59	2,391,535,435.94
shareholders' equity)			
attributable to equity holders of			
the parent company			
Minority interests		10,641,385.18	90,326,830.19
Total owners' equity (or		2,492,366,638.77	2,481,862,266.13
shareholders' equity)			
Total liabilities and owners'		3,377,752,471.47	3,636,882,185.29
equity (shareholders' equity)			

Person in charge of the Company: HOU Juncheng Chief Financial Officer: WANG Li Head of the Accounting Organization: WANG Li

Balance Sheet of the Parent Company June 30, 2021

Prepared by: Proya Cosmetics Co., Ltd

Item	Note	June 30, 2021	December 31, 2020
Current Assets:			·
Cash and bank balances		460,108,856.64	498,358,108.55
Held-for-trading financial			
assets			
Derivative financial assets			
Notes receivable			
Accounts receivable	XVII.1	487,476,860.98	565,037,411.15
Receivable financing		3,391,723.00	
Prepayments		28,408,424.58	9,389,481.27
Other receivables	XVII.2	233,121,481.53	236,585,409.48
Including: Interest			
receivable			
Dividends			
receivable			
Inventories		176,120,027.88	227,126,018.70
Contract assets			
Held-for-sale assets			
Non-current assets due			
within one year			
Other current assets		36,361,283.47	15,543,206.01
Total current assets		1,424,988,658.08	1,552,039,635.16
Non-current assets:			
Debt investments			
Other debt investments			
Long-term receivables			
Long-term equity	XVII.3	378,673,104.59	347,372,956.06
investments			
Other investments in		20,580,000.00	20,580,000.00
equity instruments			
Other non-current financial			
assets			
Investment properties		337,269,798.16	339,018,465.70
Fixed assets		283,280,852.93	291,193,420.67
Construction in progress		110,818,849.59	46,993,562.96
Bearer biological assets			
Oil and gas assets			
Right of use assets			
Intangible assets		377,215,032.72	308,401,627.24
Development expenditure			
Goodwill			
Long-term prepaid		27,410,563.79	34,817,495.54
expenses			
Deferred income tax assets		13,453,027.69	15,889,636.90
Other non-current Assets		5,995,408.95	87,545,799.42

Total non-current assets	1,554,696,638.42	1,491,812,964.49
Total assets	2,979,685,296.50	3,043,852,599.65
Current liabilities:	_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Short-term borrowings	200,000,000.00	200,163,972.59
Held-for-trading financial		
liabilities		
Derivative financial		
liabilities		
Notes payable	63,672,739.08	64,580,000.00
Accounts payable	254,020,691.00	403,605,887.84
Receipts in advance		
Contract liabilities	59,127,134.06	10,212,194.96
Employee benefits payable	26,187,595.81	29,624,549.78
Taxes payable	52,346,310.37	34,953,057.88
Other payables	19,378,091.27	24,771,086.23
Including: Interest	, ,	
payable		
Dividends payable		
Held-for-sale liabilities		
Non-current liabilities due		
within one year		
Other current liabilities		
Total current liabilities	674,732,561.59	767,910,749.28
Non-current liabilities:		
Long-term borrowings		
Bonds payable		
Including: Preferred		
stock		
Perpetual bonds		
Lease liabilities		
Long-term payables		
Long-term employee		
benefits payable		
Provisions		
Deferred income	7,455,808.33	8,495,353.33
Deferred income tax	5,627,540.89	6,283,428.68
liabilities		
Other non-current		
liabilities		
Total non-current liabilities	13,083,349.22	14,778,782.01
Total liabilities	687,815,910.81	782,689,531.29
Owner's equity (or		
shareholders' equity):		
Paid-in capital (or share	201,116,925.00	201,116,925.00
capital)		
Other equity instruments		
Including: Preferred		
stock		
Perpetual bonds	222 22 22 23 24	000 000 100 5
Capital reserve	838,006,964.60	837,075,425.32
Less: Treasury shares	7,361,933.60	12,653,905.25
Other comprehensive		
income		
Special reserve		

Surplus reserve	100,634,780.00	100,634,780.00
Retained profits	1,159,472,649.69	1,134,989,843.29
Total owners' equity (or shareholders' equity)	2,291,869,385.69	2,261,163,068.36
Total liabilities and owners' equity (or shareholders' equity)	2,979,685,296.50	3,043,852,599.65

Person in charge of the Company: HOU Juncheng Chief Financial Officer: WANG Li Head of the Accounting Organization: WANG Li

Consolidated Income Statement

January to June, 2021

Item	Note	First half of 2021	Finat half of 2020
	VII.61	First half of 2021	First half of 2020
I. Total operating income		1,917,718,497.60	1,384,323,848.88
Including: Operating income	VII.61	1,917,718,497.60	1,384,323,848.88
Interest income			
Premiums earned			
Fee and commission			
income		1.557.771.251.01	1 1 10 50 50 00 0 5
II. Total operating costs		1,667,751,364.94	1,148,706,930.06
Including: Operating costs	VII.61	695,558,289.19	555,120,455.16
Interest expenses			
Fee and commission			
expenses			
Surrenders			
Claims and policyholder			
benefits (net of mounts recoverable			
from reinsurers)			
Charges in insurance			
contract reserves (net of reinsurers'			
share)			
Insurance policyholder			
dividends			
Expenses for reinsurance			
accepted			
Taxes and levies	VII.62	19,290,055.27	11,499,023.35
Selling expenses	VII.63	807,204,631.76	457,414,432.20
General and	VII.64	116,191,173.05	100,182,355.15
administrative expenses			
Research and	VII.65	31,371,344.46	31,865,144.96
development expenses		, ,	, ,
Financial expenses	VII.66	-1,864,128.79	-7,374,480.76
Including: Interest		5,082,866.57	2,502,979.38
expenses		2,32=,330.07	_,,- : > 100
Interest income		11,723,066.05	8,171,010.26
Add: Other income	VII.67	10,159,807.90	8,526,648.97
Investment income (Loss is	VII.68	-2,378,652.94	2,318,347.17
indicated by "-")	, 11.00	2,570,052.74	2,310,317.17
Including: Income from		-2,375,106.70	-208,988.41
merading. meome from		-2,373,100.70	-200,700.41

		<u> </u>	
investments in associates and joint			
ventures Income from			
derecognition of financial assets measured at amortized cost			
Foreign exchange gains			
(Loss is indicated by "-")			
Net exposure hedging			
income (Loss is indicated by "-")			
Income from changes in fair			
value (Loss is indicated by "-")	*****	2077 502 70	1.110.055.00
Impairment losses of credit (Loss is indicated by "-")	VII.71	2,955,792.59	-1,142,266.22
Impairment losses of assets (Loss is indicated by "-")	VII.72	-8,625,168.59	-9,651,315.34
Income from disposal of	VII.73	-1,416.28	
assets (Loss is indicated by "-") III. Operating profit (Loss is indicated		252,077,495.34	235,668,333.40
by "-")		232,077,493.34	253,006,555.40
Add: Non-operating income	VII.74	114,443.12	405,868.31
Less: Non-operating expenses	VII.75	60,174.49	15,505,794.81
IV. Total profit (Total losses are indicated by "-")		252,131,763.97	220,568,406.90
Less: Income tax expenses	VII.77	43,482,270.58	46,884,003.64
V. Net profit (Net loss is indicated by	V 11.77	208,649,493.39	173,684,403.26
"-")		200,019,193.39	173,001,103.20
(I) Categorized by the nature of continu	ing operation	l l	
1. Net profit from continuing	8 17	208,649,493.39	173,684,403.26
operations (Net loss is indicated by "-")			,,
2. Net profit from discontinued operations (Net loss is indicated by "-")			
(II) Categorized by ownership			
1. Net profit attributable to		226,101,313.86	178,767,020.76
shareholders of the parent company		220,101,313.00	170,707,020.70
(Net loss is indicated by "-")			
2. Profit or loss attributable to		-17,451,820.47	-5,082,617.50
minority interests (Net loss is			, ,
indicated by "-")			
VI. Other comprehensive income, net		-396,595.34	-136,681.49
of tax		20170701	125 501 10
(I) Other comprehensive income		-396,595.34	-136,681.49
attributable to owners of the parent			
company, net of tax			
1. Other comprehensive income			
that cannot be subsequently			
reclassified to profit or loss			
(1) Changes from re-measurement of defined benefit plans			
(2) Other comprehensive income that			
cannot be reclassified to profit or loss			
under the equity method			
(3) Changes in fair value of other			
investments in equity instruments			
(4) Changes in fair value of			
(1) Changes in rail value of	I		

enterprises' own credit risks		
2. Other comprehensive income that	-396,595.34	-136,681.49
will be reclassified to profit or loss		
(1) Other comprehensive income that		
will be reclassified to profit or loss		
under the equity method		
(2) Changes in fair value of other debt		
investments		
(3) Amounts of financial assets		
reclassified into other comprehensive		
income		
(4) Provision for credit impairment of		
other debt investments		
(5) Reserve for cash flow hedges		
(6) Translation differences of financial	-396,595.34	-136,681.49
statements denominated in foreign		
currencies		
(7) Others		
(II) Other comprehensive income		
attributable to minority interests, net of		
tax		
VII. Total comprehensive income	208,252,898.05	173,547,721.77
(I) Total comprehensive income	225,704,718.52	178,630,339.27
attributable to owners of the parent		
company		
(II) Total comprehensive income	-17,451,820.47	-5,082,617.50
attributable to minority interests		
VIII. Earnings per share		
(I) Basic earnings per share	1.13	0.89
(RMB/share)		
(II) Diluted earnings per share	1.12	0.89
(RMB/share)		

For business combination involving enterprises under common control in the current period, the net profit realized by the acquirees before the combination is: RMB0, and the net profit realized thereby in the prior period is: RMB0.

Person in charge of the Company: HOU Juncheng Chief Financial Officer: WANG Li Head of the Accounting Organization: WANG Li

Income Statement of the Parent Company

January to June, 2021

Item	Note	First half of 2021	First half of 2020
I. Total operating income	XVII.4	896,751,013.59	793,053,800.28
Less: Operating costs	XVII.4	456,588,246.62	364,806,553.96
Taxes and levies		9,582,635.63	6,466,005.47
Selling expenses		81,296,635.42	91,431,939.35
General and administrative		93,298,483.53	73,330,062.18
expenses			

Expenses		1		
Financial expenses -5,242,699.84 -9,282,936.64 Including: Interest expenses 3,673,688.51 1,536,524.31 Interest income XVII.5 2,487,852.60 7,155,816.18 Investment income (Loss is indicated by "-") -2,511,473.64 1,995,502.53 Including: Income from investments in associates and joint ventures Income from -2,511,473.64 -270,798.84 Income from changes in fair value (Loss is indicated by "-") Income from changes in fair value (Loss is indicated by "-") Impairment losses of readit (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Add: Non-operating income 5,363.22 6,666.00 Income from disposal of assets (Loss is indicated by "-") Add: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "-") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") 169,286,992.40 177,538,946.16 (1) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net pro	Research and development		33,738,875.24	34,152,355.31
Including: Interest expenses 3,673,688.51 1,536,524.31 Add: Other income XVII.5 2,487,852.60 7,155,816.18 Investment income (Loss is indicated by "-") Including: Income from -2,511,473.64 1,995,502.53 Including: Income from -2,511,473.64 -270,798.84 Investments in associates and joint ventures Income from -2,511,473.64 -270,798.84 Investments in associates and joint ventures Income from Income from -2,511,473.64 -270,798.84 Investments in associates and joint ventures Income from			-5.242.699.84	-9.282.936.64
Interest income				
Add: Other income (Loss is indicated by "-") Income from derecognition of financial assets measured at amortized cost (Loss is indicated by "-") Income from derecognition of financial assets measured at amortized cost (Loss is indicated by "-") Income from denances in fair value of other income that cannot be subsequently endeastified by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Less: Non-operating income				
Investment income (Loss is indicated by "-") Including: Income from investments in associates and joint ventures Income from derecognition of financial assets measured at amortized cost (Loss is indicated by "-") Net exposure hedging income (Loss is indicated by "-") Income from changes in fair value of enterprises in dicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") In Operating profit (Loss is indicated by "-") In Operating profit (Loss is indicated by "-") Add: Non-operating income Less: Non-operating expenses 196,393,169.19 211,216,006.75 Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") IV. per profit (Net loss is indicated by "-") IV. operating the profit (Net loss is indicated by "-") IV. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of enterprises' own credit risks		XVII 5		
indicated by "-") Including: Income from investments in associates and joint ventures Income from derecognition of financial assets measured at amortized cost (Loss is indicated by "-") Net exposure hedging income (Loss is indicated by "-") Income from changes in fair value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") Less: Non-operating income Less: Non-operating expenses III. Total profit (Total losses are indicated by "-") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of other investments in equity instruments 4. Changes in fair value of other prises* own credit risks		AVII.5		
Including: Income from investments in associates and joint ventures Income from derecognition of financial assets measured at amortized cost (Loss is indicated by "") Net exposure hedging income (Loss is indicated by "") Imposiment losses of credit (Loss is indicated by "") Impairment losses of credit (Loss is indicated by "") Impairment losses of assets (Loss is indicated by "") Impairment losses of assets (Loss is indicated by "") Income from disposal of assets (Loss is indicated by "") Income from disposal of assets (Loss is indicated by "") In pairment losses of assets (Loss is indicated by "") In proper find (Ioss is indicated by "") II. Operating profit (Loss is indicated by "") Add: Non-operating income 5,363.22 6,666.00 Less: Non-operating expenses 19,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "") IV. Net profit (Net loss is indicated by "") IV. Net profit (Net loss is indicated by "") (I) Net profit from continuing operation (Net loss is indicated by "") (I) Net profit from discontinued operations (Net loss is indicated by "") (I) Net profit from discontinued operations (Net loss is indicated by "") (I) Other comprehensive income that cannot be rebessive income that cannot be rebessive income that cannot be rebessive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of onterprises' own credit risks 4. Changes in fair value of onterprises' own credit risks			-2,311,473.04	1,995,502.55
investments in associates and joint ventures Income from derecognition of financial assets measured at amortized cost (Loss is indicated by "-") Net exposure hedging income (Loss is indicated by "-") Income from changes in fair value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") In Operating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") III. Total profit (Total losses are indicated by "-") Less: Non-operating expenses 196,393,169.19 211,216,006.75 Indicated by "-") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing poperation (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicate			2 511 472 64	270 709 94
ventures Income from derecognition of financial assets measured at amortized cost (Loss is indicated by "-") Net exposure hedging income (Loss is indicated by "-") Income from changes in fair value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") III. Operating profit (Loss is indicated by "-") Add: Non-operating income 5.363.22 6.6660. Less: Non-operating expenses 9.975.00 I. Sold 15,071.217.24 III. Total profit (Total losses are indicated by "-") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") (I) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of other prises' own credit risks			-2,311,4/3.04	-270,798.84
Income from derecognition of financial assets measured at amortized cost (Loss is indicated by "-") Net exposure hedging income (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of seesti (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income				
derecognition of financial assets measured at amortized cost (Loss is indicated by "-") Net exposure hedging income (Loss is indicated by "-") Income from changes in fair value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") In Operating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") III. Operating profit (Loss is indicated by "-") Add: Non-operating expenses				
measured at amortized cost (Loss is indicated by "-") Net exposure hedging income (Loss is indicated by "-") Income from changes in fair value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") In Coperating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income				
indicated by "-") Net exposure hedging income (Loss is indicated by "-") Income from changes in fair value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") III. Operating profit (Loss is indicated by "-") Add: Non-operating income 5,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "-") IV. Net profit (Net loss is indicated by "-") (I) Net profit (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operation (Net loss is indicated by "-") (II) Net profit from discontinued operation (Net loss is indicated by "-") (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
Net exposure hedging income (Loss is indicated by "-") Income from changes in fair value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") In Operating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") III. Operating profit (Loss is indicated by "-") Add: Non-operating income				
income (Loss is indicated by ".") Income from changes in fair value (Loss is indicated by ".") Impairment losses of credit (Loss is indicated by ".") Impairment losses of assets (Loss is indicated by ".") Impairment losses of assets (Loss is indicated by ".") Impairment losses of assets (Loss is indicated by ".") Income from disposal of assets (Loss is indicated by ".") II. Operating profit (Loss is indicated by ".") Add: Non-operating income 5,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are 196,393,169.19 211,216,006.75 indicated by ".") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by ".") (I) Net profit from continuing operation (Net loss is indicated by ".") (II) Net profit from discontinued operations (Net loss is indicated by ".") (I) Net profit from discontinued operations (Net loss is indicated by ".") (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
Income from changes in fair value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") In Operating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income 5,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are 196,393,169.19 211,216,006.75 indicated by "-") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing 169,286,992.40 177,538,946.16 operations (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
value (Loss is indicated by "-") Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income 5,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "-") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
Impairment losses of credit (Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income				
(Loss is indicated by "-") Impairment losses of assets (Loss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income 5,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "-") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
Impairment losses of assets (Loss is indicated by ".") Income from disposal of assets (Loss is indicated by ".") II. Operating profit (Loss is indicated by ".") Add: Non-operating income S,363.22 6,666.00 Less: Non-operating expenses 196,393,169.19 211,216,006.75 indicated by ".") Less: Income tax expenses IV. Net profit (Net loss is indicated by ".") (I) Net profit from continuing operation (Net loss is indicated by ".") (II) Net profit from discontinued operations (Net loss is indicated by ".") (II) Net profit from discontinued operations (Net loss is indicated by ".") (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			-29,471,176.41	-10,545,554.20
CLoss is indicated by "-") Income from disposal of assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") 226,280,557.99 by "-") Add: Non-operating income 5,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "-") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Other comprehensive income that cannot be subsequently reclassified to profit or loss I. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
Income from disposal of assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income Less: Non-operating expenses III. Total profit (Total losses are indicated by "-") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") (II) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Cher comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks	Impairment losses of assets		-1,596,258.57	-4,475,027.17
assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income S,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "-") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks	(Loss is indicated by "-")			
assets (Loss is indicated by "-") II. Operating profit (Loss is indicated by "-") Add: Non-operating income S,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "-") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks	Income from disposal of			
II. Operating profit (Loss is indicated by "-") Add: Non-operating income 5,363.22 6,666.00 Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are 196,393,169.19 211,216,006.75 indicated by "-") Less: Income tax expenses 27,106,176.79 33,677,060.59 IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing 169,286,992.40 177,538,946.16 operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
by "-2") Add: Non-operating income Less: Non-operating expenses III. Total profit (Total losses are indicated by "-2") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-2") (I) Net profit from continuing operation (Net loss is indicated by "-2") (II) Net profit from discontinued operations (Net loss is indicated by "-2") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			196,397,780.97	226,280,557.99
Add: Non-operating income Less: Non-operating expenses 9,975.00 15,071,217.24 III. Total profit (Total losses are indicated by "-") Less: Income tax expenses 196,393,169.19 211,216,006.75 IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			, ,	, ,
Less: Non-operating expenses III. Total profit (Total losses are indicated by "-") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			5,363,22	6,666,00
III. Total profit (Total losses are indicated by "-") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				·
indicated by "-") Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
Less: Income tax expenses IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			170,373,107.17	211,210,000.75
IV. Net profit (Net loss is indicated by "-") (I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			27 106 176 79	33 677 060 59
(I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks	1			
(I) Net profit from continuing operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			109,280,392.40	177,550,540.10
operation (Net loss is indicated by "-") (II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			160 286 002 40	177 529 046 16
(II) Net profit from discontinued operations (Net loss is indicated by "-") V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks			109,280,992.40	177,550,540.10
operations (Net loss is indicated by "-2") V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
V. Other comprehensive income, net of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
of tax (I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
(I) Other comprehensive income that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks	-			
that cannot be subsequently reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
reclassified to profit or loss 1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
1. Changes from re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
re-measurement of defined benefit plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
plans 2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
2. Other comprehensive income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
income that cannot be reclassified to profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
profit or loss under the equity method 3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
3. Changes in fair value of other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
other investments in equity instruments 4. Changes in fair value of enterprises' own credit risks				
instruments 4. Changes in fair value of enterprises' own credit risks	•			
4. Changes in fair value of enterprises' own credit risks	other investments in equity			
enterprises' own credit risks	instruments			
enterprises' own credit risks	4. Changes in fair value of			
	•			
	(II) Other comprehensive income			

that will be reclassified to profit or		
loss		
1. Other comprehensive income		
that will be reclassified to profit or		
loss under the equity method		
2. Changes in fair value of other		
debt investments		
3. Amounts of financial assets		
reclassified into other comprehensive		
income		
4. Provision for credit impairment		
of other debt investments		
5. Reserve for cash flow hedges		
6. Translation differences of		
financial statements denominated in		
foreign currencies		
7. Others		
VI. Total comprehensive income	169,286,992.40	177,538,946.16
VII. Earnings per share:		
(I) Basic earnings per share		
(RMB/share)	 	
(II) Diluted earnings per share		_
(RMB/share)	 	

Person in charge of the Company: HOU Juncheng Chief Financial Officer: WANG Li Head of the Accounting Organization: WANG Li

Consolidated Cash Flow Statement

January to June 2021

Item	Note	First half of 2021	First half of 2020
I. Cash flows from operating			
activities:			
Cash receipts from the sale of		2,222,119,171.48	1,482,166,082.91
goods and the rendering of			
services			
Net increase in customer			
deposits and deposits from banks			
and other financial institutions			
Net increase in loans from			
the central bank			
Net increase in taking from			
other financial institutions			
Cash payments for claims			
and policyholders' benefits under			
direct insurance contracts			
Net cash receipts from			
reinsurance business			
Net cash receipts from			
policyholders' deposits and			
investment contract liabilities			

Cash receipts from interest,			
fees and commissions			
Net increase in taking from			
banks and other financial			
institutions			
Net increase in financial			
assets sold under repurchase			
arrangements			
Net cash received from			
securities trading agency			
Receipts of tax refunds		8,644,521.51	3,862,697.97
Other cash receipts relating	VII.78 (1)	41,759,657.98	27,345,841.54
to operating activities	. ,		
Sub-total of cash inflows from		2,272,523,350.97	1,513,374,622.42
operating activities			• • •
Cash payments for goods		715,847,620.70	644,518,449.15
purchased and services received			, , , , , , , , , , , , , , , , , , , ,
Net increase in loans and			
advances to customers			
Net increase in balance with			
the central bank and due from			
banks and other financial			
institution			
Cash payments for claims	1		
and policyholders' benefits under			
direct insurance contracts			
Net increase in placements			
with banks and other financial			
institutions			
Cash payments for interest,			
fees and commissions			
Cash payments for insurance	+		
1 2			
policyholder dividends		227 264 212 77	195 540 020 74
Cash payments to and on		237,264,313.77	185,549,039.74
behalf of employees		200 417 014 07	170 (71 042 07
Payments of various types of		208,417,814.87	179,671,843.97
taxes	THE 50 (2)	044.010.022.01	465.050.010.60
Other cash payments relating	VII.78 (2)	844,818,022.81	467,070,910.68
to operating activities			
Sub-total of cash outflows from		2,006,347,772.15	1,476,810,243.54
operating activities			
Net cash flow from operating		266,175,578.82	36,564,378.88
activities			
II. Cash flows from investing			
activities:			
Cash receipts from disposals			211,450,000.00
and recovery of investments			
Cash receipts from			4,145,309.14
investment income			
Net cash receipts from		1,000.00	
disposals of fixed assets,			
intangible assets and other			
long-term assets			
Net cash receipts from			
disposals of subsidiaries and other			
business entities			
F-			

Other 2-1 1 /	1	T T	
Other cash receipts relating			
to investing activities Sub-total of cash inflows from		1,000.00	215,595,309.14
investing activities		1,000.00	215,595,309.14
Cash payments to acquire or		98,334,802.52	42,817,591.52
construct fixed assets, intangible		96,334,602.32	42,017,391.32
assets and other long-term assets			
Cash payments to acquire		31,206,800.00	66,580,000.00
investments		31,200,800.00	00,300,000.00
Net increase in pledged loans			
receivables			
Net cash payments for			
acquisitions of subsidiaries and			
other business units			
Other cash payments relating	VII.78 (4)	61,087,857.19	1,579,710.89
to investing activities.			
Sub-total of cash outflows from		190,629,459.71	110,977,302.41
investing activities		46	
Net cash flow from investing		-190,628,459.71	104,618,006.73
activities			
III. Cash flows from financing			
activities:			
Cash receipts from capital		450,000.00	976,300.00
contributions			
Including: cash receipts from		450,000.00	976,300.00
capital contributions from			
minority owners of subsidiaries			
Cash receipts from		200,000,000.00	299,000,000.00
borrowings			
Other cash receipts relating			
to financing activities			
Sub-total of cash inflows from		200,450,000.00	299,976,300.00
financing activities			
Cash repayments of		299,000,000.00	212,186,065.10
borrowings			
Cash payments for		149,594,422.10	118,930,785.34
distribution of dividends or profits			
or settlement of interest expenses			
Including: payments for			
distribution of dividends or profits			
to minority owners of subsidiaries	VIII 70 (6)	406 621 52	
Other cash payments relating	VII.78 (6)	486,631.52	
to financing activities		440.001.072.62	221 117 050 44
Sub-total of cash outflows from		449,081,053.62	331,116,850.44
financing activities		249 (21 052 (2	21 140 550 44
Net cash flow from financing		-248,631,053.62	-31,140,550.44
activities		206.505.24	1 120 210 22
IV. Impact of foreign exchange		-396,595.34	-1,139,318.32
rate changes on cash and cash			
equivalents V. Net increase in cash and cash		172 490 500 95	100 000 516 05
v. Net increase in cash and cash equivalents		-173,480,529.85	108,902,516.85
Add: Opening balance of		1,401,850,754.88	1,099,092,785.07
cash and cash equivalents		1,401,030,/34.88	1,077,074,783.07
VI. Closing balance of cash and		1,228,370,225.03	1,207,995,301.92
cash equivalents		1,220,370,223.03	1,201,775,501.72
cash equivalents	1		

Person in charge of the Company: HOU Juncheng Chief Financial Officer: WANG Li Head of the Accounting Organization: WANG Li

Cash Flow Statement of the Parent Company

January to June, 2021

Item	Note	First half of 2021	First half of 2020
I. Cash flows from operating			
activities:			
Cash receipts from the sale		1,080,660,581.18	1,077,057,503.42
of goods and the rendering of			
services			
Receipts of tax refunds		2,938,756.09	3,677,812.11
Other cash receipts relating		68,370,736.09	34,759,684.89
to operating activities			
Sub-total of cash inflows from		1,151,970,073.36	1,115,495,000.42
operating activities			
Cash payments for goods		553,972,561.93	436,078,293.13
purchased and services received			
Cash payments to and on		94,985,032.15	64,111,165.24
behalf of employees			
Payments of various types		88,642,861.24	119,952,712.41
of taxes			
Other cash payments		172,843,455.28	368,745,462.06
relating to operating activities			
Sub-total of cash outflows from		910,443,910.60	988,887,632.84
operating activities			
Net cash flow from operating		241,526,162.76	126,607,367.58
activities			
II. Cash flows from investing			
activities:			
Cash receipts from disposals		506,383.08	210,000,000.00
and recovery of investments			
Cash receipts from			4,145,309.14
investment income			
Net cash receipts from			
disposals of fixed assets,			
intangible assets and other			
long-term assets			
Net cash receipts from			
disposals of subsidiaries and			
other business entities			
Other cash receipts relating			
to investing activities			
Sub-total of cash inflows from		506,383.08	214,145,309.14
investing activities			
Cash payments to acquire or		92,347,046.32	42,775,628.79
construct fixed assets, intangible			
assets and other long-term assets			
Cash payments to acquire		32,256,800.00	68,130,000.00
investments			
Net cash payments for	67 / 195		

acquisitions of subsidiaries and		
other business units		
Other cash payments		
relating to investing activities.		
Sub-total of cash outflows from	124,603,846.32	110,905,628.79
investing activities		, ,
Net cash flow from investing	-124,097,463.24	103,239,680.35
activities		
III. Cash flows from financing		
activities:		
Cash receipts from capital		
contributions		
Cash receipts from	200,000,000.00	200,000,000.00
borrowings		
Other cash receipts relating		
to financing activities		
Sub-total of cash inflows from	200,000,000.00	200,000,000.00
financing activities		
Cash repayments of	200,000,000.00	85,130,289.87
borrowings		
Cash payments for	148,641,547.10	117,856,762.75
distribution of dividends or		
profits or settlement of interest		
expenses		
Other cash payments		
relating to financing activities	240 641 547 10	202.007.052.62
Sub-total of cash outflows from	348,641,547.10	202,987,052.62
financing activities	140 641 547 10	2.007.052.62
Net cash flow from financing	-148,641,547.10	-2,987,052.62
activities		
IV. Impact of foreign exchange		
rate changes on cash and cash equivalents		
V. Net increase in cash and	-31,212,847.58	226,859,995.31
cash equivalents	-31,212,047.38	440,039,993.31
Add: Opening balance of	484,019,222.50	255,868,964.43
cash and cash equivalents	404,017,222.30	233,000,704.43
VI. Closing balance of cash and	452,806,374.92	482,728,959.74
cash equivalents	132,000,374.72	102,720,737.77
cash equitatents		

Person in charge of the Company: HOU Juncheng Chief Financial Officer: WANG Li Head of the Accounting Organization: WANG Li

Consolidated Statement of Changes in Owners' Equity January to June, 2021

	First half of 2021														
	Equity attributable to owners of the parent company														
Item	Paid-in capital	Other e	quity instrun	nents		Less:	Other			General				Minority	Total owners'
	(or share capital)	Preferred stock	Perpetual bonds	Others	Capital reserve	Treasury shares	comprehensive income	Special reserve	Surplus reserve	risk reserve	Retained profit	Others	Sub-total	interests	equity
I. Closing balance of the preceding year	201,116 ,925.00				837,03 4,836.6 9	12,653,90 5.25	-269,066.13		100,634 ,780.00		1,265,671 ,865.63		2,391,535 ,435.94	90,326,8 30.19	2,481,8 62,266.
Add: Changes in accounting policies															
Corrections of prior period errors															
Business combination involving enterprises under common															
Others															
II. Opening balance of the current year	201,116 ,925.00				837,03 4,836.6 9	12,653,90 5.25	-269,066.13		100,634 ,780.00		1,265,671 ,865.63		2,391,535 ,435.94	90,326,8 30.19	2,481,8 62,266. 13
III. Changes for the period (decrease is indicated by "-")					3,997,3 13.48	-5,291,97 1.65	-396,595.34				81,297,12 7.86		90,189,81 7.65	-79,685,4 45.01	10,504, 372.64
(I) Total							-396,595.34				226,101,3		225,704,7	-17,451,8	208,252

Income			Ι			I	I	1	13.86	18.52	20.47	909.05
III) Owners' contributions and reduction in capital 1.65 2.262.1 5.291.97 1.65 2.262.1 5.291.97 700,000. 8.254.0 90.56 1.65 1.6	comprehensive								13.86	18.52	20.47	,898.05
Contributions and reduction 18.91 1.65												
Indication 18.91 1.65				2 262 1	5 201 07					7.554.000	700,000	0.254.0
In capital												
1. Common stock				18.91	1.65					.56	00	90.56
Stock contributed by covering S,291,971 700,000 S,991,90												
Contributed by cowners 1.65					5 201 05						7 00 000	5 001 0
Downers Capital Contribution												5,991,9
2. Capital contribution from holders of other equity instruments 3. Share-based payment recognized in where 'equity 18.91 2.262,1 2.262,118 91 18.91 2.262,1 18.91 2.262,1 18.91 2.262,1 18.91 2.262,1					1.65					.65	00	71.65
Contribution From holders From												
From holders Sanare-based Sana	2. Capital											
Some continuents Some contin												
Instruments												
3. Share-based payment 2,262,1 2,262,1 2,262,1 18.91 2,262,1 2,2												
Payment recognized in recogn												
18.91 18.9												
Owners' equity 4. Others -144,804, -144,804, -144,804, -144,804, -144,800 -186,0	payment			2,262,1								
4. Others	recognized in			18.91						.91		18.91
CIII) Profit distribution	owners' equity											
Comparison Com	4. Others											
distribution	(III) Profit								-144 804	-144 804		
1. Transfer to surplus reserve 2. Transfer to general risk reserve 3. Distributions to owners (or shareholders) 4. Others (IV) Transfers within owners' equity 1. Capitalization of capital reserve												
Surplus reserve									100.00	100.00		0
2. Transfer to general risk reserve												
general risk reserve	surplus reserve											
Teserve												
3. Distributions to owners (or shareholders)												
Distributions to owners (or shareholders)												
Distributions												144.80
to owners (or shareholders) 4. Others (IV) Transfers within owners' equity 1. Capitalization of capital reserve												
shareholders) 4. Others (IV) Transfers within owners' equity 1. Capitalization of capital reserve									186.00	186.00		
(IV) Transfers within owners' equity 1. Capitalization of capital reserve												U
within owners' equity 1. Capitalization of capital reserve	4. Others											
within owners' equity 1. Capitalization of capital reserve	(IV) Transfers											
1. Capitalization of capital reserve	within owners'											
1. Capitalization of capital reserve	equity											
Capitalization of capital reserve	1.											
of capital reserve												
reserve	of capital											
	2.											

	,									
Capitalization										
of surplus										
reserve										
3. Loss offset										
by surplus										
reserve										
4. Retained										
earnings										
carried										
forward from										
changes in										
defined benefit										
plans										
5. Retained										
earnings										
carried										
forward from										
other										
comprehensive										
income										
6. Others										
(V) Special										
reserve										
 Transfer to 										
special reserve										
in the current										
period										
2. Amount										
utilized in the										
current period										
			1,735,1					1,735,194	-62,933,6	-61,198,
(VI) Others			94.57					.57	-02,933,0 24.54	429.97
THE CIL.								.57	24.34	
VI. Closing	201,116		841,03	7,361,933		100,634	1,346,968	2,481,725	10,641,3	2,492,3
balance of the	,925.00		2,150.1	.60	-665,661.47	,780.00	,993.49	,253.59	85.18	66,638.
current period	,,,23.00		7	.50		,,,,,,,,	,,,,,,,,	,233.37	05.10	77

	Fig. 4 - 16 - 6 2020
Item	
	THIST HAIT OF 2020

	Equity attributable to owners of the parent company														
	Paid-in Other equity instruments				Less:	Other			General				Minority	Total owners'	
	(or share capital)	Preferred stock	Perpetual bonds	Others	Capital reserve	Treasury shares	comprehensive income	Special reserve	Surplus reserve	risk reserve	Retained profit	Others	Sub-total	interests	equity
I. Closing balance of the preceding year	201,26 9,560.0 0				835,35 3,615.4 8	15,769,05 1.20	-212,628.22		100,634 ,780.00		908,411,6 07.62		2,029,687 ,883.68	40,370,1 59.89	2,070,0 58,043. 57
Add: Changes in accounting policies															
Corrections of prior period errors															
Business combination involving															
enterprises under common control Others															
II. Opening balance of the current year	201,26 9,560.0 0				835,35 3,615.4 8	15,769,05 1.20	-212,628.22		100,634 ,780.00		908,411,6 07.62		2,029,687 ,883.68	40,370,1 59.89	2,070,0 58,043. 57
III. Changes for the period (decrease is indicated by "-")					13,104, 738.35		-136,681.49				60,017,98 0.36		72,986,03 7.22	-4,857,9 70.57	68,128, 066.65
(I) Total comprehensive income							-136,681.49				178,767,0 20.76		178,630,3 39.27	-5,082,6 17.50	173,547 ,721.77
(II) Owners' contributions and reduction in capital					5,103,3 64.67								5,103,364 .67		5,103,3 64.67
1. Common stock															

contributed by										
owners										
2. Capital										
contribution										
from holders of										
other equity										
instruments										
3. Share-based										
payment				5, 103,					5, 103, 36	5, 103,
recognized in				364. 67					4. 67	364. 67
owners' equity										
4. Others										
							-118,749,		-118,749,	-118,74
(III) Profit							040.40		040.40	9,040.4
distribution										0
1. Transfer to										
surplus reserve										
2. Transfer to										
general risk										
reserve										
3. Distributions							-118,749,		-118,749,	-118,74
to owners (or							040.40		040.40	9,040.4
shareholders)							0.00		0.00	0
4. Others										
(IV) Transfers										
within owners'										
equity										
1.										
Capitalization										
of capital										
reserve										
2.										
Capitalization										
of surplus										
reserve										
3. Loss offset	 									
by surplus										
reserve										
4. Retained										
earnings										
carried forward										
carried forward			l			<u> </u>		Ì		

from changes										 -
in defined										
benefit plans										
5. Retained										
earnings										1
carried forward										1
from other										1
comprehensive										1
income										
6. Others										
(V) Special										
reserve										
1. Transfer to										
special reserve										I
in the current										1
period										
2. Amount										1
utilized in the										I
current period										<u> </u>
(VI) Others			8,001,3					8,001,373	224,646.	8,226,0
• •			73.68					.68	93	20.61
VI. Closing	201,26		848,45	15,769,05	-349,309.71	100,634	968,429,5	2,102,673	35,512,1	2,138,1
balance of the	9,560.0		8,353.8	1.20		,780.00	87.98	,920.90	89.32	86,110.
current period	0		3							22

Person in charge of the Company: HOU Juncheng Chief Financial Officer: WANG Li Head of the Accounting Organization: WANG Li

Statement of Changes in Owners Equity of the Parent Company

January to June, 2021

Unit: Yuan Currency: RMB

		First half of 2021										
Item	Paid-in	Othe	r equity instrui	nents	Capital	Less:	Other	Special	Surplus	Retained	Total	
110111	capital (or share	Preferred	Perpetual	Others	reserve	Treasury	comprehensive	reserve	reserve	profit	owners' equity	
	Simi	stock	bonds			shares	ıncome				equity	

	capital)					
I. Closing balance of the	201,116,92	837,075,42	12,653,905	100,634,7	1,134,989,	2,261,163,
preceding year	5.00	5.32	.25	80.00	843.29	068.36
Add: Changes in accounting						
policies						
Corrections of prior period						
errors						
Others						
II. Opening balance of the	201,116,92	837,075,42	12,653,905	100,634,7	1,134,989,	2,261,163,
current year	5.00	5.32	.25	80.00	843.29	068.36
III. Changes for the period		021 520 20	-5,291,971.		24,482,80	30,706,317
(decrease is indicated by "-")		931,539.28	65		6.40	.33
(I) Total comprehensive					169,286,9	169,286,99
income					92.40	2.40
(II) Owners' contributions and		707,296.73	-5,291,971.			5,999,268.
reduction in capital		707,296.73	65			38
1. Common stock contributed			-5,291,971.			5,291,971.
by owners			65			65
2. Capital contribution from						
holders of other equity						
instruments						
3. Share-based payment		707,296.73				707,296.73
recognized in owners' equity		707,270.73				707,270.73
4. Others						
(III) Profit distribution					-144,804,1 86.00	-144,804,1 86.00
1. Transfer to surplus reserve						
2. Distributions to owners (or shareholders)					-144,804,1 86.00	-144,804,1 86.00
3. Others						
(IV) Transfers within owners'						
equity						
Capitalization of capital						
reserve						
2. Capitalization of surplus						
reserve						
3. Loss offset by surplus						
reserve						
4. Retained earnings carried						
forward from changes in						

defined benefit plans								
5. Retained earnings carried								
forward from other								
comprehensive income								
6. Others								
(V) Special reserve								
1. Transfer to special reserve								
in the current period								
2. Amount utilized in the								
current period								
(VI) Others			224,242.55					224,242.55
VI. Closing balance of the	201,116,92		838,006,96	7,361,933.		100,634,7	1,159,472,	2,291,869,
current period	5.00		4.60	60		80.00	649.69	385.69

					st Half of 2020)20						
Item	Paid-in capital (or	Othe	Other equity instruments		- Capital	Less:	Other	Special	Surplus	Retained	Total	
	share capital)	Preferred stock	Perpetual bonds	Others	reserve	Treasury shares	comprehensive income	reserve	reserve	profit	owners' equity	
I. Closing balance of the	201,269,56				834,592,13	15,769,051			100,634,	778,293,3	1,899,020,	
preceding year	0.00				3.74	.20			780.00	40.18	762.72	
Add: Changes in accounting policies												
Corrections of prior period												
errors												
Others												
II. Opening balance of the	201,269,56				834,592,13	15,769,051			100,634,	778,293,3	1,899,020,	
current year	0.00				3.74	.20			780.00	40.18	762.72	
III. Changes for the period					16,147,546					58,789,90	74,937,451	
(decrease is indicated by "-")					.14					5.76	.90	
(I) Total comprehensive										177,538,9	177,538,94	
income										46.16	6.16	
(II) Owners' contributions					5,103,364.						5,103,364.	
and reduction in capital					67						67	
1. Common stock contributed												
by owners												

2. Capital contribution from	<u> </u>	<u> </u>			I			<u> </u>	1
holders of other equity									
instruments									
3. Share-based payment			5,103,364.						5,103,364.
recognized in owners' equity			5,105,504.						67
4. Others			07						07
4. Others								-118,749,0	-118,749,0
(III) Profit distribution								40.40	40.40
1. Transfer to surplus reserve									
2. Distributions to owners (or								-118,749,0	-118,749,0
shareholders) 3. Others								40.40	40.40
(IV) Transfers within owners' equity									
1. Capitalization of capital									
reserve									
2. Capitalization of surplus									
reserve									
3. Loss offset by surplus									
reserve									
4. Retained earnings carried									
forward from changes in									
defined benefit plans									
5. Retained earnings carried									
forward from other									
comprehensive income									
6. Others									
(V) Special reserve									
1. Transfer to special reserve									
in the current period									
2. Amount utilized in the									
current period									
(VI) Others			11,044,181 .47						11,044,181
VI. Closing balance of the	201,269,56		850,739,67	15,769,051			100,634,	837,083,2	1,973,958,
current period	0.00		9.88	.20			780.00	45.94	214.62
Г	5.50	1	2.00	0	l	·			· · · · -

III. Basic Information of the Company

1. Company profile

 $\sqrt{\text{Applicable}} \square \text{N/A}$

Proya Cosmetics Co., Ltd. (the "Company"), formerly known as Proya (Huzhou) Cosmetics Co., Ltd., was registered in Wuxing Branch of Huzhou Municipal Administration for Industry and Commerce on May 24, 2006. Headquartered in Hangzhou, Zhejiang Province, the Company now holds its business license with the Unified Social Credit Code being 91330100789665033F, having its current registered capital amounting to RMB201.1169 million, and 201,116,925 shares (par value of RMB1 per share) in aggregate, comprising 454,160 A shares as restricted outstanding shares, and 200,662,765 A shares as unrestricted outstanding shares, which were listed for trading on SSE on November 15, 2017.

The Company is in the industry of Cosmetics stores, primarily engaged in R&D, production and sales of cosmetics, the main products:. Cosmetics.

The financial statements herein have been approved for disclosure by the 20th meeting of the second Board of Directors on August 24, 2021.

2. Scope of consolidated financial statements

 $\sqrt{\text{Applicable}} \square \text{N/A}$

42 subsidiaries including Hangzhou Proya Trade Co., Ltd., Hanya (Huzhou) Cosmetics Co., Ltd., Zhejiang Meili Valley E-commerce Co., Ltd., Huzhou Chuangdai E-commerce Co., Ltd., Leqing Laiya Trading Co., Ltd. and Hapsode (Hangzhou) Cosmetics Co., Ltd. have been included by the Company into the scope of consolidated financial statements in the Reporting Period. For details, please refer to the descriptions of VIII "Changes in the Consolidation Scope" and IX "Interests in Other Entities" in Section X Financial Report hereof.

IV. Basis of Preparation of Financial Statements

1. Basis of preparation

The Company's financial statements are prepared on a going-concern basis.

2. Going concern

 $\sqrt{\text{Applicable}} \square \text{N/A}$

The Company has involved in no events or circumstances that may cast significant doubt upon its ability to continue as a going concern within 12 months from the end of the Reporting Period.

V. Significant Accounting Policies and Accounting Estimates

L	Prompte of	n snecific	accounting	norn∩li	cies and	accounting	ectimates
1	Tompts of	и эрссиис	accounting	ng pon	cics and	accounting	cstilliates.

 $\sqrt{\text{Applicable}} \square \text{N/A}$

Please refer to "44. Changes in significant accounting policies and accounting estimates" in "V. Significant Accounting Policies and Accounting Estimates" in "Section X Financial Report" hereof.

1. Statement of compliance with the Accounting Standards for Business Enterprises

The financial statements prepared by the Company comply with the requirements of the Accounting Standards for Business Enterprises, truly and completely reflecting the Company's financial position, operating results, and cash flows, among others.

2. Accounting period

The accounting year of the Company commences from January 1 and ends on December 31 in each calendar year.

3. Operating cycle

 $\sqrt{\text{Applicable}} \square \text{N/A}$

The Company has a relatively short operating cycle, and determines the liquidity of assets and liabilities on the basis of 12 months.

4. Functional currency

The Company adopts RMB as its functional currency.

5. Accounting treatment of business combinations involving enterprises under common control and business combinations involving enterprises not under common control

 $\sqrt{\text{Applicable}} \square \text{N/A}$

1. Accounting treatment of business combinations involving entities under common control

Assets and liabilities that are obtained by the Company in a business combination shall be measured at their carrying amounts in the consolidated financial statements of the ultimate controller at the combination date as recorded by the acquiree. The difference between the carrying amount of the owners' equity of the acquiree as stated in the consolidated financial statements of the ultimate controller and the carrying amount of the total consideration paid or total par value of the shares issued in connection with the combination is treated as an adjustment to the capital reserve. In case the capital reserve is insufficient to absorb the difference, the remaining balance is adjusted against the retained earnings.

2. Accounting treatment of business combinations involving entities not under common control

Where the cost of the combination exceeds the Company's share of the fair value of the acquiree's identifiable net assets, the difference is recognized as goodwill on the date of acquisition. Where the cost of combination is lower than the Company's share of the fair value of the acquiree's identifiable net

assets, the Company reviews the measurement of the fair value of each of the identifiable assets, liabilities and contingent liabilities acquired from the acquiree and the cost of combination, and if the cost of combination as reviewed is still lower than the Company's share of the fair value of the acquiree's identifiable net assets, the difference is recognized in profit or loss for the current period.

6. Method for preparation of financial statements

 $\sqrt{\text{Applicable}} \square \text{N/A}$

The parent company includes all of its controlled subsidiaries in its consolidated financial statements. The consolidated financial statements are prepared by the parent company in accordance with the *Accounting Standards for Business Enterprises No. 33 - Consolidated Financial Statements*, on the basis of the respective financial statements of the parent company and its subsidiaries, by reference to other relevant data.

7. Classification of joint arrangements and accounting treatment of joint operations

 $\sqrt{\text{Applicable}} \square \text{N/A}$

- 1. Joint arrangements are classified into joint operations and joint ventures.
- 2. When the Company is a party to a joint operation, it recognizes the following items relating to its interest in the joint operation:
- (1) The assets individually held by the Company, and the Company's share of the assets held jointly;
- (2) The liabilities incurred individually by the Company, and the Company's share of the liabilities incurred jointly;
 - (3) The Company's revenue from the sale of its share of output of the joint operation;
 - (4) The Company's share of revenue from the sale of assets by the joint operation; and
- (5) The expenses incurred individually by the Company, and the Company's share of the expenses incurred jointly.

8. Recognition of cash and cash equivalents

The cash listed in the cash flow statement refers to the cash on hand and deposits that are available for payment at any time. The cash equivalents refer to the short-term and highly liquid investments held by the enterprise that are readily convertible to known amounts of cash and subject to an insignificant risk of changes in value.

9. Foreign currency transactions and translation of foreign currency financial statements

 $\sqrt{\text{Applicable}} \square \text{N/A}$

1. Translation of foreign currency transactions

Upon initial recognition, foreign currency transactions are translated into RMB at the approximate rate of spot rate on the transaction dates. On the balance sheet date, monetary items denominated in foreign currencies are translated into RMB using the spot exchange rates on the balance sheet date. Exchange differences arising from such translations are recognized in profit or loss for the current period, except for those attributable to foreign currency borrowings that have been taken out specifically for the acquisition or construction of qualifying assets and accrued interest. Non-monetary items denominated in foreign currencies that are measured at historical cost are translated at the approximate rate of spot rate on the transaction dates, without adjusting the amounts in RMB. Non-monetary items denominated in foreign currencies that are measured at fair value are translated using the foreign exchange rates prevailing on the dates the fair value was determined, and exchange differences arising from such translations are recognized in profit or loss for the current period or other comprehensive income.

2. Translation of foreign currency financial statements

The asset and liability items in the balance sheet are translated at the spot exchange rates on the balance sheet date. The owners' equity items other than "retained profits" are translated at the spot exchange rates on the transaction dates. The income and expense items in the income statements are translated at the approximate spot exchange rates on the transaction dates. Exchange differences arising from such translations are recognized in other comprehensive income.

10. Financial instruments

 $\sqrt{\text{Applicable}} \square \text{N/A}$

1. Classification of financial assets and financial liabilities

Upon initial recognition, financial assets are classified into: (1) financial assets at amortized cost; (2) financial assets at fair value through other comprehensive income; and (3) financial assets at fair value through profit or loss.

Upon initial recognition, financial liabilities are classified into: (1) financial liabilities at fair value through profit or loss; (2) financial liabilities arising from the transfer of financial assets not meeting the criteria for derecognition or continuing involvement in the financial assets transferred; (3) financial guarantee contracts not falling under items (1) and (2), and loan commitments not falling under item (1) at interest rate below the market level; and (4) financial liabilities at amortized cost.

- 2. Recognition, measurement and derecognition of financial assets and financial liabilities
- (1) Recognition and initial measurement of financial assets and financial liabilities

When the Company becomes a party to a financial instrument contract, a financial asset or liability is recognized. Financial assets and liabilities are initially measured at fair value. Transaction costs relating to financial assets or liabilities at fair value through profit or loss are directly recognized in profit or loss for the current period. Transaction costs relating to other kinds of financial assets or liabilities are included in their initially recognized amount. However, where the accounts that do not contain any significant financing component or are recognized by the Company without taking into consideration the significant financing components under the contracts with a term of less than one year

upon initial recognition are initially measured at transaction price defined in the *Accounting Standard for Business Enterprises No. 14*—*Revenue*.

- (2) Subsequent measurement of financial assets
- 1) Financial assets at amortized cost

Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest method. Gains or losses on financial assets at amortized cost that do not belong to any hedging relationship are recognized in profit or loss for the current period upon derecognition, reclassification, amortization using the effective interest method or recognition of impairment.

2)Investments in debt instruments at fair value through other comprehensive income

Investments in debt instruments at fair value through other comprehensive income are subsequently measured at fair value. Interest, impairment losses or gains and exchange gains or losses calculated using the effective interest method are recognized in profit or loss for the current period, and other gains or losses are recognized in other comprehensive income. On derecognition, the cumulative gain or loss previously included in other comprehensive income is removed out from other comprehensive income and included in profit or loss for the current period.

3)Investments in equity instruments at fair value through other comprehensive income

Investments in debt instruments at fair value through other comprehensive income are subsequently measured at fair value. Dividends received (other than those received as recovery of investment cost) are recognized in profit or loss for the current period, and other gains or losses are recognized in other comprehensive income. On derecognition, the cumulative gain or loss previously included in other comprehensive income is removed out from other comprehensive income and included in retained earnings.

4) Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are subsequently measured at fair value. Gains or losses thereon, including interest and dividend income, are recognized in profit or loss for the current period, except the financial assets belonging to any hedging relationship.

- (3) Subsequent measurement of financial liabilities
- 1) Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading (including derivatives classified as financial liabilities), and financial liabilities derectly designated as at fair value through profit or loss. Such financial liabilities are subsequently measured at fair value. Changes in the fair value of financial liabilities designated as at fair value through profit or loss arising out of changes in the Company's credit risk are recognized in other comprehensive income, unless such treatment will result in or increase any accounting mismatch in profit or loss. Other gains or losses on such financial liabilities, including interest expenses and changes in fair value not arising out of changes in the Company's credit risk, are recognized in profit or loss for the current period, except the financial liabilities belonging to any hedging relationship. Upon derecognition, the aggregate gains or losses previously recognized in other comprehensive income are transferred to retained earnings.

2)Financial liabilities arising as a result of the transfer of financial assets not meeting the criteria for derecognition or continuing involvement in the financial assets transferred

Such financial liabilities are measured in accordance with the *Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets*.

3) Financial guarantee contracts not falling under items 1) and 2) above, and loan commitments not falling under item 1) above at below-market interest rate

Such financial liabilities are subsequently measured at the higher of ① provision for impairment losses determined according to the policy for impairment of financial instruments; and ② balance of the initially recognized amount after deduction of the accumulated amortization determined in accordance with *Accounting Standard for Business Enterprises No. 14 - Revenue*.

4) Financial liabilities at amortized cost

Such financial liabilities are measured at amortized cost using the effective interest method. Gains or losses on financial liabilities at amortized cost that do not belong to any hedging relationship are recognized in profit or loss for the current period upon derecognition or amortization using the effective interest method.

- (4) Derecognition of financial assets and financial liabilities
- 1)Financial assets are derecognized when:
- 1) The contractual right to receive cash flows from the financial assets has expired; or
- ② The financial assets have been transferred and such transfer meets the criteria for derecognition of financial assets as set forth in the *Accounting Standards for Business Enterprises No. 23 Transfer of Financial Assets*.
- 2) A financial liability (or part thereof) is derecognized when all or part of the outstanding obligations thereon have been discharged.
 - 3. Determination and measurement of financial assets transferred

When a financial asset of the Company is transferred, if substantially all the risks and rewards incidental to the ownership of the financial asset have been transferred, the financial asset is derecognized, and the rights and obligations incurred or retained in such transfer are separately recognized as assets or liabilities. If the Company retains substantially all the risks and rewards of ownership of a financial asset, the Company shall not derecognize the financial asset. If the Company neither transferred nor retained a substantial portion of all risks and rewards incidental to the ownership of the financial asset, then: (1) if the Company does not retain control over the financial asset, the financial asset is derecognized, and the rights and obligations incurred or retained in such transfer are separately recognized as assets or liabilities; and (2) if the Company retains control over the financial asset, the financial asset continues to be recognized to the extent of the Company's continuing involvement in the financial asset transferred, and a corresponding liability is recognized.

If an entire transfer of a financial asset meets the criteria for derecognition, the difference between (1) the carrying amount of the financial asset transferred on the date of derecognition; and (2) the sum of the consideration received from the transfer and the portion of the cumulative amount of changes in fair

value directly recorded as other comprehensive income originally that corresponds to the part derecognized (where the financial asset transferred is an investment in debt instruments at fair value through other comprehensive income) is recognized in profit or loss for the current period. If part of a financial asset is transferred and the part transferred entirely meets the criteria for derecognition, the total carrying amount of the financial asset immediately prior to the transfer is allocated between the part derecognized and the part not derecognized in proportion to their relative fair value on the date of transfer, and the difference between (1) the carrying amount of the part derecognized and (2) the sum of the consideration received from the transfer of the part derecognized and the portion of the cumulative amount of changes in fair value directly recorded as other comprehensive income originally that corresponds to the part derecognized (where the financial asset transferred is an investment in debt instruments at fair value through other comprehensive income) is recognized in profit or loss for the current period.

4. Determination of fair value of financial assets and financial liabilities

The Company adopts the valuation techniques applicable to the current situations and with sufficient data available and support of other information to determine the fair value of financial assets and financial liabilities. The Company classifies the inputs used by the valuation techniques in the following levels and uses them in turn:

- (1) Level 1 inputs: quoted market price (unadjusted) in an active market for an identical asset or liability available on the date of measurement;
- (2) Level 2 inputs: inputs other than those included within Level 1 that are observable directly or indirectly, including quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, observable inputs other than quoted prices (such as interest rate and yield curves observable during regular intervals of quotation), and inputs validated by the market;
- (3) Level 3 inputs: inputs that are unobservable, including interest rate or stock volatility that cannot be directly observed or validated by observable market data, future cash flows from retirement obligation incurred in business combinations, and financial forecasts made using own data.
 - 5. Impairment of financial instruments
 - (1) Measurement and accounting treatment of impairment of financial instruments

The Company determines the impairment and assesses provision for impairment losses of financial assets at amortized cost, investments in debt instruments at fair value through other comprehensive income, lease receivable, loan commitments other than financial liabilities designated at fair value through profit or loss, and financial guarantee contracts other than financial liabilities designated at fair value through profit or loss and financial liabilities arising as a result of the transfer of financial assets not meeting the criteria for derecognition or continuing involvement in the financial assets transferred, on the basis of expected credit losses.

Expected credit loss is the weighted average of credit losses on financial instruments taking into account the possibility of default. Credit loss is the present value of the difference between all

contractual cash flows receivable under the contract and estimated future cash flows discounted at the original effective interest rate, i.e., the present value of all cash shortage, wherein the Company's purchased or originated financial assets that have become credit impaired are discounted at their credit-adjusted effective interest rate.

With respect to purchased or originated financial assets that have become credit impaired, on the balance sheet date, the Company recognizes a loss allowance equal to the cumulative amount of changes in lifetime expected credit losses since initial recognition.

With respect to accounts receivable and contract assets that arise from the transactions regulated under the *Accounting Standard for Business Enterprises No. 14 - Revenue* and do not contain any significant financing component or are recognized by the Company without taking into account the significant financing components under the contracts with a term of less than one year, the Company uses the simple measurement method and recognizes a loss allowance equal to the lifetime expected credit losses.

With respect to lease receivable, as well as accounts receivable and contract assets that arise from the transactions regulated under the *Accounting Standard for Business Enterprises No. 14 - Revenue* containing significant financing components, the Company uses the simple measurement method and recognizes a loss allowance equal to the lifetime expected credit losses.

With respect to financial assets not using the measurement methods stated above, on each balance sheet date, the Company assesses whether the credit risk has increased significantly since initial recognition, and recognizes a loss allowance equal to the lifetime expected credit losses if the credit risk has increased significantly since initial recognition, or to the expected credit losses within the next 12 months if the credit risk has not increased significantly since initial recognition.

The Company uses reasonable and supportable information, including forward-looking information, and compares the possibility of default on the balance sheet date with the possibility of default upon initial recognition, to determine whether the credit risk of the financial instruments has increased significantly since initial recognition.

On the balance sheet date, if the Company determines that a financial instrument has low credit risk, the Company assumes that its credit risk has not increased significantly since initial recognition.

The Company assesses expected credit risk and measures expected credit losses of financial instruments individually or by portfolio. When assessing the financial instruments by portfolio, the Company divides the financial instruments into different portfolio according to their common risk characteristics.

At each balance sheet date, the Company re-assesses the expected credit losses, with the amount of increase in or reversal of loss allowance recognized in profit or loss for the current period as impairment losses or gains. With respect to a financial asset at amortized cost, its carrying amount recorded in the balance sheet is written off against the loss allowance. With respect to an investment in debt instruments at fair value through other comprehensive income, the Company recognizes the loss allowance in other comprehensive income, without reducing its carrying amount.

6. Offsetting of financial assets and financial liabilities

Financial assets and financial liabilities are presented separately in the balance sheet and are not offset. However, a financial asset and a financial liability shall be offset, and the net amount presented in the balance sheet when both of the following conditions are satisfied: (1) the Company has a legal right to set off the recognized amounts and the legal right is currently enforceable; and (2) the Company intends either to settle on a net basis, or to realize the financial asset and settle the financial liability simultaneously.

In accounting for a transfer of a financial asset that does not qualify for derecognition, the Company do not offset the transferred financial asset and the associated liability.

11. Notes receivable

Determination and accounting treatment of expected credit losses for notes receivable

 \square Applicable $\sqrt{N/A}$

12. Accounts receivable

Determination and accounting treatment of expected credit losses for accounts receivable

- $\sqrt{\text{Applicable}} \square \text{N/A}$
- 1) Measurement of expected credit losses by portfolio: the expected credit losses are calculated by reference to historic credit loss experience, and preparation of the comparison table of the age of accounts receivable and rate of lifetime expected credit loss, taking into account the current situations and prediction of future economic conditions.
- 2) Accounts receivable comparison table of the age of accounts receivable and rate of lifetime expected credit loss

Aging	Accounts receivable
Aging	Rate of expected credit loss (%)
Within 1 year (inclusive, the same below)	5
1-2 years	30
2-3 years	50
More than 3 years	100

13. Receivables financing

 $\sqrt{\text{Applicable}} \square \text{N/A}$

Measurement of expected credit losses by portfolio: the expected credit losses are calculated according to the default risk exposure and rate of lifetime expected credit loss by reference to historic credit loss experience, and taking into account the current situations and prediction of future economic conditions.

14. Other receivables

Determination and accounting treatment of expected credit losses for other receivables

 $\sqrt{\text{Applicable}} \square \text{N/A}$

Evaluation of expected credit risks and measurement of expected credit losses by portfolio: the expected credit losses are calculated according to the default risk exposure and the expected credit loss rate of the period within the future 12 months or the lifetime by reference to historic credit loss experience, and taking into account the current situations and prediction of future economic conditions.

15. Inventories

 $\sqrt{\text{Applicable}} \square \text{N/A}$

1. Classification of inventories

Inventories include finished goods or merchandise held by the Company for sale in the ordinary course of business, or work in progress in the process of production for such sale, or materials or supplies to be consumed in the production process or in the rendering of services.

2. Pricing methods of inventories in transit

Inventories in transit are priced using the moving weighted average method.

3. Determination basis of net realizable value of inventories

On the balance sheet date, inventories are measured at the lower of cost and net realizable value, and the provision for decline in value of inventories is determined by the difference between the higher cost and the net realizable value of a single inventory. For inventories available for sales, in the ordinary production and operation process, their realizable net value is determined at the estimated selling price of these inventories less the estimated costs necessary to make the sale and relevant taxes; for the inventories that need to be processed, in the ordinary production and operation process, their realizable net value is determined at the estimated selling price of finished products less the estimated costs of completion and the estimated costs necessary to make the sale and relevant taxes. On the balance sheet date, where a part of an inventory is subject to the contract price agreement and other parts of the same inventory has no such agreement, their realizable net value is determined separately, and by comparing them with their corresponding cost, the amount made for or reversal of the provision for decline in value of inventories is determined separately.

4. Inventory systems for inventories

A perpetual inventory system is adopted for the inventories.

- 5. Amortization of low-value consumables and packing materials
- (1)Low-value consumables

The low-value consumables are amortized using immediate write-off method.

(2) Packing materials

The packing materials are amortized using immediate write-off method.

16. Contract assets

(1). Methods and standards for recognizing contract assets

 $\sqrt{\text{Applicable}} \square \text{N/A}$

The Company presents contract assets or liabilities in the balance sheet based on the relationship between performance obligations and customer payments. The Company shall set off the contract assets and contract liabilities under the same contract and present them on a net basis.

The Company presents its owned right to unconditionally (that is, only depending on the passage of time) receive consideration from customers as the accounts receivable, and the right to receive the consideration for which the goods that have been transferred to customers (that is, depending on factors other than the passage of time) as the contract assets.

(2). Determination and accounting treatment of expected credit losses for contract assets

 \square Applicable $\sqrt{N/A}$

17. Held-for-sale assets

 \square Applicable $\sqrt{N/A}$

18. Debt investments

Determination and accounting treatment of expected credit losses for debt investments

 \square Applicable $\sqrt{N/A}$

19. Other debt investments

Determination and accounting treatment of expected credit losses for other debt investments

 \square Applicable $\sqrt{N/A}$

20. Long-term receivables

Determination and accounting treatment of expected credit losses for long-term receivables

 \square Applicable $\sqrt{N/A}$

21. Long-term equity investments

 $\sqrt{\text{Applicable}} \square \text{N/A}$

1. Judgment criteria of joint control and significant influence

Joint control is the agreed sharing of control over an arrangement, and the relevant activities of such arrangement must be decided upon the unanimous consent of the parties sharing control. Significant influence is the power of the investing enterprise to participate in the financial and operating

policy decisions of an investee, but is not control or joint control with other parties over the establishment of those policies.

2.Determination of investment cost

(1) In case of an equity investment acquired through a business combination involving entities under common control, if the acquirer pays consideration for the business combination by cash, transfer of non-monetary assets, assumption of liabilities or issuance of equity securities, the initial investment cost of the long-term equity investment is the Company's share of the carrying amount of the owners' equity of the acquiree in the consolidated financial statements of the ultimate controller on the date of combination. The difference between the initial investment cost of the long-term equity investment and the carrying amount of the consideration paid for the combination or the total par value of the shares issued (as applicable) is treated as an adjustment to the capital reserve. In case the capital reserve is insufficient to absorb the difference, the remaining balance is adjusted against the retained earnings.

In case of a long-term equity investment acquired through a business combination involving entities under common control and through multiple transactions by steps, the Company judges whether they constitute a "package deal" or not. If they belong to a "package deal", the Company accounts for all transactions as one transaction to acquire control. If such transactions do not constitute a "package deal", the initial investment cost is the Company's post-combination share of the carrying amount of the owners' equity of the acquiree in the consolidated financial statements of the ultimate controller on the date of combination; The difference between the initial investment cost of the long-term equity investment on the date of combination and the sum of the carrying amount of long-term equity investment before the combination and the carrying amount of the consideration paid for acquisition of the additional shares on the date of combination is adjusted against the capital reserve. In case the capital reserve is insufficient to absorb the difference, the remaining balance is adjusted against the retained earnings.

(2) In case of an equity investment acquired through a business combination not involving enterprises under common control, the initial investment cost is the fair value of the carrying amount of the consideration paid for the combination on the date of acquisition.

With respect to a long-term equity investment acquired through a business combination not involving enterprises under common control that is achieved through multiple transactions by steps, the accounting treatment thereof in the separate financial statements is different from that in the consolidated financial statements as stated below:

- 1) In the separate financial statements, the initial investment cost for which the Company changes to the cost method is the sum of the carrying amount of the long-term equity investment originally held and the new investment cost.
- 2) In the consolidated financial statements, the Company judges whether the transactions constitute a "package deal" or not. If they belong to a "package deal", the Company accounts for all transactions as one transaction to acquire control. If such transactions do not constitute a "package deal", the Company re-measures the fair value of the equity held in the acquiree prior to the date of acquisition, and records

the difference between the fair value and the carrying amount as investment income for the current period; if the equity held in the acquiree prior to the date of acquisition involves other comprehensive income under equity method, such other comprehensive income is transferred to the income of the period in which the date of acquisition falls, except for other comprehensive income arising from re-measurement by the investee of changes in net liabilities or net assets of defined benefit plans.

- (3) In case of an equity investment not acquired through business combination, the initial investment cost is the purchase price actually paid if it is acquired by cash, or the fair value of the equity securities issued if it is acquired through issuance of equity securities, or is determined in accordance with the *Accounting Standards for Business Enterprises No. 12 Debt Restructuring* if it is acquired through debt restructuring, or in accordance with the *Accounting Standards for Business Enterprises No. 7 Exchange of Non-monetary Assets* if it is acquired through exchange of non-monetary assets.
 - 3. Subsequent measurement and recognition of profit of loss

Long-term equity investments in investees are measured using the cost method. Long-term equity investments in associates and joint ventures are measured using the equity method.

4. Disposal of investment in a subsidiary through multiple transactions by steps until loss of control over the subsidiary

(1) Separate financial statements

The difference between the carrying amount of the equity disposed of and the proceeds of disposal actually received is recognized in profit or loss for the current period. If the remaining equity empowers the Company to exercise significant influence or joint control over the investees, the remaining equity is accounted for using the equity method; if the remaining equity does not empower the Company to exercise control, joint control or significant influence over the investees, the remaining equity is accounted for in accordance with the *Accounting Standards for Business Enterprises No.* 22 - *Recognition and Measurement of Financial Instruments*.

(2)Consolidated financial statements

1)Disposal of investment in a subsidiary through multiple transactions by steps until loss of control over the subsidiary which do not constitute a "package deal"

Prior to the loss of control, the difference between the proceeds from disposal and the share owned by the Company in the net assets of the subsidiary in relation to the long-term equity investment disposed of that is calculated continuously from the date of acquisition or combination is adjusted against the capital reserve (capital premium). In case the capital premium is insufficient to absorb the difference, the remaining balance is adjusted against the retained earnings.

When losing control over an original subsidiary, the remaining equity is re-measured at its fair value on the date of loss of control. The sum of the consideration received from the disposal of the equity and the fair value of the remaining equity, net of the share owned by the Company in the net assets of the subsidiary in relation to the long-term equity investment disposed of as calculated continuously from the date of acquisition or combination according to the previous shareholding ratio, is recognized in the investment income for the period in which the control is lost, and the goodwill is

reduced accordingly. Other comprehensive income relating to the equity investment in the original subsidiary should be transferred to the investment income for the period in which the control is lost.

2)Disposal of investment in a subsidiary through multiple transactions by steps until loss of control over the subsidiary which constitute a "package deal"

The Company accounts for such transactions as one transaction to dispose of and lose its control over the subsidiary. However, the difference between the proceeds from each disposal before loss of control and the share owned by the Company in the net assets of the subsidiary in relation to the investment disposed of is recognized in other comprehensive income in the consolidated financial statements, which is wholly transferred to the profit or loss in the period in which the control is lost.

22. Investment properties

(1). Measured at cost

- 1. The investment properties include land use rights that have been leased out, land use rights that are held and read to be transferred after appreciation and buildings that have been leased out.
- Investment properties are initially measured at cost, subsequently measured using the cost model, and depreciated or amortized by following the same policies as those of fixed assets and intangible assets.

23. Fixed assets

(1). Criteria for recognition

 $\sqrt{\text{Applicable }} \square N/A$

Fixed assets are tangible assets held for production of goods, rendering of service, lease or operation and management with a useful life of more than one accounting year. A fixed asset is recognized if the economic benefits relating to it are very likely to flow to the Company and its cost can be reliably measured.

(2). Method of depreciation

√Applicable □N/A

Category	Depreciation methods	Depreciation periods (years)	Residual value rate	Annual depreciation rate
				•
Housing and	Straight-line	10 or 30	5%	9.50% or 3.17%
buildings	depreciation			
General	Straight-line	3-10	5%	31.67%-9.50%
equipment	depreciation			
Special	Straight-line	5-10	5%	19.00%-9.50%
equipment	depreciation			
Transportation	Straight-line	5	5%	19.00%
facility	depreciation			

(3). Identification basis, pricing and depreciation methods of fixed assets leased in under financing leases

 \Box Applicable $\sqrt{N/A}$

24. Construction in progress

 $\sqrt{\text{Applicable}} \square N/A$

- 1. A construction in progress is recognized if the economic benefits relating to it are very likely to flow to the Company and its cost can be reliably measured. A construction in progress is measured at the actual cost incurred for bringing the asset to working condition for its intended use.
- 2. The construction in progress is transferred to fixed assets at its actual construction cost when meeting working conditions for its intended use. If a project under construction has not undergone final accounts for completion when the project meets the working condition for its intended use, the project is transferred to fixed assets at the estimated value, and after final accounts for completion are handled, the original value provisionally estimated is adjusted at the actual cost, but no adjustment is made to originally provided depreciation.

25. Borrowing costs

 $\sqrt{\text{Applicable }} \square N/A$

1. Recognition of capitalization of borrowing costs

Borrowing costs incurred by the Company that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalized as part of the cost of the relevant asset. The amounts of other borrowing costs incurred are expensed when incurred and included in profit or loss for the current period.

- 2. Period of capitalization of borrowing costs
- (1) A borrowing cost is capitalized when all of the following conditions are satisfied: 1) the expenditures on the asset have already been incurred; 2) the borrowing cost has already been incurred; and 3) the acquisition, construction or production activities necessary to prepare the asset for its intended use or sale have already commenced.
- (2) Capitalization of borrowing costs is suspended during periods in which the acquisition, construction or production of a qualifying asset is interrupted abnormally, when the interruption is for a continuous period of more than 3 months. The borrowing costs incurred during these periods are recognized as an expense for the current period until the acquisition, construction or production is resumed.
- (3) When the qualifying asset being acquired, constructed or produced has become ready for its intended use or sale, the capitalization ceases.
 - 3. Rate and amount of capitalization of borrowing costs

If funds are borrowed under a specific-purpose borrowing for the acquisition, construction or production of a qualifying asset, the amount of interest to be capitalized is the actual interest expense incurred on that borrowing for the period (including amortized discount or premium determined using the effective interest method) less any bank interest earned from depositing the borrowed funds before

being used on the asset or any investment income on the temporary investment of those funds. If funds are borrowed under general-purpose borrowings and are utilized for the acquisition, construction or production of a qualifying asset, the Company determines the amount of interest to be capitalized on such borrowings by multiplying a capitalization rate of the utilized general-purpose borrowings by the weighted average of the excess amounts of cumulative expenditures on the asset over and above the amounts of specific-purpose borrowings.

26. Biological assets

 \Box Applicable $\sqrt{N/A}$

27. Oil and gas assets

 \Box Applicable $\sqrt{N/A}$

28. Use of right assets

 \Box Applicable $\sqrt{N/A}$

29. Intangible assets

(1). Pricing methods, useful lives and impairment tests

√Applicable □N/A

- 1. Intangible assets include land use rights, patent rights and nonpatented technology, which are initially measured at cost.
- 2. The depreciable amount of an intangible asset with a finite useful life is allocated on a systematic and rational basis over its useful life in the pattern in which the asset's economic benefits are expected to be realized. If that pattern cannot be determined reliably, the straight-line method is used. The specific life is shown as follows:

Item	Amortization periods
	(years)
Land use rights	40 or 50
Nonpatented	5
technology	
Office software	3-10
Patent rights	5
Customer resources	3
Trademark rights	10

(2). Accounting policies for internal research and development expenditure

 $\sqrt{\text{Applicable }} \square N/A$

Expenditure on the research phase of an internal research and development project is recognized in profit or loss in the period in which it is incurred. Expenditure on the development phase of an internal research and development project is recognized as an intangible asset only when the Company demonstrates all of the following: (1) the technical feasibility of completing the intangible asset so that it

will be available for use or sale; (2) the intention to complete the intangible asset and use or sell it; (3) how the intangible asset will generate economic benefits. Among other things, the Company can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself or, if it is to be used internally, the usefulness of the intangible asset; (4) the availability of adequate technical, financial and other resources to complete the development and the ability to use or sell the intangible asset; and (5) its ability to measure reliably the expenditure attributable to the intangible asset during its development phase.

30. Impairment of long-term assets

 $\sqrt{\text{Applicable }} \square N/A$

With respect to long-term equity investments, investment properties measured at the cost model, fixed assets, construction in progress, intangible assets with a finite useful life and other long-term assets, if there's an indication of impairment at the balance sheet date, the Company assesses their recoverable amount. Goodwill arising in a business combination and an intangible asset with an indefinite useful life are tested for impairment annually, irrespective of whether there is any indication that the asset may be impaired. For the purpose of impairment testing, goodwill is considered together with the related asset portfolio or sets of asset portfolio.

The the recoverable amount of the long-term asset above is lower than its carrying amount, the difference is measured as impairment loss of the asset and recognized in profit or loss for the current period.

31. Long-term prepaid expenses

√Applicable □N/A

Long-term prepaid expenses that have already been incurred but should be amortized over a period of more than one year (exclusive) are accounted for. Long-term prepaid expenses are stated as the amount actually incurred and are amortized evenly by stages within the benefit period or specified period. If an item of long-term deferred expenses will not benefit the subsequent periods, the amortized value of the item that has not yet been amortized is wholly transferred to profit or loss in the period in which it is actually incurred.

32. Contract liabilities

Recognition methods of contract liabilities

√Applicable □N/A

The Company presents the obligations to transfer goods to customers for the consideration received or receivable from customers as the contract liabilities.

33. Employee benefits

(1). Accounting for short-term benefits

√Applicable □N/A

The Company recognizes the short-term benefits actually incurred during the accounting period when the employees provide services for the Company as liabilities, and includes same in profit or loss

for the current period or the cost of related assets.

(2). Accounting for post-employment benefits

 $\sqrt{\text{Applicable }} \square N/A$

Post-employment benefits are classified into defined contribution plans and defined benefit plans.

- (1) During the accounting period in which the employees serve the Company, the amounts payable under the defined contribution plan are recognized as liabilities, and charged to profit or loss for the current period or the cost of related assets.
 - (2) The accounting treatment of a defined benefit plan generally involves the following steps:
- 1) According to the projected unit credit method, use the unbiased and consistent actuarial assumptions to estimate demographic variables and financial variables, measure the obligations arising from the defined benefit plan and determine the period to which the relevant obligations belong. Meanwhile, discount the obligations arising from the defined benefit plan, in order to determine the present value of the benefit plan obligations and the current service cost;
- 2) If the defined benefit plan has assets, the deficit or surplus resulting after reducing the present value of the defined benefit plan obligation by the fair value of the defined benefit plan is recognized as a net liability or asset of the defined benefit plan. If the defined benefit plan has a surplus, the net assets of the defined benefit plan are measured at the lower of surplus in the defined benefit plan and asset ceiling;
- 3) At the end of the reporting period, the cost of employee benefits arising from the defined benefit plan is recorded as service cost, net interest on the net liabilities or net assets of the defined benefit plan, and changes arising from re-measurement of the net liabilities or net assets of the defined benefit plan, wherein the service cost and the net interest on the net liabilities or net assets of the defined benefit plan are included in profit or loss for the current period or the cost of related assets, and the changes arising from re-measurement of the net liabilities or net assets of the defined benefit plan are included in other comprehensive income, which will not be converted back to profit or loss in subsequent periods, but may be transferred within the scope of equity.

(3). Accounting for termination benefits

√Applicable □N/A

The employee benefit liabilities arising from recognition of termination benefits offered to employees are recognized in profit or loss for the current period on the earlier of: (1) when the Company can no longer withdraw the offer of termination benefits as a result of termination of employment or redundancy; or (2) when the Company recognizes the restructuring costs or expenses relating to payment of termination benefits.

(4). Accounting for other long-term employee benefits

√Applicable □N/A

Other long-term employee benefits offered to employees are accounted for in accordance with the provisions applicable to defined contribution plans if they are qualified as defined contribution plans,

otherwise, they are accounted for in accordance with the provisions applicable to defined benefit plans. In order to simplify the accounting treatment, the total net amount of the cost of employee benefits arising from the defined benefit plans that is recorded as service cost, net interest on the net liabilities or net assets of other long-term employee benefits, changes arising from re-measurement of the net liabilities or net assets of other long-term employee benefits and other components is included in profit or loss for the current period or the cost of related assets.

34. Lease liabilities

 \Box Applicable $\sqrt{N/A}$

35. Provisions

 $\sqrt{\text{Applicable }} \square N/A$

- 1. An obligation arising from any external guarantee, litigations, product quality warranty, onerous contract or other contingencies is recognized as a provision if it is a present obligation assumed by the Company, and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably measured.
- Provisions are initially measured according to the best estimates of the expenditures required to settle the related present obligations. The carrying amount of estimated liabilities is reviewed at the balance sheet date.

36. Share-based payments

 $\sqrt{\text{Applicable }} \square N/A$

1. Category of share-based payment

A share-based payment is classified as either an equity-settled share-based payment or a cash-settled share-based payment.

- 2. Accounting for implementation, modification and termination of share-based payment plans
- (1) Equity-settled share-based payment

If the equity instruments granted under an equity-settled share-based payment for services received from employees vest immediately following the grant, the Company shall, on grant date, recognize related costs or expenses at an amount equal to the fair value of the equity instruments, with a corresponding increase in capital reserve. If the rights under a share-based payment for services received from employees do not vest until the completion of services for a vesting period, or until the achievement of a specified performance condition, at each balance sheet date during the vesting period, the Company makes the best estimate of the number of equity instruments expected to vest, and based on this, recognizes the services received in the current period in the related costs or expenses at an amount equal to the fair value on the grant date, with a corresponding increase in capital reserve.

For the equity instruments granted under an equity-settled share-based payment for services from other parties, if the fair value of services received from other parties can be measured reliably, the fair value of the equity instruments is measured at the fair value of services from other parties on the grant date; if the fair value of services received from other parties cannot be measured reliably but the fair

value of the equity instruments can be measured reliably, the fair value of the equity instruments on the date on which services are received shall be recognized as related costs or expenses, with a corresponding increase in owners' equity.

(2) Cash-settled share-based Payment

If the right under the cash-settled share-based payment for services from employees vests immediately following the grant, the Company, on grant date, recognizes related costs or expenses at an amount equal to the fair value of the liability assumed by the Company, with a corresponding increase in liability. If the rights under a cash-settled share-based payment for services from employees do not vest until the completion of services for a vesting period, or until the achievement of a specified performance condition, the Company, at each balance sheet date during the vesting period, recognize the services received for the current period as related costs or expenses, with a corresponding increase in liability, at an amount equal to the fair value of the liability based on the best estimate of the outcome of vesting.

(3) Modification and termination of share-based payment plans

If the modification increases the fair value of the equity instruments granted, the Company recognizes the increase in services received based on the increase in the fair value of the equity instruments; if the modification increases the number of equity instruments granted, the Company recognizes the fair value of the increased equity instruments as the increase in services correspondingly; if the Company modifies the vesting conditions in a way that is beneficial to employees, the Company considers the revised vesting conditions when dealing with the vesting conditions.

If the modification reduces the fair value of the equity instruments granted, the Company continues to use the fair value of the equity instruments on the grant date as the basis to recognize the amounts of the service received, regardless of the decrease in the fair value of the equity instruments; if the modification reduces the number of equity instruments granted, the Company treats the reduced portion as the cancellation of the granted equity instruments; if the exercising conditions are modified in a way that is not conducive to the employees, the Company does not consider the revised vesting conditions when dealing with the exercising conditions.

If the Company cancels or settles the equity instruments granted during the vesting period (except as cancelled because vesting conditions are not satisfied), the Company treats the cancellation or settlement as the accelerated exercise, and the amount to be recognized during the remaining vesting period is immediately recognized.

37. Preferred shares, perpetual bonds and others financial instruments \Box Applicable $\sqrt{N/A}$

38. Revenue

(1). The accounting policies adopted for the recognition and measurement of revenue

 $\sqrt{\text{Applicable }} \square N/A$

1. Revenue recognition

On the commence date of a contract, the Company evaluates the contract, identifies each individual performance obligation contained therein and determine whether each individual performance obligation

is performed over time or at a point in time.

When meeting one of the following criteria, it belongs to the obligation performed over time, otherwise it constitutes the obligation performed at a point in time: (1) the customer obtains and consumes the economic benefits generated by the Company's performance when the Company performs the contract; (2) the customer can control the products under construction in the process of the Company's performance; (3) the products produced in the process of the Company's performance have irreplaceable uses, and the Company has the right to collect payment for the cumulative performance that has been completed up to date throughout the term of the contract.

For the obligation performed over time, the Company recognizes the revenue based on the performance progress over time. When the performance progress cannot be reasonably determined, and the costs incurred are expected to be recoverable, revenue is recognized to the extent of costs incurred until the performance progress can be reasonably determined. For the obligation performed at a point in time, the revenue is recognized at the time point when the customer obtains the control of the related goods and services. When judging whether the customer has obtained the control of goods, the Company considers the followings signs: (1) the Company has the current right to receive payment for such goods, that is, the customer has the current obligation to make payment for such goods; (2) the Company has transferred the legal ownership of such goods to the customer, that is, the customer has the legal ownership of such goods; (3) the Company has transferred such goods to the customer physically, that is, the customer has taken possession of such goods physically; (4) the Company has transferred material risks and rewards of such goods to the customer, that is, the customer has obtained material risks and rewards of such goods; (5) the customer has accepted such goods; and (6) other signs that the customer has obtained control of such goods.

2. Revenue measurement

- (1) The Company measures revenue based on the transaction price allocated to each individual performance obligation. The transaction price is the amount of consideration to which the Company is entitled arising from the transfer of goods or services to the customer, excluding the amount collected on behalf of a third party and expected to be returned to the customer.
- (2) If there is variable consideration in the contract, the Company determines the best estimate of the variable consideration based on the expected value or the most likely amount. However, variable consideration is included in the transaction price if, and to the extent that, it is highly probable that its inclusion will not result in a significant revenue reversal of accumulatively recognized revenue in the future when the uncertainty has been subsequently resolved.
- (3) If there is a major financing component in the contract, the Company determines the transaction price based on the presumed amount payable in cash when the customer obtains the control of goods or services. The difference between such transaction price and the contract consideration is amortized over the period of the contract using the effective interest method. If on the commence date of a contract, the Company expects that the customer's acquisition of control of goods or services is not more than one year from the customer's payment therefor, the major financing component in the contract will not be

considered.

(4) If the contract has two or multiple performance obligations, the Company, on the commence date of a contract, allocates the transaction price to each individual performance obligation in the contract by reference to relative standalone selling prices of goods promised thereby.

(2). Difference in the accounting policy for revenue recognition arising from adoption of different modes of operation for the same kind of business

 $\sqrt{\text{Applicable }} \square N/A$

The Company mainly engages in sales of cosmetics. The Company adopts such methods as distribution, direct sales and agency sales.

(1) Distribution

The Company recognizes the sales revenue after delivering the products to a purchaser as agreed in the contract and upon inspection by the purchaser.

(2) Direct sales

The Company recognizes the sales revenue after it delivers the products to a customer and the customer confirms the acceptance and pays for the products.

(3)Agency sales

The Company recognizes the sales revenue after it delivers the products to an entrusted party and the entrust party realizes the sales and issues the list of agency sales to the Company.

39. Contract costs

 $\sqrt{\text{Applicable }} \square N/A$

Assets related to contract costs include contract acquisition costs and contract performance costs.

If the incremental cost incurred by the Company to obtain a contract is expected to be recovered, it is recognized as an asset as the cost of obtaining a contract. If the amortization period of the cost of obtaining a contract does not exceed one year, such cost is directly included in the profit or loss for the current period.

The cost incurred by the Company to perform a contract is not be governed by the standards on inventories, fixed assets or intangible assets, and if meeting the following criteria, is recognized as an asset as the contract performance cost:

- 1. Such cost is directly related to an existing or expected contract, including expenses for direct labor, direct materials and manufacturing (or similar expenses), costs to be clearly borne by the customer and other costs incurred only due to the contract;
- 2. Such cost increases the the Company's future resources for fulfilling its performance obligations; and
 - 3. Such cost is expected to be recovered.

The Company amortizes the asset related to the contract cost on the same basis as the recognition of the revenue of the goods or services related to the asset, and includes it into the profit or cost for the current period.

If the carrying amount of the asset related to the contract cost is higher than the remaining

consideration expected to be obtained due to the transfer of the goods or services related to the asset less the estimated cost, then the Company makes the provision for impairment of the excess and recognizes it as an impairment loss for the asset. If the impairment factors for prior periods have changed afterwards so that the remaining consideration expected to be obtained due to the transfer of the goods or services related to the asset less the estimated cost is higher than the carrying amount of the asset, then the Company reverses the provision for impairment originally made and includes it in the profit or loss for the current period, provided that the carrying amount after reverse shall not exceed the carrying amount the asset would have reached on the date of reverse had the provision for impairment been not made.

40. Government grants

 $\sqrt{\text{Applicable}} \square N/A$

- 1. Government grants are recognized if (1) the Company meets the conditions attaching to the government grants; and (2) the Company will receive the government grants. If a government grant is in the form of a transfer of a monetary asset, the item is measured at the amount received or receivable. If a government grant is in the form of a transfer of a non-monetary asset, the item is measured at fair value. If fair value is not reliably determinable, the item is measured at a nominal amount.
 - 2. Determination of and accounting for government grants related to assets

Government grants related to assets are government grants which are offered for purchasing, constructing or otherwise acquiring long-term assets as provided by the applicable government documents, or or in the absence of such express provision in the applicable government documents, government grants whose basic condition is that such grants judged to be offered for purchasing, constructing or otherwise acquiring long-term assets on the basis of basic conditions that must be met for acquisition of such grants. The government grants related to assets are offset against the carrying amount of the related assets or recognized as deferred income. Government grants related to assets, if recognized as deferred income, are included in profit or loss over the service life of the relevant assets on a reasonable and systemic basis. Government grants measured at nominal amount are directly recognized in profit or loss for the current period. In case of sale, transfer, retirement or damage of the relevant assets before the end of intended service life, the balance of the unallocated deferred income is transferred to profit or loss for the period in which the assets are disposed of.

3. Determination of and accounting for government grants related to income

Government grants related to income are government grants other than those related to assets. Government grants related to both assets and income in which it is difficult to make a distinction between the portion related to assets and the portion related to income are wholly classified as government grants related to income. Government grants related to income as compensation for expenses or losses to be incurred in subsequent periods are recognized as deferred income and in the period for recognizing the relevant costs, expenses or losses, included in profit or loss for the current period or offset against the relevant costs. Government grants related to income as compensation for expenses or losses already incurred are directly included in profit or loss for the current period or offset against the relevant costs.

4. Government grants related to day-to-day operations of the Company are recognized in other income or offset against the relevant costs and expenses depending on the nature of economic business. Government grants not related to day-to-day operations of the Company are recognized in non-operating revenues or expenses.

41. Deferred tax assets / deferred tax liabilities

√Applicable □N/A

- 1. The difference between the carrying amount of an asset or liability and the tax base (or in case of an item not recognized as asset or liability whose tax base can be determined according to the applicable tax law, the difference between the tax base and the carrying amount) is recognized as a deferred tax asset or deferred tax liability according to the tax rate applicable to the period in which the asset or liability is expected to be recovered or settled.
- 2. Deferred tax assets are recognized to the extent of the amount of income tax payable that will be available in future periods against which deductible temporary differences are deductible. At the balance sheet date, deferred tax assets not recognized in prior periods are recognized if there's conclusive evidence that it is probable that sufficient taxable income will be available in future periods against which the deductible temporary differences are deductible.
- 3. At the balance sheet date, the carrying amount of a deferred tax asset is reviewed. The Company reduces the carrying amount of a deferred tax asset to the extent that it is no longer probable that sufficient taxable profits will be available in future periods to allow the benefit of the deferred tax asset to be utilized. Any such reduction in amount is reversed to the extent that it becomes probable that sufficient taxable profits will be available.
- 4. Current and deferred tax of the Company is recognized as income or an expense and included in profit or loss for the current period, except to the extent that the tax arises from: (1) business combination; or (2) a transaction or event which is recognized directly in owner's equity.

42. Leases

(1). Accounting for operating leases

 \Box Applicable $\sqrt{N/A}$

(2). Accounting for financing leases

□Applicable √N/A

(3). Determination of and accounting for leases under new lease standards

 $\sqrt{\text{Applicable }} \square N/A$

1. Identification of leases

On the commencement date of a contract, the Company assesses whether the contract is a lease or includes a lease. Where a party to a contract transfers the right to control the use of one or more identified assets for a certain period of time in return for consideration, the contract is a lease or includes a lease. To determine whether the right to control the use of identified assets within a certain period of time under a contract has been transferred, the Company assesses whether a client in the contract has the

right to use almost all of the economic benefits arising from the use of the identified assets during the period of use, and has the right to control the use of identified assets during this period of use.

2. Identification of separate leases

Where a contract concurrently contains multiple separate leases, the Company splits the contract and conduct accounting treatment respectively for all separate leases. Where the following conditions are concurrently met, use of the rights of identified assets constitutes a separate lease in a contract: (1) a lessee may earn profits from separate use of the assets or joint use with other resources readily available; and (2) there is no high dependence or high correlation between the assets and other assets in the contract.

3. Accounting for leases to which the Company acts as a lessee

On the lease inception date, the Company considers a lease with a term of not more than 12 months and excluding the purchase option as a short-term lease, and a lease of a single leased asset with relatively low value when the single leased assets is a new asset as a low-value asset lease.

For all the short-term leases and low-value asset leases, the Company includes lease payments in the cost of related assets or profit or loss for the current period on a straight-line basis for each period during the lease term.

On the lease inception date, the Company recognizes the right-of-use assets and the lease liability for the lease, except for the short-term lease and low-value asset lease that are subject to simplified treatment.

On the lease inception date, the Company recognizes the present value of the lease payments that have not been paid as a lease liability. When calculating the present value of the lease payments, the Company adopts the interest rate implicit in the lease as the discount rate, and adopts its incremental borrowing rate of the Company as the discount rate where it is unable to determine the interest rate implicit in the lease. The difference between the lease payment and its present value is regarded as an unrecognized financing expense. For each period during the lease term, the interest expense is recognized at the discount rate of the present value of the recognized lease payments and included in profit and loss for the current period. Variable lease payments not included in the measurement of lease liability are included in profit or loss in the period in which it is incurred.

On the lease inception date, in case of changes in substantial fixed payments, the residual value of the guarantee, the index or ratio used for determining the lease payments, the evaluation results and actual exercise of the purchase option, renewal option or termination of the lease option, the Company re-measures the lease liability at the present value of changed lease payments.

4. Accounting for the changed leases to which the Company acts as a lessee

1)Lease change as a separate lease

Where the lease changes and meets the following conditions, the Company conducts accounting treatment for the lease change as a separate lease: ① the lease change expands the lease scope by increasing the right to use one or more leased assets; ② the increased consideration is equivalent to the individual price of the expanded lease scope adjusted as per the contract.

2) Lease change not as a separate lease

On the effective date of the lease change, the Company re-determines the lease term and re-calculates the lease liability on the basis of the present value calculated as per the changed lease payments or revised discount rate. When calculating the present value of the lease payments after change, the Company adopts the interest rate implicit in the lease during the residual lease term as the discount rate, and its incremental borrowing rate on the effective date of the lease change as the discount rate, where it is unable to determine the interest rate implicit in the lease during the lease term.

The above effects of adjustment to the lease liability are accounted for separately by the Company according to the following circumstances:

- ①Where the lease change results in a narrower lease scope or a shorter lease term, the Company accordingly reduces the carrying amount of the right-of-use assets and includes the relevant gain or loss of the partially or fully terminated lease in profit and loss for the current period.
- ②Where other lease changes result in re-measurement of the lease liability, the Company accordingly adjusts the book value of the right-of-use assets.
 - 5. Accounting for leases to which the Company acts as a lessor

The Company recognizes the receipts of leases in current profit or loss on a straight-line basis for each period during the lease term. The initial direct cost incurred by the Company is capitalized and apportioned on the same basis for the recognition of rental income, and be included in the current loss and profit in installments. Variable lease payments obtained by the Company in relation to operating leases but not included in the lease receipts are included in profit or loss in the period in which they are incurred.

6. Accounting for changed leases to which the Company acts as a lessor

In the event of any change in an operating lease, the Company regards it as a new lease for accounting treatment from the effective date of the change, and the advance or receivable lease receipts related to the lease prior to the change are regarded as receipts of a new lease.

43. Other significant accounting policies and accounting estimates $\Box Applicable \ \sqrt{N/A}$

44. Changes in significant accounting policies and accounting estimates

(1). Changes in significant accounting policies

√Applicable □N/A

Changes in accounting policies and related reasons	Approval procedure	Note (name and amount of materially affected items of the statements)
The Company implements the	The Company held the 19th	1.The Company has not assessed
revised Accounting Standard for	meeting of the second board of	whether or not it is a lease or
Business Enterprises No. 21 -	directors and the 18th meeting of	includes a lease for contracts that
Lease ("New Lease Standard")	the second board of supervisors	existed prior to January 1, 2021.
from January 1, 2021.	on April 21, 2021, reviewing and	2. As the lessee, the Company
	approving the Proposal on	shall not adjust the information

Change of Accounting Policies,	for the comparable period in
and the independent directors of	accordance with the relevant
the Company gave the	regulations on the convergence
independent opinions on consent.	of old and new standards, and the
The Company's changes of	differences arising from the
accounting policy do not need to	implementation of new lease
be submitted to the general	standard on the first
meeting of shareholders for	implementation date is
review. For details, please refer	retrospectively adjusted to the
to No. 2021-012, No. 2021-013	amount of retained earnings and
and 2021-016 Announcements of	other related items in the
the Company.	financial statements at the
	beginning of the reporting
	period.

Other descriptions:

- (1) The implementation of new lease standards has no impact on the financial statements on January 1, 2021.
 - (2) The operating leases prior to January 1, 2021 are accounted for in a simplified manner.

The Company regards the leases completed within 12 months from the date of first implementation as short-terms for accounting treatment, include the lease payments in the cost of related assets or profit or loss for the current period on a straight-line basis for each period during the lease term.

(3) The Company does not retrospectively adjust the leases to which the Company acts as a lessor.

(2). Changes in significant accounting estimates

 \Box Applicable $\sqrt{N/A}$

(3). Description of adjustments in opening balances of line items in financial statements of the current year due to first implementation of new lease standard since 2021

 \Box Applicable $\sqrt{N/A}$

(4). Description of retrospective adjustments in comparative data in prior periods due to first implementation of new lease standard in 2021

 \Box Applicable $\sqrt{N/A}$

45. Others

 \Box Applicable $\sqrt{N/A}$

VI. Tax

Major categories of taxes and tax rates

Major categories of taxes and tax rates $\sqrt{\text{Applicable }} \square N/A$

Tax category	Taxation basis	Tax rate
VAT	VAT payable is the output tax	13%, 9%, 6%
	based on the sales of goods and	
	taxable labor income calculated	
	pursuant to the tax law, net of the	
	input tax that is allowed to be	

	deducted in the current period	
Consumption tax	Taxable sales turnover (volume)	15%
Business tax		
Urban maintenance and construction tax	Actually paid turnover tax	7%, 5%
Enterprise income tax	Taxable income	
Property tax	If it is levied on an ad valorem basis, the tax is calculated as 1.2% of the remaining value after being deducted 30% of the original value of the property; if it is levied subject to rent, the tax is calculated as 12% of the rental income.	1.2%, 12%
Education surcharges	Actually paid turnover tax	3%
Local education surcharges	Actually paid turnover tax	2%

Disclosure of taxpayers (if any) with different rates of enterprise income tax $\sqrt{Applicable}$ $\square N/A$

Taxpayer	Rate of enterprise income tax (%)
Proya Cosmetics Co., Ltd.	15%
Y.N.M. Cosmetics Co., Ltd.	
HANNA COSMETICS CO., LTD.	
HAPSODE Co., Ltd.	
Hongkong Keshi Trading Limited	
Hongkong Xinghuo Industry Limited	
Hongkong Wanyan Electronic Commerce Co.,	
Limited	
Hong Kong Zhongwen Electronic Commerce Co.,	
Limited	
Hongkong Xuchen Trading Limited	
BOYA (Hong Kong) Investment Management Co.,	
Limited	
Proya Europe SARL	
Off & Relax Co., Ltd.	
Tax payers other than those mentioned above [Note]	25%

[Note]: Y.N.M. Cosmetics Co., Ltd., HANNA COSMETICS CO., LTD. and HAPSODE Co., Ltd. pay the relevant taxes and fees in accordance with local tax regulations of South Korea; Hongkong Keshi Trading Limited, Hongkong Xinghuo Industry Limited, Hongkong Wanyan Electronic Commerce Co., Limited, Hong Kong Zhongwen Electronic Commerce Co., Limited, Hongkong Xuchen Trading Limited and BOYA (Hong Kong) Investment Management Co., Limited pay the relevant taxes and fees in accordance with local tax regulations of Hong Kong; Proya Europe SARL pays the relevant taxes and fees in accordance with local tax regulations of Luxembourg; Off & Relax Co., Ltd. pays the relevant taxes and fees in accordance with local tax regulations of Japan.

2. Tax incentives

 $\sqrt{\text{Applicable}} \square N/A$

The Company passed the high-tech enterprise review on December 1, 2020, obtained the High-tech Enterprise Certificate which is valid for three years, and enjoys tax preferences from 2020 to 2022. The Company paid the enterprise income tax at the reduced tax rate of 15% in 2021.

In accordance with the Notice of the Ministry of Finance and the State Administration of Taxation on Implementing the Inclusive Tax Deduction and Exemption Policies for Micro and Small Enterprises (C.S. [2019] No. 13) and the Announcement of the State Administration of Taxation on Issues 105/185

Concerning the Implementation of the Inclusive Income Tax Deduction and Exemption Policies for Small Low-Profit Enterprises (Announcement No. 2 [2019] of the State Administration of Taxation), the subsidiaries including Chaozhao Niuke Technology Co., Ltd. meet the tax payment standards as a micro and small enterprise, and the annual taxable income of a small low-profit enterprise that is not more than RMB 1 million shall be included in its taxable income at the reduced rate of 25%, with the applicable enterprise income tax rate of 20%; and the annual taxable income that is not less than RMB 1 million nor more than RMB 3 million shall be included in its taxable income at the reduced rate of 50%, with the applicable enterprise income tax rate of 20%.

In accordance with the Announcement on Relevant Policies for Deepening the Value-Added Tax Reform (Announcement No. 39 by the Ministry of Finance, the State Taxation Administration and the General Administration of Customs in 2019) jointly issued by the Ministry of Finance, the State Taxation Administration and the General Administration of Customs, Hangzhou Proya Commercial Management Co., Ltd. as the subsidiary meets the conditions of general taxpayers in production and life service industry and thus is allowed to credit the amount of input tax deductible in the current period plus 10% thereof against the amount of taxes payable from April 1, 2019 to December 31, 2021.

3. Others

 \Box Application $\sqrt{N/A}$

VII. Notes to consolidated financial statements

1. Cash

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance
Cash on hand	4,920.44	26,853.58
Deposits	1,211,789,299.48	1,368,800,012.77
Other currency funds	24,543,486.83	47,827,774.58
Total	1,236,337,706.75	1,416,654,640.93
Including: Total	95,782,171.06	83,771,568.02
amount deposited aboard		

Other descriptions:

Among the bank deposits at the end of the period, the security deposit of fixed time deposit for the transformer amounting to RMB 293,481.72, and the other currency funds including L/C security deposit of RMB 7,000,000.00, and Tmall and Alipay security deposit of RMB 674,000.00 are restricted in their use.

Among the bank deposits at the opening of the period, the security deposit of fixed time deposit for the transformer amounting to RMB 293,481.72, and other currency funds including land construction security deposit of RMB 7,036,404.33, L/C security deposit of RMB 7,000,000.00, ETC vehicle security deposit of RMB 69,000.00, and Tmall and Alipay security deposit of RMB 405,000.00 are restricted in their use.

2. Held-for-trading financial assets

 \Box Application $\sqrt{N/A}$

3. Derivative financial assets

 \Box Application $\sqrt{N/A}$

4. Notes receivable

(1). Notes receivable by category

 \Box Application $\sqrt{N/A}$

(2). Notes receivable that have been pledged at the closing of the period

 \Box Application $\sqrt{N/A}$

(3). Notes receivable endorsed or discounted by the Company that are not matured at the balance sheet date

 \Box Application $\sqrt{N/A}$

(4). Notes that are reclassified into accounts receivable by the Company at the closing of the period due to the default of the drawer

 \Box Application $\sqrt{N/A}$

(5). Disclosure by category based on methods of determination of provision for bad debts

 \Box Application $\sqrt{N/A}$

(6). Provision for debt debts

 \Box Application $\sqrt{N/A}$

(7). Notes receivable actually written off for the current period

 \Box Application $\sqrt{N/A}$

Other descriptions:

 \Box Application $\sqrt{N/A}$

5. Accounts receivable

(1). Disclosure by aging

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Aging	Gross carrying amount at the end of the period
Within 1 year	
Including: Subdivision within 1 year	
Sub-total within 1 year	180,297,431.50
1-2 years	16,855,014.19
2-3 years	4,806,673.54
Over 3 years	3,227,933.65
3-4 years	
4-5 years	
Above 5 years	
Total	205,187,052.88

$(2). \hspace{0.5cm} \textbf{Disclosure by category based on methods of determination of provision for bad debts}$

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

	Closing balance		Opening balance							
	Gross c	arrying	Provisio	n for bad		Gross c	arrying	Provisio	n for bad	
Category	amo	unt	de	bts	Carrying	amo	unt	de	bts	Carrying
	Amount	Proportion (%)	Amount	Proportion (%)	amount	Amount	Proportion (%)	Amount	Proportion (%)	amount
Provision	17,721,15	8.64	17,721,1	100.00		16,916,21	5.29	16,916,21	100.00	
for bad	5.26		55.26			0.88		0.88		
debts made										
individually:										
Including:									T	
Provision	187,465,89	91.36	13,149,21	7.01	174,316,68	303,007,48	94.71	18,129,06	5.98	284,878,41
for bad	7.62		6.16		1.46	7.69		8.11		9.58
debts made										
by portfolio:										
Including:									1	
Total	205,187,05	/	30,870,37	/	174,316,68	319,923,69	/	35,045,27	/	284,878,41
Total	2.88		1.42		1.46	8.57		8.99		9.58

Provision for bad debts made individually:

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB					
		Closing balance			
Name	Gross carrying amount	Provision for bad debts	Proportion (%)	Reasons for provisions	
Provision for bad debts made individually	17,721,155.26	17,721,155.26	100.00	Expected to uncollectible	
Total	17.721.155.26	17.721.155.26	100.00	/	

Descriptions of provision for bad debts made individually:

 $\Box Applicable \ \ \sqrt{N/A}$

Provision for bad debts made by portfolio:

 $\sqrt{\text{Applicable } \square N/A}$

Items of portfolio provision: aging portfolio

I Init.	Viion	Currency:	DMD
	1 11/411	CHILENCY	NIVID

Name	Closing balance				
Name	Accounts receivable	Provision for bad debts	Proportion (%)		
Aging portfolio	187,465,897.62	13,149,216.16	7.01		
Total	187,465,897.62	13,149,216.16	7.01		

Standards of provision for bad debts made by portfolio and descriptions thereof:

 $\sqrt{\text{Applicable } \square N/A}$

Accounts receivable for which the provide for bad debts is made by aging portfolio

A -:		Closing balance				
Aging	Gross carrying amount	Provision for bad debts	Provision (%)			
Within 1 year	180,159,562.31	9,007,978.10	5.00			
1-2 years	4,360,229.05	1,308,068.72	30.00			
2-3 years	225,873.85	112,936.93	50.00			
Over 3 years	2,720,232.41	2,720,232.41	100.00			

Sub-total	187,465,897.62	13,149,216.16	7.01

If the provision for bad debts is made in accordance with the general model of expected credit losses, please refer to other receivables disclosure:

 \Box Applicable $\sqrt{N/A}$

(3). Provision for bad debts

√ Applicable □N/A

Unit: Yuan Currency: RMB

			Changes for	the current period		-
Category	Opening balance	Provision	Recovery or reversal	Removal/write-off	Other changes	Closing balance
Provision	16,916,210.88	804,944.38				17,721,155.26
for bad						
debts made						
individually						
Provision	18,129,068.11	-4,590,040.14		2,488.18	387,323.63	13,149,216.16
for bad						
debts made						
by portfolio						
Total	35,045,278.99	-3,785,095.76		2,488.18	387,323.63	30,870,371.42

Other decrease of RMB387,323.63 in the current period on provision for bad debts made by portfolio is attributable to the disposal of the equity of Shanghai Healthlong Biochemical Technology Co., Ltd. (hereinafter referred to as Shanghai Healthlong Company), and the provision for bad debts of accounts receivable were transferred out accordingly.

Significant recovery or reversal of bad debt provision for the current period:

□Applicable √N/A

(4). Accounts receivable actually written off for the current period

 $\sqrt{\text{Applicable }} \square N/A$

	Unit: Yuan Currency: RMB
Item	Write-off amount
Accounts receivable actually written off	2,488.18

Descriptions of significant accounts receivable that are written off:

□Applicable √N/A

Descriptions of write-off of accounts receivable:

□Applicable √ N/A

(5). Top five closing balances of accounts receivable categorized by debtor

 $\sqrt{\text{Applicable }} \square N/A$

Entity	Gross carrying amount	Proportion to the balance of accounts receivable (%)	Provision for bad debts
Beijing Jingdong Century Trade Co.,	48,927,371.11	23.85	2,446,368.56
Ltd.	40,727,371.11	23.03	2,440,300.30
Zhejiang Youcaihua Network	28,000,003.20	13.65	1,400,000.16

Technology Co., Ltd.			
Vipshop (China) Co., Ltd.	17,522,428.20	8.54	876,121.42
Zhejiang Tmall Network Technology	12,935,983.66	6.30	646,799.19
Co., Ltd.	12,733,703.00	0.50	040,777.17
Jinhua Zhuangmei Cosmetics Co., Ltd.	6,703,225.88	3.27	335,161.29
Sub-total	114,089,012.05	55.61	5,704,450.62

(6). Accounts receivable derecognized due to the transfer of financial assets

□Applicable √N/A

(7). Assets and liabilities generated by the transfer of accounts receivable and continuing involvement therein

□Applicable √N/A

Other descriptions:

□Applicable √N/A

6. Receivable financing

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance
Notes receivable	5,263,729.60	5,531,997.32
Total	5,263,729.60	5,531,997.32

Increase or decrease of receivable financing for the current period and changes in its fair value $\Box Applicable \ \ \sqrt{N/A}$

If the provision for bad debts is made in accordance with the general model of expected credit losses, please refer to other receivables disclosure:

□Applicable √N/A

Other descriptions:

√ Applicable □N/A

Notes receivable endorsed or discounted at the end of the period by the Company that are not matured at the balance sheet date

Item	Balance	derecognized	at
	the end of	f the period	
Bank acceptance bills		10,003,394.9	98
Sub-total		10,003,394.9	98

The acceptor of bank acceptance bills is a commercial bank with high credit, and the possibility that bank acceptance bills fail to be paid at maturity is low. Therefore, the Company derecognized the endorsed or discounted bank acceptance bills. However, if such notes fail to be paid when they are due, the Company will still be jointly and severally liable to the holders in accordance with the provisions of the *Negotiable Instruments Law*.

7. Prepayments

(1). Prepayments by aging

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Aging	Closing	balance	Opening balance	
Aging	Amount	Proportion (%)	Amount	Proportion (%)
Within 1 year	88,000,110.35	98.67	81,149,897.32	98.07
1-2 years	250,958.21	0.28	802,393.47	0.97
2-3 years	932,894.12	1.05	790,525.13	0.96
Over 3 years				
Total	89,183,962.68	100.00	82,742,815.92	100.00

Reasons for overdue settlement of prepayments with significant amounts and aged more than 1 year: None

(2). Top five closing balances of prepayments categorized by receivers

√ Applicable □N/A

Entity		Proportion to the balance of prepayments (%)
Beijing Linkworld Network Technology Co., Ltd.	14,906,011.57	16.71
Alipay (China) Network Technology Co., Ltd.	11,712,263.48	13.13
Guangxi Jingdong Xinjie E-commerce Co., Ltd.	11,034,497.87	12.37
Beauty Hi-tech Innovation Co., Ltd.	9,239,419.07	10.36
MEDICOS CO., LTD.	2,963,918.24	3.32
Sub-total	49,856,110.23	55.89

Other descriptions \Box Applicable $\sqrt{N/A}$

8. Other receivables

Line items

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance
Interest receivable		
Dividends receivable		
Other receivables	47,275,902.55	48,733,527.35
Total	47,275,902.55	48,733,527.35

Other descriptions: \Box Applicable $\sqrt{N/A}$

Interest receivable

(1). Classification of interest receivable

 \Box Applicable $\sqrt{N/A}$

(2). Significant overdue interest

 \Box Applicable $\sqrt{N/A}$

(3). Provision for bad debts

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

Dividends receivable

(1). Dividends receivable

 \Box Applicable $\sqrt{N/A}$

(2). Significant dividends receivable aged more than 1 year

 \Box Applicable $\sqrt{N/A}$

(3). Provision for bad debts

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

Other receivables

(1). Disclosure by aging

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Aging	Gross carrying amount at the closing of the period
Within 1 year	
Including: Subdivision within 1 year	
Sub-total within 1 year	44,708,548.69
1-2 years	6,391,816.19
2-3 years	657,020.04
Over 3 years	1,126,431.27
3-4 years	
4-5 years	
Above 5 years	
Total	52,883,816.19

(2). Classification of other receivables by nature

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Nature	Gross carrying amount at the	Gross carrying amount at the
	closing of the period	opening of the period
Security deposit	23,068,954.00	15,177,436.77
Temporary payments receivable	27,640,452.53	39,073,769.81
Revolving fund	1,092,552.47	712,751.90
Others	1,081,857.19	744,011.86
Total	52,883,816.19	55,707,970.34

(3). Provision for bad debts

 $\sqrt{\text{Applicable }} \square N/A$

	Stage I	Stage II	Stage III		
Provision for bad debts	Future 12-month ECL	Lifetime ECL (without credit impairment)	Lifetime ECL (with credit impairment)	Total	
Balance as of	2,141,110.96	3,171,320.29	1,662,011.74	6,974,442.99	
January 1, 2021					
In the current period, balance as					

at January 1, 2021				
transferred to	-528,624.19	528,624.19		
Stage II				
transferred to		-970,286.21	970,286.21	
Stage III				
transferred back				
to Stage II				
transferred back				
to Stage I				
Provisions for the	1,240,174.06	442,086.89	-852,957.78	829,303.17
current period				
Reversal for the				
current period				
Removal for the				
current period				
Write-off for the				
current period				
Other changes	-617,233.34	-1,254,200.30	-324,398.88	-2,195,832.52
Balance as of June	2,235,427.49	1,917,544.86	1,454,941.29	5,607,913.64
30, 2021				

Descriptions of the significant changes in the gross carrying amount of other receivables for which the changes in loss allowance occur for the current period:

 \Box Applicable $\sqrt{N/A}$

Provision for bad debts in the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly:

 \Box Applicable $\sqrt{N/A}$

(4). Provision for bad debts

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Category	Opening balance	Provision	Recovery or reversal	Removal/write-off	Other changes	Closing balance
Aging portfolio	6,974,442.99	829,303.17			-2,195,832.52	5,607,913.64
Total	6,974,442.99	829,303.17			-2,195,832.52	5,607,913.64

Other changes of RMB -2,195,832.52 related to the disposal of the equity of Shanghai Healthlong Company, and the provision for bad debts of other receivables were transferred out accordingly. Significant recovery or reversal of provision for bad debts for the current period: $\Box Applicable \sqrt{N/A}$

(5). Other receivables actually written off for the period

 \Box Applicable $\sqrt{N/A}$

(6). Top five closing balances of other receivables categorized by debtor

 $\sqrt{\text{Applicable }} \square N/A$

Entity	Nature	Closing balance	Aging	Proportion to total closing balance of other receivables (%)	Closing balance of provision for bad debts
People's	Security	13,493,392.00	Within 1 year	25.52	674,669.60
Government of	deposit				
Taixi Town,					
Wuxing					
District,					
Huzhou City					
EURL	Temporary	12,001,399.00	Within 1 year	22.69	600,069.95
PHARMATICA	payments				
[Note]	receivable				
SIKEROM	Temporary	7,857,909.71	Within 1 year	14.86	392,895.49
EUROPE	payments				
GMBH	receivable				
Hangzhou	Security	4,708,614.72	1-2 years	8.90	1,412,584.42
Property	deposit				
Maintenance					
Fund					
Management					
Center					
Vipshop	Security	500,000.00	Within 1 year	0.95	25,000.00
(China) Co.,	deposit				
Ltd.					
Total	/	38,561,315.43	/	72.92	3,105,219.46

[Note] The amounts in the line of EURL PHARMATICA are combined amounts of EURL PHARMATICA, PARISEZHAN HK LIMITED, SARL ORTUS and S.A.S AREDIS, which are controlled by the same person.

(7). Receivables involving government grants

 \Box Applicable $\sqrt{N/A}$

(8). Other receivables derecognized due to the transfer of financial assets

 \Box Applicable $\sqrt{N/A}$

(9). Assets and liabilities generated by the transfer of other receivables and continuing involvement therein

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

9. Inventory

(1). Classification of inventories

 $\sqrt{\text{Applicable }} \square N/A$

Item	Closing balance	Opening balance

	Gross carrying amount	Provision for decline in value of inventories/ provision for decline in value of contract performance costs	Carrying amount	Gross carrying amount	Provision for decline in value of inventories/ provision for decline in value of contract performance costs	Carrying amount
Raw materials	16,756,263.44	930,262.55	15,826,000.89	25,023,198.10	790,191.51	24,233,006.59
Goods in process	13,068,407.69	279,667.64	12,788,740.05	19,699,809.41	333,215.45	19,366,593.96
Goods on hand	304,227,868.16	25,731,578.58	278,496,289.58	402,419,036.40	21,221,419.14	381,197,617.26
Revolving materials						
Consumable biological assets						
Contract performance costs						
Packing materials	39,795,929.46	1,789,866.25	38,006,063.21	32,988,469.32	1,383,453.99	31,605,015.33
Low-value consumables	1,350,048.61	209,956.27	1,140,092.34	2,643,028.64	268,617.88	2,374,410.76
Outsourcing gifts	11,858,116.84	1,832,658.48	10,025,458.36	11,494,429.58	1,630,055.73	9,864,373.85
Total	387,056,634.20	30,773,989.77	356,282,644.43	494,267,971.45	25,626,953.70	468,641,017.75

(2). Provision for decline in value of inventories and provision for decline in value of contract performance costs

 $\sqrt{Applicable} \square N/A$

-	Opening	Increase for t		Decrease for	Closing	
Item	balance	Provision Others		Recovery or reversal	Others	balance
Raw materials	790,191.51	140,198.05			127.01	930,262.55
Goods in process	333,215.45	38,845.85		92,393.66		279,667.64
Goods on hand	21,221,419.14	7,122,040.90		2,173,222.75	438,658.71	25,731,578.58
Revolving materials						
Consumable biological assets						
Contract performance costs						
Packing	1,383,453.99	947,035.84		540,623.58		1,789,866.25

materials					
Low-value	268,617.88	17,763.19	59,081.59	17,343.21	209,956.27
consumables					
Outsourcing	1,630,055.73	359,284.76	156,682.01		1,832,658.48
gifts					
Total	25,626,953.70	8,625,168.59	3,022,003.59	456,128.93	30,773,989.77

The other decrease in the provision for decline in value of inventories for the period is RMB 456,128.93 in the current period because the equity of Shanghai Healthlong Company was disposed and provision for decline in value of inventories was reversed.

At the end of the period, the net realizable value of some products is lower than the corresponding cost, so the provision for decline in value of inventories is made based on the excess of the cost over the net realizable value.

(3). Descriptions of the closing balance of inventories including capitalized amount of borrowing costs

 \Box Applicable $\sqrt{N/A}$

(4). Descriptions of amortization of contract performance costs for the current period

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

10. Contract assets

(1). Descriptions of contract assets

 \Box Applicable $\sqrt{N/A}$

(2). Significant changes in the carrying amount during the reporting period and reasons therefor: $\Box Applicable \ \sqrt{N/A}$

(3). Descriptions of the provision for impairment made for contract assets for the current period \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

11. Held-for-sale assets

 \Box Applicable $\sqrt{N/A}$

12. Non-current assets due within 1 year

 \Box Applicable $\sqrt{N/A}$

13. Other current assets

 $\sqrt{\text{Applicable }} \square N/A$

Item	Closing balance	Opening balance		
Contract acquisition cost				
Cost of returns receivable	2,401,805.37	4,434,684.01		
VAT input tax to be deducted	42,865,528.18	24,162,220.64		

Pre-paid taxes		6,638,906.62
Total	45,267,333.55	35,235,811.27

None

14. Debt investments

(1). Descriptions of debt investments

□Applicable √N/A

(2). Other significant debt investments at the closing of the period

 \Box Applicable $\sqrt{N/A}$

(3). Provisions for impairment

 \Box Applicable $\sqrt{N/A}$

15. Other debt investments

(1). Descriptions of other debt investments

 \Box Applicable $\sqrt{N/A}$

(2). Other significant debt investments at the closing of the period

 \Box Applicable $\sqrt{N/A}$

(3). Provision for impairment

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

16. Long-term receivables

(1) Descriptions of long-term receivables

 \Box Applicable $\sqrt{N/A}$

(2) Provision for bad debts

 \Box Applicable $\sqrt{N/A}$

(3) Long-term receivables derecognized due to the transfer of financial assets

 \Box Applicable $\sqrt{N/A}$

(4) Assets and liabilities generated by the transfer of long-term receivables and continuing involvement therein

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

17. Long-term equity investments

 $\sqrt{\text{Applicable }} \square N/A$

I	Investee	Beginni-	Increase or Current decrease	Closing	Closing

	ng balance	Additional investment	Decreased investment	Investm -ent gains or losses under equity method	Adjustme -nt in other comprehe nsive income	Other equity changes	Declared cash dividends or profits	Provisions for impairment	Others	balance	balance of provisions for impairment
I. Joint ventures											
Huzhou Panrui Industrial Investment Partnership (LP)	3,306,63 0.57			-5,579. 63						3,301,050 .94	
Sub-total	3,306,63 0.57			-5,579. 63						3,301,050 .94	
II. Associates	0.37			0.5						.74	
Xiongke Culture Media (Hangzhou) Co., Ltd.	2,985,51 1.35			-53,464 .43						2,932,046 .92	
Metis Information Technology (Guangzhou) Co., Ltd.	6,304,43 0.78			136,36 6.94						6,440,797 .72	
Jiaxing Woyong Investment Partnership (LP)	45,623,4 86.90	28,206,800		-24,953 .93						73,805,33 2.97	
Zhuhai Healthlong Biotechnology Co., Ltd. [Note]		99,540,881		-2,349, 263.38						97,191,61 7.72	
Beijing Xiushi Culture Development Co., Ltd.		3,000,000. 00		-78,212 .27						2,921,787 .73	
Sub-total	54,913,4 29.03	130,747,68 1.10		-2,369, 527.07						183,291,5 83.06	
Total	58,220,0 59.60	130,747,68 1.10		-2,375, 106.70						186,592,6 34.00	

[Note] In April 2021, the Company increased the capital contribution to Zhuhai Healthlong Biotechnology Co., Ltd. in the form of 52% of equity held by it in Shanghai Healthlong Company. After the increase in capital contribution completes, Shanghai Healthlong Company becomes a wholly-owned subsidiary of Zhuhai Healthlong Biotechnology Co., Ltd., and the Company holds 10.00% of equity in Zhuhai Healthlong Biotechnology Co., Ltd. and has the right to appoint one director to Zhuhai Healthlong Biotechnology Co., Ltd..

18. Other equity investment

(1). Descriptions of other equity investment

 $\sqrt{\text{Applicable }} \square N/A$

Item	Closing balance	Opening balance
Regenovo Biotechnology Co., Ltd.	20,580,000.00	20,580,000.00

Total	20,580,000.00	20,580,000.00

(2). Descriptions of investments in non-trading equity instruments

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 $\sqrt{\text{Applicable }} \square N/A$

The Company makes external equity investments based on its strategic investment purposes, and the investee will regard such investments made by the Company as an equity instrument. Therefore, the Company designates the aforesaid equity instrument as financial assets at fair value through other comprehensive income.

19. Other non-current financial assets

 \Box Applicable $\sqrt{N/A}$

20. Investment property

Measurement of investment properties

(1). Investment properties measured at cost

Item	Housing and buildings	Land use rights	Construction in progress	Total
I. Original costs:				
1. Opening balance	76,860,032.10			76,860,032.10
2. Current increase	954,717.67			954,717.67
(1) Outsourcing				
(2) Transfer from inventories/fixed assets/construction in progress	954,717.67			954,717.67
(3) Increase due to business combinations				
3. Current decrease				
(1) Disposal				
(2) Other transfer-out				
4. Closing balance	77,814,749.77			77,814,749.77
II. Accumulated depreciation and amortization				
1. Opening balance	4,622,422.00			4,622,422.00
2. Current increase	1,372,911.82			1,372,911.82
(1) Provision or amortization	1,372,911.82			1,372,911.82
3. Current decrease				
(1) Disposal				
(2) Other transfer-out				
4. Closing balance	5,995,333.82			5,995,333.82
III. Provisions for impairment				
1. Opening balance				
2. Current increase				
(1) Provision				

3. Current decrease			
(1) Disposal			
(2) Other transfer-out			
4. Closing balance			
VI. Carrying Amount			
1. Closing carrying	71,819,415.95		71,819,415.95
amount			
2. Opening carrying	72,237,610.10		72,237,610.10
amount			

(2). Investment properties whose title certificate has not completed:

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

21. Fixed assets

Line items

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance		
Fixed assets	553,956,322.47	565,864,152.62		
Disposal of fixed assets				
Total	553,956,322.47	565,864,152.62		

Other descriptions:

None

Fixed assets

(1). Descriptions of fixed assets

 $\sqrt{\text{Applicable }} \square N/A$

Item	Houses and	Special	Transportation		Total
I O : : 1	buildings	equipment	facility		
I. Original costs:					
1. Opening balance	533,689,138.34	177,652,603.03	21,224,973.25	62,250,935.84	794,817,650.46
2. Current increase	4,729,102.52	4,584,670.52	51,327.43	3,314,473.03	12,679,573.50
(1) Purchase	1,111,363.72	4,584,670.52	51,327.43	3,314,473.03	9,061,834.70
(2) Transfer from	3,617,738.80				3,617,738.80
construction in progress					
(3) Increase due					
to business combinations					
3. Current			1,612,387.59	2,459,613.77	4,072,001.36
decrease					
(1) Disposal or				88,459.72	88,459.72
retirement					
(2) Other			1,612,387.59	2,371,154.05	3,983,541.64
transfer-out [note]					
4. Closing balance	538,418,240.86	182,237,273.55	19,663,913.09	63,105,795.10	803,425,222.60
II. Accumulated					
depreciation	_				
1. Opening balance	89,221,072.09	101,568,423.97	12,505,940.35	25,658,061.43	228,953,497.84

2. Current increase	9,747,892.79	6,479,920.33	960,417.13	4,801,042.96	21,989,273.21
(1) Provision	9,747,892.79	6,479,920.33	960,417.13	4,801,042.96	21,989,273.21
3. Current decrease			425,968.71	1,047,902.21	1,473,870.92
(1) Disposal or				71,332.84	71,332.84
retirement				/1,332.64	71,332.64
(2) Other			425,968.71	976,569.37	1,402,538.08
transfer-out					
4. Closing balance	98,968,964.88	108,048,344.30	13,040,388.77	29,411,202.18	249,468,900.13
III. Provisions for					
impairment					
 Opening balance 					
2. Current increase					
(1) Provision					
3. Current decrease					
(1) Disposal or					
retirement					
(2) Other					
transfer-out					
4. Closing balance					
VI. Carrying Amount					
1. Closing carrying	130 110 275 08	74,188,929.25	6 623 524 32	33 604 502 02	553,956,322.47
amount	737,447,413.30	17,100,727.23	0,023,324.32	33,034,332.32	555,750,544.47
2. Opening carrying	444,468,066.25	76,084,179.06	8,719,032.90	36,592,874.41	565,864,152.62
amount					
[N]-4-1 O414				D1 (D 0 000 5	11 64 1 1

[Note] Other transfer-out in the original costs of fixed assets amounts to RMB 3,983,541.64 and other transfer-out in the accumulated depreciation amounts to RMB 1,402,538.08 because the equity in Shanghai Healthlong Company was disposed, and the original costs and accumulated depreciation of fixed assets were transferred out correspondingly.

(2). Temporarily idle fixed assets

 \Box Applicable $\sqrt{N/A}$

(3). Fixed assets leased in under financing leases

 \Box Applicable $\sqrt{N/A}$

(4). Fixed assets leased out under operating leases

 \Box Applicable $\sqrt{N/A}$

(5). Fixed assets whose title certificate has not completed

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

Disposal of fixed assets

 \Box Applicable $\sqrt{N/A}$

22. Construction in progress

Line items

 $\sqrt{\text{Applicable }} \square N/A$

Item	Closing balance	Opening balance	
Construction in progress	115,081,293.14	47,324,523.36	
Project material			
Total	115,081,293.14	47,324,523.36	

None

Construction in progress

(1). Descriptions of construction in progress

√Applicable □N/A

Unit: Yuan Currency: RMB

	C	losing balan	ce	Opening balance			
Item	Gross carrying amount	Provision for impairment	Carrying amount	Gross carrying amount	Provision for impairment	Carrying amount	
Decoration project	1,544,747.89		1,544,747.89	1,725,308.02		1,725,308.02	
Makeup factory	27,281,335.63		27,281,335.63	28,236,822.35		28,236,822.35	
Proya building							
Longwu R&D center construction project	9,009,078.59		9,009,078.59				
Huzhou production base expansion construction project (phase I)	53,035,577.18		53,035,577.18				
Other sporadic projects	24,210,553.85		24,210,553.85	17,362,392.99		17,362,392.99	
Total	115,081,293.14		115,081,293.14	47,324,523.36		47,324,523.36	

(2). Changes in significant construction in progress for the period

 $\sqrt{Applicable} \square N/A$

Unit: Yuan Currency: RMB

Items	Expected amount	Opening balance	Current increase	Amount reclassified into fixed assets for the period	Other decreases for the period	Closing balance	Proportion of accumulated project investments to the budget (%)	Project progress	Accumulated amount of interest capitalization	Including: Accumulated amount of interest capitalization for the period	Rate of interest capitalization for the current period (%)	Funding source
Makeup factory	66,110, 000	28,236,82 2.35		1,361,06 1.95		27,281,3 3 5.63		97.31				Self- collected
Proya building	458,936, 300		4,572,45 6.47	3,617,73 8.80	954,71 7.67		83.22	100.00	9,206,1 86.05			Self- collected
Longwu R&D center construction project	217,744, 500		9,009,07 8.59			9,009,07 8.59	4.14	4.14				Self- collected
Huzhou expansion production base construction project (phase I)	437,525, 400		53,035,57 7.18			53,035,5 7 7.18		12.12				Self-collected
Total	1,180,31 6, 200	28,236,82 2.35	67,022,68 7.47	4,978,80 0.75	954,71 7.67	89,325,9 9 1.40		/	9,206,1 86.05		/	

(3). Provision for decline in value of construction in progress for the period

□Applicable √N/A

Other descriptions \Box Applicable $\sqrt{N/A}$

Project materials

 \Box Applicable $\sqrt{N/A}$

23. Bearer biological assets

(1). Bearer biological assets measured at cost

 \Box Applicable $\sqrt{N/A}$

(2). Bearer biological assets measured at fair value

 \Box Applicable $\sqrt{N/A}$ Other descriptions

 \Box Applicable $\sqrt{N/A}$

24. Oil and gas assets

 \Box Applicable $\sqrt{N/A}$

25. Use of right assets

 \Box Applicable $\sqrt{N/A}$

26. Intangible assets

(1). Descriptions of intangible assets

 $\sqrt{Applicable} \square N/A$

					Unit. 1	dan Carre	ncy. Kwib
Item	Land use	Software	Patent	Nonpatented	Customer	Tradema	Total
Item	rights	Software	rights	technology	recourses	rk right	Total
I. Original costs:							
1. Opening	376,212,9	19,559,1	420,000	659,500.00	12,833,6	137,131.	409,822,
balance	28.47	30.84	.00		84.00	75	375.06
2. Current	71,073,39	4,199,36					75,272,7
increase	4.50	6.07					60.57
(1)	71,073,39	4,115,29					75,188,6
Purchase	4.50	5.27					89.77
(2) Internal							
research and							
development							
(3) Increase							
due to business							
combinations							
(4)		84,070.8					84,070.8
Transfer-in from		0					0
construction in							
progress							
3. Current		427,966.		126,900.00			554,866.
decrease		61					61
(1)							
Disposal							
(2) Other		427,966.		126,900.00			554,866.
transfer-out [note]		61					61
4. Closing	447,286,3	23,330,5	420,000	532,600.00	12,833,6	137,131.	484,540,

balance	22.97	30.30	.00		84.00	75	269.02
II. Accumulated							
amortization							
1. Opening	68,955,03	17,764,8	420,000	528,525.00	7,486,31	24,354.0	95,179,0
balance	1.99	24.37	.00		5.67	6	51.09
2. Current	5,633,846.	935,930.		1,630.00	2,138,94	13,637.3	8,723,99
increase	55	62			7.33	7	1.87
(1)	5,633,846.	935,930.		1,630.00	2,138,94	13,637.3	8,723,99
Provision	55	62			7.33	7	1.87
3. Current		288,075.					288,075.
decrease		61					61
(1)							
Disposal							
(2) Other		288,075.					288,075.
transfer-out [Note]		61					61
4. Closing	74,588,87	18,412,6	420,000	530,155.00	9,625,26	37,991.4	103,614,
balance	8.54	79.38	.00		3.00	3	967.35
III. Provisions for							
impairment							
1. Opening							
balance							
2. Current							
increase							
(1)							
Provision							
3. Current							
decrease							
(1)							
Disposal							
4. Closing							
balance							
VI. Carrying							
Amount							
1. Closing	372,697,4	4,917,85		2,445.00	3,208,42	99,140.3	380,925,
carrying amount	44.43	0.92			1.00	2	301.67
2. Opening	307,257,8	1,794,30		130,975.00	5,347,36	112,777.	314,643,
carrying amount	96.48	6.47		vad assats amour	8.33	69	323.97

[Note] Other transfer-out in the original costs of fixed assets amounts to RMB 554,866.61 and other transfer-out in the accumulated depreciation amounts to RMB 288,075.61 because the equity in Shanghai Healthlong Company was disposed, and the original costs and accumulated depreciation of fixed assets were transferred out correspondingly.

Proportion of intangible assets generated from the Company's internal research and development to the balance of intangible assets at the closing of the period: 0.00%

(2). The right to use the land whose title certificate has not completed

 \Box Applicable $\sqrt{N/A}$

Other descriptions: none $\Box Applicable \sqrt{N/A}$

27. Development expenditure

 \Box Applicable $\sqrt{N/A}$

28. Goodwill

(1). Original costs of goodwill

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

		Current increa	ise	Current decre	ease	-
Investee or event forming goodwill	Opening balance	Formed by business combinations		Disposal		Closing balance
Shanghai Healthlong	31,034,161.20			31,034,161.20		
Biochemical						
Technology Co., Ltd.						
Total	31,034,161.20			31,034,161.20		

(2). Provision for impairment of goodwill

 \Box Applicable $\sqrt{N/A}$

Unit: Yuan Currency: RMB

Investee or event	Opening	Currer	nt increase	Current	decrease	Closing
forming goodwill	Opening balance	Provisi on		Disposal		balance
Shanghai Healthlong						
Biochemical						
Technology Co., Ltd.						
Total						

- (3). Relevant information regarding the asset portfolio and set of asset portfolios to which the goodwill belongs
- \Box Applicable $\sqrt{N/A}$
- (4). Descriptions of the process of goodwill impairment testing, key parameters (such as the growth rate of the forecast period, the growth rate of the stable period, the profit rate, the discount rate and the forecast period, etc. when the present value of future cash flows are expected, if applicable) and the recognition method of the impairment losses on goodwill:

 \Box Applicable $\sqrt{N/A}$

(5). Impacts of goodwill impairment testing

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

29. Long-term prepaid expenses

 $\sqrt{\text{Applicable }} \square N/A$

Item	Opening balance	Increase	Amortization	Other decreases	Closing balance
Decoration and rental fee	33,212,097.20	5,128,945.23	8,511,189.18	1,038,383.80	28,791,469.45
Endorsement fee	16,863,206.70		7,783,018.86		9,080,187.84
Garage usage fee	385,900.48		96,474.96		289,425.52
Software service fee	115,589.15	50,068.15	26,543.16	139,114.14	

Total	50,576,793.53	5,179,013.38	16,417,226.16	1,177,497.94	38,161,082.81

Other decreases amount to RMB 1,177,497.94 because the equity in Shanghai Healthlong Company was disposed, and other long-term prepaid expenses were transferred out correspondingly.

30. Deferred tax assets / deferred tax liabilities

(1). Deferred income tax assets that are not offset

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

	Closing	balance	Opening	balance
Item	Deductible	Deferred income	Deductible	Deferred income
Item	temporary	taxes	temporary	taxes
	differences	Assets	differences	Assets
Provision for impairment				
of assets				
Unrealized profits of	34,777,937.02	7,384,724.22	28,021,116.50	7,005,279.12
in-house transactions				
Deductible losses	54,823,543.17	13,705,885.79	14,342,610.24	3,585,652.56
Provision for bad debts of	22,958,476.78	5,739,196.02	27,188,715.77	6,796,972.50
accounts receivable				
Provision for decline in	15,841,244.67	2,537,346.55	15,796,150.28	2,634,264.73
value of inventories				
Effect of share-based	76,964,315.53	16,807,484.60	103,953,760.07	22,803,327.25
payment				
Government grants	7,455,808.33	1,118,371.25	8,495,353.33	1,274,303.00
related to assets				
Member credits not	8,836,723.45	2,209,180.86	4,487,591.14	1,121,897.79
exchanged				
Expected losses on return	5,900,432.41	1,475,108.11	5,755,415.21	1,438,853.81
Total	227,558,481.36	50,977,297.40	208,040,712.54	46,660,550.76

(2). Deferred tax liabilities that are not offset

 $\sqrt{\text{Applicable }} \square N/A$

	Closing balance		Opening balance	
Item	Taxable	Deferred income	Taxable	Deferred income
Item	temporary	taxes	temporary	taxes
	differences	Liabilities	differences	Liabilities
Value-added valuation of				
business combination not				
involving enterprises				
under common control				
Changes in fair value of				
other debt investments				
Changes in fair value of				
other investments in				
equity instruments				
One-time deduction of	39,572,107.58	6,141,332.95	44,252,231.66	6,874,105.45
depreciation of fixed				
assets				
Total	39,572,107.58	6,141,332.95	44,252,231.66	6,874,105.45

(3). Deferred income tax assets or liabilities listed as net amount after offset

 \Box Applicable $\sqrt{N/A}$

(4). Details of unrecognized deferred tax assets

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance
Deductible temporary differences	28,452,553.38	25,362,258.78
Deductible losses	409,443,960.15	379,300,493.32
Total	437,896,513.53	404,662,752.10

(5). Deductible losses, for which no deferred tax assets are recognized, will expire in the following year

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Year	Closing balance	Opening balance	Note:
2021	48,418,743.43	48,812,246.22	
2022	62,924,802.76	62,924,802.76	
2023	63,485,783.30	63,485,783.30	
2024	99,748,285.21	99,748,285.21	
2025	104,329,375.83	104,329,375.83	
2026	30,536,969.62		
Total	409,443,960.15	379,300,493.32	

Other descriptions: \Box Applicable $\sqrt{N/A}$

31. Other non-current assets

 $\sqrt{Applicable} \square N/A$

Cint. Tuan Currency, Iti/ID						
	(Closing balance	e	C	Opening balanc	e
Item	Gross carrying amount	Provision for impairment	Carrying amount	Gross carrying amount	Provision for impairment	Carrying amount
Contract acquisition cost						
Contract performance cost						
Cost of returns receivable						
Contract assets						
Prepayment for long-term asset purchase	5,731,163.01		5,731,163.01	87,322,780.03		87,322,780.03
Total	5,731,163.01		5,731,163.01	87,322,780.03		87,322,780.03

None

32. Short-term borrowings

(1). Classification of short-term borrowings

 $\sqrt{\text{Applicable }} \square N/A$

 Item
 Closing balance
 Opening balance

 Pledged borrowings
 Mortgaged borrowings

 Guaranteed borrowings
 99,116,462.50

 Credit borrowings
 200,000,000.00
 200,163,972.59

 Total
 200,000,000.00
 299,280,435.09

Descriptions of classification of short-term borrowings:

None

(2). Descriptions of overdue short-term borrowings

□Applicable √N/A

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

33. Held-for-trading financial liabilities

 \Box Applicable $\sqrt{N/A}$

34. Derivative financial liabilities

 \Box Applicable $\sqrt{N/A}$

35. Notes payable

 $\sqrt{\text{Applicable }} \square N/A$

		Unit: Yuan Currency: RMB
Category	Closing balance	Opening balance
Commercial acceptance bills		
Bank acceptance bills	63,672,739.08	64,580,000.00
Total	63,672,739.08	64,580,000.00

The total of notes payable due but not yet paid at the closing of the period is RMB 0.00.

36. Accounts payable

(1). Presentations of accounts payable

 $\sqrt{\text{Applicable }} \square N/A$

		Unit: Yuan Currency: RMB
Item	Closing balance	Opening balance
Loan	277,661,939.49	428,697,891.17
Expenses payable	56,545,217.33	69,493,675.06
Engineering equipment payment	12,530,902.29	17,640,465.04
Total	346,738,059.11	515,832,031.27

(2). Significant accounts payable aged more than one year

□Applicable √N/A

 \Box Applicable $\sqrt{N/A}$

37. Advances from customers

(1). Presentation of advances from customers

 \Box Applicable $\sqrt{N/A}$

(2). Significant advances from customers aged more than one year

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

38. Contract liabilities

(1). Descriptions of contract liabilities

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance
Advances from customers	43,983,461.92	25,430,738.70
Member credits not exchanged	8,836,723.45	5,188,040.29
Total	52,820,185.37	30,618,778.99

(2). Significant changes in the carrying amount during the reporting period and reasons therefor

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

39. Employee benefits payable

(1). Presentation of employee benefits payable

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Opening balance	Current increase	Current decrease	Closing balance
1. Short-term benefits	70,254,622.82	210,468,522.10	228,089,801.82	52,633,343.10
II. Post-employment	573,616.88	10,309,869.38	10,607,813.89	275,672.37
benefits - defined				
contribution plans				
III. Termination benefits				
IV. Other benefits due				
within 1 year				
Total	70,828,239.70	220,778,391.48	238,697,615.71	52,909,015.47

(2). Presentation of short-term benefits

 $\sqrt{\text{Applicable }} \square N/A$

Unit:	Yuan	Currency:	RN	ſΒ
-------	------	-----------	----	----

			Omit. I dan	Currency: Tuilb
Item	Opening	Current	Current	Closing balance
Item	balance	increase	decrease	Closing balance
I. Wages or salaries,				
bonuses, allowances and	68,643,838.60	191,612,938.58	208,338,101.90	51,918,675.28
subsidies				
II. Staff welfare	6,815.56	5,858,508.97	5,855,932.97	9,391.56
III. Social insurance;	882,228.00	7,172,419.81	7,638,847.11	415,800.70

Including: Medical care	776,190.95	6,812,844.77	7,207,183.76	381,851.96
Work-related injury	57,859.33	203,411.07	257,095.72	4,174.68
Maternity	48,177.72	156,163.97	174,567.63	29,774.06
IV. Housing funds;	721,740.66	5,425,796.06	5,858,061.16	289,475.56
V. Union running costs and employee education costs;		398,858.68	398,858.68	
VI. Short-term paid				
absences				
VII. Short-term profit share				
plan				
Total	70,254,622.82	210,468,522.10	228,089,801.82	52,633,343.10

(3). Presentation of defined benefit plan

√Applicable □N/A

Unit: Yuan Currency: RMB

Item	Opening balance	Current increase	Current decrease	Closing balance
1. Basic endowment	546,117.72	9,957,166.67	10,237,307.78	265,976.61
2. Unemployment	27,499.16	352,702.71	370,506.11	9,695.76
3. Enterprise pension fund				
Total	573,616.88	10,309,869.38	10,607,813.89	275,672.37

Other descriptions: $\Box Applicable \sqrt{N/A}$

40. Taxes payable

 $\sqrt{Applicable} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance
VAT	37,072,212.41	25,557,167.53
Consumption tax	465.21	359.31
Business tax		
Enterprise income tax	27,853,623.09	32,994,016.76
Individual Income Tax	1,143,757.11	1,193,830.42
Urban maintenance and	1,998,938.64	2,971,080.02
construction tax		
Property tax	4,052,264.13	5,822,344.89
Education surcharges	975,674.47	1,469,430.26
Local education surcharges	650,449.65	979,620.14
Stamp tax	84,218.47	330,703.60
Disability security fund	5,886.80	16,737.84
Total	73,837,489.98	71,335,290.77

Other descriptions:

None

41. Other payables

Line items

√Applicable □N/A

Item	Closing balance	Opening balance
Interest payable		
Dividends payable		

Other payables	73,609,323.68	75,546,323.32
Total	73,609,323.68	75,546,323.32

None

Interest payable

□Applicable √N/A

Dividends payable

□Applicable √N/A

Other payables

(1). Other payables by nature

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance
Security deposit	54,254,673.00	54,289,062.52
Repurchase obligations of restricted shares	7,361,933.60	12,653,905.25
Others	11,992,717.08	8,603,355.55
Total	73,609,323.68	75,546,323.32

(2). Other significant payables aged more than one year

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Closing balance	Reasons for failure to be repaid or carried forward
Repurchase obligations of restricted shares	7,361,933.60	Repurchase obligations of restricted shares have not been fulfilled fully
Total	7,361,933.60	/

Other descriptions:

□Applicable √N/A

42. Held-for-sale liabilities

□Applicable √N/A

43. Non-current liabilities due within one year

□Applicable √N/A

44. Other current liabilities

 $\sqrt{\text{Applicable }} \square N/A$

Item	Closing balance	Opening balance
Short-term bonds payable		
Returns payable		

Pending output VAT	2,149,196.85	1,439,262.02
Total	2,149,196.85	1,439,262.02

Changes in short-term bonds payable:

□Applicable √N/A

Other descriptions: None \Box Applicable $\sqrt{N/A}$

45. Long-term borrowings

(1). Classification of long-term borrowings

□Applicable √N/A

Other explanations, including interest rate range:

□Applicable √N/A

46. Bonds payable

(1). Bonds payable

□Applicable √N/A

(2). Changes in bonds payable (excluding preferred stocks, perpetual bonds and other financial instruments classified as financial liabilities)

□Applicable √N/A

(3). Descriptions of conversion condition and time for convertible corporate bonds

□Applicable √N/A

(4). Descriptions of other financial instruments classified as financial liabilities

Basic information of outstanding preferred shares, perpetual bonds and others financial instruments at the closing of the period

□Applicable √N/A

Table of changes in outstanding preferred shares, perpetual bonds and others financial instruments at the closing of the period

□Applicable √N/A

Basis for other financial instruments classified as financial liabilities

□Applicable √N/A

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

47. Lease liabilities

□Applicable √N/A

48. Long-term payables

Line items

 \Box Applicable $\sqrt{N/A}$

Long-term payables

 \Box Applicable $\sqrt{N/A}$

Special payables

□Applicable √N/A

49. Long-term employee benefits payable

 \Box Applicable $\sqrt{N/A}$

50. Estimated liabilities

 $\sqrt{\text{Applicable }} \square N/A$

		Uni	t: Yuan Currency: RMB
Item	Opening balance	Closing balance	Reason
Guarantees provided to			
outsiders			
Pending lawsuits			
Quality assurance			
Restructuring			
obligations			
Onerous contract to be performed			
Returns payable	10,190,099.22		Possible future losses on return expected
Others			
Total	10,190,099.22	6,052,681.88	/

Other descriptions, including those of important assumptions and estimation related to significant estimated liabilities:

None

51. Deferred income

Deferred income

 $\sqrt{\text{Applicable }} \square N/A$

				Unit: Yuan	Currency: RMB
Item	Opening balance	Current increase	Current decrease	Closing balance	Reason
Government	8,495,353.33		1,039,545.00	7,455,808.33	Allocated by the
grants					government
Total	8,495,353.33		1,039,545.00	7,455,808.33	/

Projects involving government grants

 $\sqrt{\text{Applicable }} \square N/A$

					Uni	it: Yuan Cur	rency: RMB
Liabilities	Opening balance	Additional government grants for the current period	non-operating income for	Amount recognized in other comprehensive income for the current period	C	Closing balance	Related to assets/income
Subsidy for	8,495,353.33			1,039,545.00		7,455,808.33	Related to

technological				assets
innovation of				
cosmetics				

√ Applicable □N/A

The government subsidies recognized in profit or loss for the current period are seen in the VII. 84 Descriptions of government grants in Section X Financial Report for details.

52. Other non-current liabilities

□Applicable √N/A

53. Share capital

√ Applicable □N/A

Unit: Yuan Currency: RMB

			Changes this time (+ or -)				
	Opening balance	Issue of new shares	Bonus shares	Reserves Conversion of shares	Others	Sub-total	Closing balance
Total shares	201,116,925						201,116,925

Other descriptions:

Descriptions of share pledge

As of June 30, 2021, the details of the frozen shares of majority shareholders of the Company are as follows:

Shareholder	Total number of Number of frozen		Freeze type
	shares held (share)	shares (share)	
Fang Yuyou	42,211,691	11,920,000	Pledge
Sub-total	42,211,691	11,920,000	

54. Other equity instruments

(1) Basic information of outstanding preferred shares, perpetual bonds and others financial instruments at the closing of the period

 \Box Applicable $\sqrt{N/A}$

(2) Table of changes in outstanding preferred shares, perpetual bonds and others financial instruments at the closing of the period

□Applicable √N/A

Changes in other equity instruments, reasons therefor and basis for relevant accounting treatment:

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

□Applicable √N/A

55. Capital reserve

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Opening balance	Current increase	Current decrease	Closing balance
Capital premium	794,285,959.20	8,816,160.85	790,675.05	802,311,445.00
(share premium)				
Other capital	42,748,877.49	4,787,988.53	8,816,160.85	38,720,705.17
reserves				
Total	837,034,836.69	13,604,149.38	9,606,835.90	841,032,150.17

Other descriptions, including changes for the current period and reasons therefor:

1) Changes in capital premium

The capital premium (share premium) for the period increased by RMB 8,816,160.85, because other capital reserves recognized during the vesting period for the vested portion of restricted shares issued under share incentive plan were transferred to the share premium.

The capital premium (share premium) for the period decreased by RMB 790,675.05, because: ① the decrease by RMB 706,570.34 was caused by purchase of the minority shareholders' equity of the subsidiary Shanghai Zhongwen Electronic Commerce Co., Limited, and was the difference between the payment and the share of the subsidiary's identifiable net assets calculated according to the newly-increased shareholding ratio; ② the decrease by RMB 84,104.71 was caused by purchase of the minority shareholders' equity of Hongkong Zhongwen Electronic Commerce Co., Limited by the subsidiary Hongkong Xinghuo Industry Limited, and was the difference between the payment and the share of the subsidiary's identifiable net assets calculated according to the newly-increased shareholding ratio.

2) Changes in other capital reserves

Other capital reserves for the period increased by RMB 4,787,988.53 because: ① the increase by RMB 3,763,087.45 included RMB 2,262,118.91 of the restricted share incentive expenses from January to June 2021 recognized pursuant to the Company's share incentive plan, which was charged to other capital reserves; and included RMB 1,500,968.54 of the deferred tax assets for the excess of the amount expected to be deductible before tax in the future periods over the recognized restricted share incentive expenses, which was charged to other capital reserves; ② the increase by RMB 1,024,901.08 was the difference between the actual deductible amount of the vested portion and the amount previously recognized, which was treated an adjustment to the capital reserve.

Other capital reserves for the period decreased by RMB 8,816,160.85, because the other capital reserves recognized during the vesting period for the vested portion of restricted shares issued under share incentive plan were transferred to the share premium.

56. Treasury stock

 $\sqrt{\text{Applicable}} \square N/A$

Total

Unit: Yuan Currency: RMBItemOpening balanceCurrent increaseCurrent decreaseClosing balanceRestricted shares
with repurchase
obligations12,653,905.255,291,971.657,361,933.60

5.291,971.65

7.361.933.60

Other descriptions, including changes for the current period and reasons therefor:

12,653,905,25

The reason for the current decrease by RMB 5,291,971.65 was that: 1) the decrease by RMB 4,964,976.45 was caused by the release of 293,265 restricted shares (the grant price of RMB 17.95/share less RMB 1.02/share for accumulated dividends) by the Company pursuant to the *Proposal on the Satisfaction of Vesting Conditions for the Second Release Period of the Initially Granted Restricted Shares and the Granted Reserved Portion* under the 2018 Restricted Share Incentive Plan reviewed and approved by the 18th meeting of the second board of directors dated January 5, 2021; 2) the decrease by RMB 326,995.20 was caused by the distributed dividends of 454,160 restricted shares that have not been vested being offset against treasury shares and the corresponding adjustments to other payables.

57. Other comprehensive income

 $\sqrt{\text{Applicable}} \square N/A$

						Unit: Yu	an Currei	ncy: RMB
				Amount for the cu	rrent period			
Item	Opening balance	Amounts before income tax for the current period	less: Amounts included in other comprehensive income for prior periods and transferred to the profit or loss for the current period	less: Amounts included in other comprehensive income for prior periods and transferred to the retained earnings for the current period	less: Income tax expenses	Attributable to the parent company after tax	Attributable to minority interests after tax	Closing balance
(I) Other comprehensive income that cannot be subsequently reclassified to profit or loss								
Including: Changes from re-measurement of defined								
Other comprehensive								
income that cannot be reclassified to profit or loss under the								
equity method Changes in fair value of other								
investments in equity instruments								
Changes in fair value of enterprises' own credit risks								
II. Other comprehensive income that will be reclassified to profit or loss	-269,066.13	-396,595.34				-396,595.34		-665,661.47
Including: Other comprehensive income that will be								
reclassified to profit or loss under the equity method								
Changes in fair value of other debt investments								
Amounts of financial assets reclassified into other comprehensive income								
Provision for credit impairment of other debt investments								
Reserve for cash flow								

hedges					
Translation	-269,066.13	-396,595.34		-396,595.34	-665,661.47
differences of					
financial					
statements					
denominated in					
foreign					
currencies					
Total of other	-269,066.13	-396,595.34		-396,595.34	-665,661.47
comprehensive					
income					

Other descriptions, including adjustment of the effective part of the cash flow hedge gains and losses transferred to initially recognized amount of hedged items:

None

58. Special reserve

□Applicable √N/A

59. Surplus reserve

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Opening balance	Current increase	Current decrease	Closing balance
Statutory surplus	100,634,780.00			100,634,780.00
reserve				
Discretionary				
surplus reserve				
Reserve funds				
Enterprise				
development fund				
Others				
Total	100,634,780.00			100,634,780.00

Descriptions of surplus reserve, including changes for the current period and reason therefor:

In accordance with the provisions of the *Company Law*, where the accumulated amount of the statutory surplus fund of the Company exceeds 50 percent of its registered capital, further allocation may be dispensed with.

60. Unappropriated profit

 $\sqrt{\text{Applicable } \square N/A}$

Item	Repayment for the period	Previous year
Adjustments to unappropriated profit at the closing of the period period	1,265,671,865.63	908,411,607.62
Total adjustments to unappropriated profits at the opening of the period (increase indicated by "+", or decrease indicated by "-")		
Unappropriated profit at the opening of the period after adjustment	1,265,671,865.63	908,411,607.62
Add: Net profit attributable to owners of the parent company for the current period	226,101,313.86	476,009,298.41
less: Appropriation to statutory surplus reserve		
Appropriation to discretionary surplus reserve		

Appropriation to general risk		
reserve		
Common stock dividends payable	144,804,186.00	118,749,040.40
Common stock dividends		
transferred to share capital		
Closing unappropriated profit	1,346,968,993.49	1,265,671,865.63

Details of adjustments to unappropriated profit at the opening of the period:

- 1. As a result of the retrospective adjustment under the *Accounting Standards for Business Enterprises* and related new regulations, unappropriated profit at the opening of the period were affected by RMB0.00.
- 2. Unappropriated profit at the opening of the period was affected by RMB0.00 due to changes in accounting policies.
- 3. Unappropriated profit at the opening of the period was affected by RMB0.00 due to the correction of significant accounting errors.
- 4. Unappropriated profit at the opening of the period was affected by RMB0.00 due to changes in the scope of consolidation resulting from business combination involving enterprises under common control.
- 5. Unappropriated profit at the opening of the period was affected by RMB0.00 in total due to other adjustments.

61. Revenue and cost of revenue

(1). Descriptions of revenue and cost of revenue

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Amount for the current period		Amount for the current period		Amount for th	Amount for the prior period	
Item	Revenue	Revenue Cost		Cost			
Main operations	1,911,280,464.91	690,938,535.18	1,382,135,112.85	552,948,536.81			
Other operations	6,438,032.69	4,619,754.01	2,188,736.03	2,171,918.35			
Total	1,917,718,497.60	695,558,289.19	1,384,323,848.88	555,120,455.16			

(2). Descriptions of revenue generated from contacts

□Applicable √N/A

(3). Descriptions of performance obligations

 \Box Applicable $\sqrt{N/A}$

(4). Descriptions of allocation to remaining performance obligations

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

None

62. Taxes and surcharges

 $\sqrt{\text{Applicable }} \square N/A$

Item	Amount for the current period	Amount for the prior period
Consumption tax	56,425.63	19,373.48
Business tax		

Urban maintenance and	7,913,902.31	4,642,273.84
construction tax		
Education surcharges	3,977,896.25	2,391,100.89
Resource tax		
Property tax	4,052,644.03	2,136,089.34
Land use taxes		
Vehicle and vessel use tax	2,670.00	3,210.00
Stamp Tax	634,586.22	712,908.54
Local education surcharges	2,651,930.83	1,594,067.26
Total	19,290,055.27	11,499,023.35

None

63. Selling expenses

√Applicable □N/A

Unit: Yuan Currency: RMB

		inti ruun Currency. rumb
Item	Amount for the current	Amount for the prior
Item	period	period
Image publicity and promotion	651,005,247.16	334,763,800.09
Employee benefits	127,270,225.97	97,805,241.40
Travel	6,519,683.82	6,426,413.51
Conference	5,684,285.16	2,382,019.59
Office	14,176,924.87	8,889,179.33
Investigation and consulting	513,801.62	5,697,435.22
Others	2,034,463.16	1,450,343.06
Total	807,204,631.76	457,414,432.20

Other descriptions:

None

64. General and administrative expenses

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Amount for the current	Amount for the prior
	period	period
Employee benefits and labor costs	64,177,881.74	47,708,602.55
Share-based payments	2,262,118.91	5,103,364.67
Depreciation, amortization and lease	22,632,216.20	23,380,666.23
Office and business entertainment	16,334,487.33	10,813,515.29
Consulting and intermediary agency	4,861,065.35	9,116,773.89
Travel, transportation and conference	996,613.03	956,944.85
Others	4,926,790.49	3,102,487.67
Total	116,191,173.05	100,182,355.15

Other descriptions:

None

65. Research and development expenses

√Applicable □N/A

Item	Amount for the current	Amount for the prior
	period	period

Labor costs	20,466,648.49	21,620,983.90
Entrusted research and development fees	8,826,262.44	5,508,591.48
Depreciation, amortization and lease fees	1,053,552.11	1,985,453.64
Direct investments	785,036.60	1,202,200.16
Others	239,844.82	1,547,915.78
Total	31,371,344.46	31,865,144.96

None

66. Financial expenses

 $\sqrt{Applicable} \ \Box N/A$

Unit: Yuan Currency: RMB

Item	Amount for the current	Amount for the prior
	period	period
Interest expenses	5,082,866.57	2,502,979.38
Interest income	-11,723,066.05	-8,171,010.26
Handling costs	406,429.79	458,089.60
Foreign exchange gains or losses	4,369,640.90	-2,164,539.48
Total	-1,864,128.79	-7,374,480.76

Other descriptions:

None

67. Other income

 $\sqrt{\text{Applicable }} \square N/A$

Item	Amount for the current	Amount for the prior
	period	period
Government grants	9,370,319.81	8,020,757.76
Return of handling costs	467,054.66	394,975.03
Additional VAT input tax credit	322,433.43	110,916.18

10,159,807.90

Other descriptions:

The government subsidies recognized in profit or loss for the current period are seen in the VII. 84 Descriptions of government grants in Section X Financial Report for details.

68. Investment income

Total

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Unit: Yuan Currency: RMB

8,526,648.97

Item	Amount for the current period	Amount for the prior period
Income from long-term equity	-2,375,106.70	-208,988.41
investment accounted for using the		
equity method		
Income from disposal of long-term	-3,546.24	261,034.21
equity investments		
Investment income from		
held-for-trading financial assets during		
the holding period		
Dividend income from other equity		
investment instruments during the		
holding period		
Interest income from debt investment		

during the holding period		
Interest income from other debt		
investments during the holding period		
Investment income from disposal of		
held-for-trading financial assets		
Investment income from disposal of		
other investments in equity instruments		
Investment income from disposal of		
debt investments		
Investment income from disposal of		
other debt investments		
Income from wealth management		2,266,301.37
products		
Total	-2,378,652.94	2,318,347.17

None

69. Net exposure hedging income

 \Box Applicable $\sqrt{N/A}$

70. Income from changes in fair values

 \Box Applicable $\sqrt{N/A}$

71. Impairment losses of credit

 $\sqrt{\text{Applicable }} \square N/A$

		Unit: Yuan Currency: RMB
Item	Amount for the current period	Amount for the prior period
Losses on bad debts of notes receivable		
Losses on bad debts of accounts receivable	3,785,095.76	3,700,637.96
Losses on bad debts of other receivables	-829,303.17	-4,842,904.18
Losses on impairment of debt investments		
Losses on impairment of other debt investments		
Losses on bad debts of long-term receivables		
Losses on impairment of contract assets		
Total	2,955,792.59	-1,142,266.22

Other descriptions:

None

72. Asset impairment losses

√Applicable □N/A

PP		Unit: Yuan Currency: RMB
Item	Amount for the current period	Amount for the prior period
I. Losses on bad debts	-8,625,168.59	
II Losses on decline in value of		-9 651 315 34

inventories and on impairment of		
contract performance costs		
III. Losses on impairment of		
long-term equity investments		
IV. Losses on impairment of property		
V. Losses on impairment of fixed		
assets		
VI. Losses on impairment of project		
materials		
VII. Losses on impairment of		
construction in progress		
VIII. Losses on impairment of bearer		
biological assets		
IX. Losses on impairment on oil and		
gas assets		
X. Losses on impairment of		
intangible assets		
XI. Losses on impairment of		
goodwill		
XII. Others		
Total	-8,625,168.59	-9,651,315.34

None

73. Income from disposal of assets

 $\checkmark Applicable \; \Box N/A$

Unit: Yuan Currency: RMB

Item	Amount for the current period	Amount for the prior period
Income from disposal of fixed	-1,416.28	
assets		
Total	-1,416.28	

Other descriptions: \Box Applicable $\sqrt{N/A}$

74. Non-operating income

 $\sqrt{Applicable} \square N/A$

Item	Amount for the current period	Amount for the prior period	Amount included in the non-recurring profit or loss for the current period
Total gains or losses			
from disposal of			
non-current assets;			
Including: Gains from			
disposal of fixed			
assets			
Gain from			
disposal of intangible			
assets			
Gains from debt			
restructuring			

Gains from exchange			
of non-monetary			
assets			
Acceptance of			
donations			
Government grants			
Payments that do not		258,167.68	
need to be paid			
Income from	54,435.00		54,435.00
confiscation and			
liquidated damages			
Others	60,008.12	147,700.63	60,008.12
Total	114,443.12	405,868.31	
1 Otal			114,443.12

Government grants included in current profit or loss

 $\Box Applicable \quad \sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

75. Non-operating expenses

 $\sqrt{\text{Applicable }} \square N/A$

Tippiicuoie = 1771		Uni	t: Yuan Currency: RMB
Item	Amount for the current period	Amount for the prior period	Amount included in the non-recurring profit or loss for the current period
Total losses on disposal of non-current assets;		2,541.25	•
Including: Losses on disposal of fixed assets			
Losses on disposal of assets			
Losses on debt restructuring			
Losses on exchange of non-monetary assets			
Offer of donations		15,106,421.65	
Others	60,174.49	396,831.91	60,174.49
Total	60,174.49	15,505,794.81	60,174.49

Other descriptions:

None

76. Income tax expenses

(1) Table of income tax expenses

√Applicable □N/A

Item	Amount for the current period	Amount for the prior period
Current income tax	46,005,920.10	48,977,958.94
Deferred income tax	-2,523,649.52	-2,093,955.30
Total	43,482,270.58	46,884,003.64

(2) Reconciliation of income tax expenses to the accounting profit

 $\sqrt{\text{Applicable }} \square N/A$

	Unit: Yuan Currency: RMB
Item Amount for the current period	
Total profit	252,131,763.97
Income tax expenses calculated at legal/applicable tax rate	63,032,940.99
Effect of different tax rates among different subsidiaries on income tax expenses	-19,639,316.92
Effect of adjustments to income tax in prior periods	301,443.10
Effect of nontaxable income	
Effect of non-deductible costs, expenses and	269,390.94
losses	
Effect of deductible tax losses for which no deferred tax assets were recognized in prior periods	-1,024,901.08
Effect of deductible tax losses or deductible	4,591,378.58
temporary differences for which no deferred tax	
asset was recognized in the current period	
Additional deduction of R&D expense	-4,048,665.03
Income tax expenses	43,482,270.58

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

77. Other comprehensive income

 $\checkmark Applicable \; \Box N/A$

For details, please see the Note VII 57 of Section X Financial Report.

78. Items in the cash flow statement

(1). Other cash receipts relating to operating activities

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Amount for the current period	Amount for the prior period
Bank deposit interest income	11,723,066.05	6,293,169.16
Government grants	2,840,774.81	7,066,546.09
Intercourse funds and others	27,195,817.12	13,986,126.29
Total	41,759,657.98	27,345,841.54

Descriptions of other cash receipts relating to operating activities:

None

(2). Other cash payments relating to operating activities

		Unit: Yuan Currency: RMB
Item	Amount for the current period	Amount for the prior period

Image publicity and promotion	629,544,186.17	339,476,948.33
Other cash payments	165,528,596.63	60,364,118.72
Intercourse funds and others	49,745,240.01	67,229,843.63
Total	844,818,022.81	467,070,910.68

Descriptions of other cash payments relating to operating activities:

None

(3). Other cash receipts relating to investing activities

 \Box Applicable $\sqrt{N/A}$

(4). Other cash payments relating to investing activities

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Item	Amount for the current period	Amount for the prior period
Net cash payments received from disposal of subsidiaries	61,087,857.19	1,579,710.89
Total	61,087,857.19	1,579,710.89

Descriptions of other cash payments relating to investing activities:

None

(5). Other cash receipts relating to financing activities

□Applicable √N/A

(6). Other cash payments relating to financing activities

 $\sqrt{Applicable} \square N/A$

Unit: Yuan Currency: RMB

Item	Amount for the current period	Amount for the prior period
Payments for share repurchase		
Payments for minority shareholders'		
equity	486,631.52	
Total	486,631.52	

Descriptions of other cash payments relating to financing activities:

None

79. Supplementary information to the cash flow statement

(1) Supplementary information to the cash flow statement

 $\sqrt{\text{Applicable }} \square N/A$

		ome rum currency, rumb
Supplementary information	Amount for the current period	Amount for the prior period
1. Reconciliation of net profit to		
cash flow from operating activities:		
Net profit	208,649,493.39	173,684,403.26
Add: Provision for asset impairment	8,625,168.59	9,651,315.34
Losses on credit impairment	-2,955,792.59	1,142,266.22
Depreciation of fixed assets, depletion	23,362,185.03	21,086,926.72
of oil and gas assets, depreciation of		
bearer biological assets		
Amortization of use of right assets		
Amortization of intangible assets	8,723,991.87	7,451,720.65

Amortization of long-term prepaid expenses	16,417,226.16	15,323,234.42
Losses on disposal of fixed assets, intangible assets and other long-term assets (gain is indicated by "-")	1,416.28	
Losses on retirement of fixed assets (gain is indicated by "-")		2,541.25
Losses on changes in fair values (gain is indicated by "-")		
Financial expenses (gain is indicated by "-")	5,082,866.57	2,502,979.38
Investment losses (gain is indicated by "-")	2,378,652.94	-2,318,347.17
Decrease in deferred tax assets (increase is indicated by "-")	-1,790,877.02	-9,803,891.20
Increase in deferred tax liabilities (decrease is indicated by "-")	-732,772.50	1,320,203.93
Decrease in inventories (increase is indicated by "-")	94,250,565.71	-95,079,103.25
Decrease in receivables from operating activities (increase is indicated by "-")	49,348,525.29	-42,304,967.59
Increase in payables from operating activities (decrease is indicated by "-") Others	-145,185,070.90	-46,094,903.08
Net cash flow from operating activities	266,175,578.82	36,564,378.88
2. Significant investing and financing activities that do not involve cash receipts and payments:		
Conversion of debts into capital		
Convertible corporate bonds due within one year		
Fixed assets leased in under financing leases		
3. Net changes in cash and cash		
equivalents:		
Closing balance of cash	1,228,370,225.03	1,207,995,301.92
less: Opening balance of cash Add: Closing balance of cash	1,401,850,754.88	1,099,092,785.07
less: Opening balance of cash equivalents		
Net increase in cash and cash equivalents	-173,480,529.85	108,902,516.85

(2) Net cash payments paid for acquisitions of subsidiaries for the current period $\hfill\Box Applicable\hfill\hfil$

(3) Net cash payments received from disposal of subsidiaries for the current period $\sqrt{\text{Applicable}} \ \square N/A$

Unit: Yuan Currency: RMB
amount

Net cash payments received in the current period from current	
disposal of subsidiaries	
Including: Shanghai Healthloog Company	
Less: Cash and cash equivalents held by subsidiaries on the date	61,087,857.19
when the control is lost	
Including: Shagnhai Healthloog Company	61,087,857.19
Add: Net cash payments received in the current period from prior	
disposal of subsidiaries	
Net cash payments received from disposal of subsidiaries	-61,087,857.19

Other descriptions:

- 1) In April 2021, the Company increased the capital contribution to Zhuhai Healthlong Biotechnology Co., Ltd. in the form of 52% of equity held by it in Shanghai Healthlong Company. After the increase in capital contribution completes, Shanghai Healthlong Company becomes a wholly-owned subsidiary of Zhuhai Healthlong Biotechnology Co., Ltd., and the Company holds 10.00% of equity in Zhuhai Healthlong Biotechnology Co., Ltd. and has the right to appoint one director to Zhuhai Healthlong Biotechnology Co., Ltd..
- 2) RMB 61,087,857.19 of cash and cash equivalents held by Shanghai Healthlong Company on the date when the control is lost is presented in the item "Other cash payments relating to investing activities" in the statements.

(4) Composition of cash and cash equivalents

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB Opening balance Item Closing balance 1,228,370,225.03 1,401,850,754.88 I. Cash 4,920.44 Including: Cash on hand 26,853.58 Cash at bank that can be readily 1,211,495,817.76 1,368,515,531.05 drawn on demand Other cash balances that can be 16,869,486.83 33,308,370.25 readily drawn on demand Other cash balances with the central bank that can be readily drawn on demand Interbank deposit Interbank loans II. Cash equivalents Including: Debt investments within three months III. Closing balance of cash and cash 1,228,370,225.03 1,401,850,754.88 equivalents Including: Cash and cash equivalent with the limited use of the parent company or subsidiaries within the Group

Other descriptions:

 \checkmark Applicable $\square N/A$

Descriptions of supplementary information to the cash flow statement

			Uni	t: Yuan Currency: RMB
Date	Balance of currency	Cash and cash	Difference	Reason
Date	funds	equivalents	Difference	Reason

June 30, 2021	1,236,337,706.75	1,228,370,225.03	7,967,481.72	Closing bank deposits include RMB 293,481.72 of the security deposit of fixed time deposit for the transformer, and the other currency funds including RMB 7,000,000.00 of L/C security deposit, and RMB 674,000.00 of Tmall and Alipay security deposit
December 31, 2020	1,416,654,640.93	1,401,850,754.88	14,803,886.05	i.e. RMB 293,481.72 of security deposit of fixed time deposit for the transformer, RMB 69,000.00 of ETC vehicle security deposit, and RMB 7,036,404.33 of land construction security deposit, RMB 7,000,000.00 of L/C security deposit and RMB 405,000.00 of Tmall and Alipay security deposit

80. Notes to statement of changes in owners' equity

Descriptions of name of the item "Others" and amount adjusted for the balance at the end of the previous year:

 \Box Applicable $\sqrt{N/A}$

81. Assets with restrictions in ownership or use right

 $\sqrt{\text{Applicable } \square \text{N/A}}$

		Unit: Yuan Currency: RMB
Item	Carrying balance at the end of the	Reasons for restriction
	period	
Currency funds	7,967,481.72	Security deposit for the
		transformer, L/C security
		deposit, and Tmall and Alipay
		security deposit, etc.
Notes receivable		
Inventories		
Fixed assets		
Intangible assets		
Total	7,967,481.72	/

Other descriptions:

None

82. Monetary items denominated in foreign currency

(1). Monetary items denominated in foreign currency

 $\sqrt{\text{Applicable }} \square N/A$

Item	Closing balance of foreign currency	Exchange rate	Translated balance in RMB at the closing of the period
Currency funds	-	1	89,218,164.09
Including: USD	546,815.67	6.4601	3,532,483.91
EUR	10,773,685.74	7.6862	82,808,703.33
HKD	3,080,390.55	0.83208	2,563,131.37
JPY	2,080.00	0.058428	121. 53

CHF	22,953.14	7.0134	160,979.55
KRW	26,727,215.68	0.005714939	152,744.40
Accounts receivable	-	-	10,600,782.49
Including: EUR	435,991.03	7.6862	3,351,114.25
HKD	57,139.03	0.83208	47,544.24
KRW	1,260,227,657.83	0.005714939	7,202,124.00
Long term loans	-	-	
Including: USD			
EUR			
HKD			
Other receivables	-	-	22,478,490.10
Including: USD	31,473.43	6.4601	203,321.51
EUR	2,865,596.08	7.6862	22,025,544.59
HKD	300,000.00	0.83208	249,624.00
Accounts payable	-	-	14,083,527.34
Including: USD	92,803.00	6.4601	599,516.66
EUR	1,700,134.55	7.6862	13,067,574.18
HKD	192,437.43	0.83208	160,123.34
KRW	44,849,676.83	0.005714939	256,313.16
Other payables	-	-	160, 672. 30
Including: HKD	5,975.00	0.83208	4,971.68
KRW	27,244,495.00	0.005714939	155,700.62

Other descriptions:

None

(2). Descriptions of overseas operating entities, including disclosure of the main overseas business locations, functional currency and the basis for selection of important overseas operating entities, and the reasons for changes in functional currency (if any)

 $\sqrt{\text{Applicable }} \square N/A$

HAPSODE Co., Ltd., HANNA COSMETICS CO., LTD and Y.N.M. Cosmetics Co., Ltd. operate in South Korea and their operating income and costs are mainly denominated in KRW, so they use KRW as their functional currency; Hongkong Xinghuo Industry Limited, Hong Kong Zhongwen Electronic Commerce Co., Limited, Hong Kong Xuchen Trading Limited, Hongkong Keshi Trading Limited, BOYA (Hong Kong) Investment Management Co., Limited and Hongkong Wanyan Electronic Commerce Co., Limited operate in Hong Kong, with RMB as the accounting currency; Off & Relax Co., Ltd. is located in Japan, with business income and expenditure dominated by Japanese Yen, which is used as the accounting currency.

83. Hedging

□Applicable √N/A

84. Government grants

1. Basic information of government grants

 $\sqrt{\text{Applicable }} \square N/A$

Category	Amount	Line item	Amount included in profit or loss for the current period
Government subsidies related to assets	1,039,545.00	Other income	1,039,545.00
Government subsidies related to income	8,330,774.81	Other income	8,330,774.81

2. Return of government grants

 \Box Applicable $\sqrt{N/A}$ Other descriptions

1) Government subsidies related to assets

Items	Opening deferred income	Newly-added grants for the period	Amortization for the period	Closing deferred income	Line items of amortization for the period	Note
Subsidy for technological innovation of cosmetics	8,495,353.33		1,039,545.00	7,455,808.33	Other income	
Sub-total	8,495,353.33		1,039,545.00	7,455,808.33		

According to the Decision on Awards for Technological Innovation of Proya Cosmetics Co., Ltd. Huzhou Branch by the People's Government of Daixi Town, Huzhou City, the Company received a technological innovation subsidy of RMB 14,561,400.00 from the People's Government of Daixi Town in 2014, which was apportioned evenly over the useful life of related assets resulted therefrom by the Company, and RMB 728,070.00 of which was recognized in other income for the current period.

According to the *Notice on Distributing the 2015 Industry-driven City Construction and Development Funds (First Batch)* (Hu Cai Qi [2015] No. 150) by Huzhou Finance Bureau and Huzhou Economic and Information Technology Commission, the Company received a technological innovation subsidy of RMB 2,350,000.00 from Huzhou Finance Bureau in 2015, which was apportioned evenly over the useful life of related assets resulted therefrom by the Company, and RMB 117,500.00 of which was recognized in other income for the current period.

According to the *Notice on Distributing 2014 Special Funds (Second Batch) for District "Machine Replacing People" Project* (Wu Fa Gai [2015] No. 18) by the Development Reform and Economic Commission of Wuxing District, Huzhou City and the Finance Bureau of Wuxing District, the Company received a technological innovation subsidy of RMB 500,000.00 from the Finance Bureau of Wuxing District in 2015, which was apportioned evenly over the useful life of related assets resulted therefrom by the Company, and RMB 25,000.00 of which was recognized in other income for the current period.

According to the *Notice on Distributing the 2018 Special Funds for Industrial Development in Huzhao City (Second Batch)* (Hu Cai Qi [2018] No. 319) by Huzhou Finance Bureau and Huzhou Economic and Information Technology Commission, the Company received a technological innovation subsidy of RMB 1,379,500.00 from Huzhou Finance Bureau in December 2018, which was apportioned evenly over the useful life of related assets resulted therefrom by the Company, and RMB 68,975.00 of which was recognized in other income for the current period.

According to the *Notice on Appropriation of Special Subsidy Funds for Demonstration Smart Workshops in Wuxing District in 2019* (Wu Cai Qi Han [2020] No. 145), issued by the Finance Bureau of Wuxing District and the Development Reform and Economic Commission of Wuxing District, the Company received a special subsidy for demonstration smart workshops of RMB 2,000,000.00 from the Finance Bureau of Wuxing District in May 2020, which was apportioned evenly over the useful life of related assets resulted therefrom by the Company, and RMB 100,000.00 of which was recognized in other income for the current period.

2) Government grants related to income as compensation for related expenses or losses of the

Company to be incurred in subsequent periods

Project	Amount	Line item	Description
Subsidy for work-based trainings	294,500.00	Other income	According to the <i>Notice on Implementing Subsidies</i> for Corporate Work-based Trainings (Hang Ren She Fa [2020] No. 94) by Hangzhou Bureau of Human Resources and Social Security and Hangzhou Finance Bureau, Hangzhou Vocational Ability Building Guidance Service Center caused the special fund account for employment (funds for

			skill improvement actions) to allocate the subsidy to the Company.
Subsidy for invention patent	127,160.00	Other income	According to the Notice of Zhejiang Department of Finance on Early Distributing 2020 Special Funds for Market Supervision and Intellectual Property (Zhe Cai Hang [2019] No. 51), the Market Supervision and Administration of Xihu District, Hangzhou City allocated the subsidy to the Company.
Industry support subsidy	5,490,000.00	Other income	,The Finance Bureau of Meishan Free Trade Port Zone, Ningbo allocated the subsidy to the Company.
Special funds for scientific and technological development	250,000.00	Other income	According to the Notice on Distributing the Second Batch of Special Funds for Scientific and Technological Development in 2021 (Zhe Cai Ke Jiao [2021] No. 11) by Zhejiang Department of Finance and Zhejiang Department of Science and Technology, the Finance Bureau of Wuxing District allocated the subsidy to the Company.
Awards for high and new technology enterprises that are supported by the State	200,000.00	Other income	According to the <i>Three-year Action Plan for the Cultivation of High-tech Enterprises in Hangzhou</i> (2018-2020) by the General Office of the Hangzhou Municipal People's Government, the Science and Technology Bureau of Xihu District, Hangzhou City allocated the subsidy to the Company.
Special funds for talent development	180,000.00	Other income	According to the <i>Notice on Distributing the Fifth Batch of Special Funds for Talent Development in 2020</i> by the Organization Department of the CPC Huzhou City Committee, the Finance Bureau of Wuxing District, Huzhou City allocated the subsidy to the Company.
Job stabilization subsidy, special fund subsidy for service enterprises, intellectual property subsidy, financial support fund from Finance Bureau of Qingpu, etc.	1,789,114.81	Other income	The Resources and Social Security Bureau of Wuxing District, Huzhou City, Hangzhou Employment Management Service Center, the Market Supervision and Administration of Xihu District, Hangzhou City, and the Finance Bureau of Qingpu District, Shanghai allocated the subsidy to the Company.
Sub-total	8,330,774.81		

³⁾ RMB 9,370,319.81 of government grants was recognized in profit or loss for the current period.

85. Others

 $\Box Applicable \ \sqrt{N/A}$

VIII. Changes in the Consolidation Scope

1. Business combination not involving enterprises under common control:

 $\Box Applicable \ \sqrt{N/A}$

2. Business combination involving enterprises under common control

 $\Box Applicable \ \sqrt{N/A}$

3. Reverse purchase

 $\Box Applicable \ \sqrt{N/A}$

4. Disposal of subsidiaries

Was there any circumstance under which a single disposal of the investment in subsidiaries will lose control?

□Applicable √N/A

Other descriptions: \Box Applicable $\sqrt{N/A}$

5. Changes in scope of consolidation due to other reasons

Descriptions of changes in scope of consolidation caused by other reasons (such as establishment of a new subsidiary and liquidation of a subsidiary, etc.) and their relevant information:

 $\sqrt{\text{Applicable }} \square N/A$

(I) Increase in the scope of consolidation

Company name	Method of equity acquisition	Time of equity acquisition	Capital contribution (RMB)	Contribution ratio
Xuzhou Proya Information Technology Co., Ltd.	Newly established subsidiary	January 2021	500,000.00	100.00%
Proya (Hainan) Cosmetics Co., Ltd.	Newly established subsidiary	January 2021		100.00%

(II) Decrease in the scope of consolidation

Company name	Method of disposal of equity	Time of disposal of equity	Daily net assets disposed (RMB)	Net profit from the opening of the period to the disposal date (RMB)
Shanghai Tiyu Cosmetics Co., Ltd.	Cancellation	April 2021	-2,729,077.89	-676.18
Shanghai Healthlong Biochemical Technology Co., Ltd.	[Note]	April 2021	131,743,692.10	-14,434,836.72

[Note] In April 2021, the Company increased the capital contribution to Zhuhai Healthlong Biotechnology Co., Ltd. in the form of 52% of equity held by it in Shanghai Healthlong Company. After the increase in capital contribution completes, Shanghai Healthlong Company becomes a wholly-owned subsidiary of Zhuhai Healthlong Biotechnology Co., Ltd., and the Company holds 10.00% of equity in Zhuhai Healthlong Biotechnology Co., Ltd. and has the right to appoint one director to Zhuhai Healthlong Biotechnology Co., Ltd..

6. Others

 \Box Applicable $\sqrt{N/A}$

IX. Interests in Other Entities

1. Interests in subsidiaries

(1). Composition of enterprise group

 $\sqrt{\text{Applicable }} \square N/A$

Name of	Main	Place of	Business	Sharehol	ding (%)	Method of
subsidiary	business place	registration	nature	Direct	Indirect	acquisition
Hangzhou Proya Trading Co., Ltd.	Hangzhou	Hangzhou	Wholesale and retail	100.00		Establishment
Zhejiang Meili Valley E-commerce Co., Ltd.	Hangzhou	Hangzhou	Wholesale and retail	100.00		Establishment
Huzhou Chuangdai E-commerce Co., Ltd.	Huzhou	Huzhou	Wholesale and retail		100.00	Establishment
HAPSODE (Hangzhou) Cosmetics Co., Ltd.	Hangzhou	Hangzhou	Wholesale and retail	100.00		Establishment
Huzhou Youzilai Trading Co., Ltd.	Huzhou	Huzhou	Wholesale and retail	100.00		Establishment
Hongkong Xinghuo Industry Limited	Hong Kong	Hong Kong	Wholesale and retail	100.00		Establishment
Ningbo TIMAGE Cosmetics Co., Ltd.	Ningbo	Ningbo	Wholesale and retail	61.36		Establishment

Descriptions of the difference between the shareholding ratio and the proportion of voting rights in a subsidiary:

None

Basis for holding half or less of the voting rights but still controlling the investee, and holding majority of the voting right but having no control over the investee:

None

Basis for control over significant structured entities included in consolidation scope: None

Basis for determining whether the Company acts as the agent or the principal: None

Other descriptions:

None

(2). Significant non-wholly subsidiaries

Unit: Yuan Currency: RMB

Name of subsidiary	Shareholding of minority shareholders (%)	Profit or loss attributable to minority interests for the current period	Dividends declared for distribution to minority shareholders for the current period	Closing balance of minority interests
Ningbo TIMAGE Cosmetics Co., Ltd.	38.64	-3,270,441.67		-11,907,069.70

Descriptions of the difference between the shareholding ratio of minority shareholders and their proportion of voting rights in a subsidiary:

□Applicable √N/A

Other descriptions: \Box Applicable $\sqrt{N/A}$

(3). Key financial information of significant non-wholly subsidiaries

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Name of Closing balance				Opening balance								
subsidiary	Current	Non-current	Total	Current	Non-current	Total	Current	Non-current	Total	Current	Non-current	Total
	assets	assets	assets	liabilities	liabilities	liabilities	assets	assets	assets	liabilities	liabilities	liabilities
Ningbo	42,270,95	84,124.14	42,355,07	72,556,87		72,556,87	42,477,9	85,01	42,562,97	64,300,89		64,300,89
TIMAGE	0.45		4.59	2.37		2.37	67.12	0.07	7.19	9.00		9.00
Cosmetics												
Co., Ltd.												

	Amount for the current period				Amount for the prior period			
Name of subsidiary	Revenue	Net profit	Total comprehensive income	Cash flows from operating activities	Revenue	Net profit	Total comprehensive income	Cash flows from operating activities
Ningbo TIMAGE CosmetiQcs Co., Ltd.	116,044,099.29	-8,463,875.97	-8,463,875.97	-2,465,779.00	12,124,535.17	-4,341,954.94	-4,341,954.94	3,280,263.73

Other descriptions:

None

(4). Significant restrictions on the use of enterprise group assets and settlement of enterprise group debts:

 \Box Applicable $\sqrt{N/A}$

(5). Financial supports or other supports offered for the structured entities included in the scope of consolidated financial statements:

 \Box Applicable $\sqrt{N/A}$

Other descriptions:

 \Box Applicable $\sqrt{N/A}$

2. Transactions through which the share of the owner's equity in the subsidiary has changed and the control on the subsidiary is still maintained

(1). Descriptions of changes in the share of owner's equity in the subsidiary

 $\sqrt{\text{Applicable }} \square N/A$

Name of subsidiary	Change time	Shareholding ratio prior to change	Shareholding ratio after change
Shanghai Zhongwen Electronic Commerce Co.,	January 2021	83.00%	100.00%
Limited			
Hong Kong Zhongwen			
Electronic Commerce Co.,	January 2021	83.00%	100.00%
Limited			

(2). Impacts of transactions on minority interests and equity attributable to owners of the parent company

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

	Shanghai Zhongwen	Hong Kong Zhongwen	
	Electronic Commerce	Electronic Commerce	
	Co., Limited	Co., Limited	
Purchase cost/disposal consideration			
Cash			
Fair value of assets other than cash			
Total purchase costs/disposal considerations			
Less: Shares of net assets of the subsidiaries			
calculated at the acquired/disposed equity	-706,570.34	-84,104.71	
proportion			
Difference	706,570.34	84,104.71	
Including: Adjustments to capital reserve	706,570.34	84,104.71	
Adjustments to surplus reserve		_	
Adjustments to unappropriated profits			

Other descriptions \Box Applicable $\sqrt{N/A}$

3. Interests in joint ventures or associates

 $\sqrt{\text{Applicable }} \square N/A$

(1). Significant joint ventures or associates

 \Box Applicable $\sqrt{N/A}$

(2). Key financial information of significant joint ventures

 \Box Applicable $\sqrt{N/A}$

(3). Key financial information of significant associates

 \Box Applicable $\sqrt{N/A}$

(4). Summary of financial information of insignificant joint ventures and associates

Unit: Yuan Currency: RMB

	Closing balance / Amount for the current period	Opening balance / Amount for the prior period		
Joint ventures:				
Total investment carrying	3,301,050.94	3,306,630.57		
amount				
Total of the following items calcu	alated based on the shareholding ratio)		
Net profit	-5,579.63	-3,033.40		
Other comprehensive income				
Total comprehensive income	-5,579.63	-3,033.40		
Associates:				
Total investment carrying	183,291,583.06	54,913,429.03		
amount				
Total of the following items calculated based on the shareholding ratio				
Net profit	-2,369,527.07	-205,955.01		
Other comprehensive income				
Total comprehensive income	-2,369,527.07	-205,955.01		

Other descriptions

None

(5). Descriptions of significant restrictions on the ability of joint ventures or associates to transfer funds to the Company

 \Box Applicable $\sqrt{N/A}$

(6). Excess losses incurred by joint ventures or associates

 \Box Applicable $\sqrt{N/A}$

(7). Unrecognized commitments related to investments in joint ventures

□Applicable √N/A

(8). Contingent liabilities related to investments in joint ventures or associates

 \Box Applicable $\sqrt{N/A}$

4. Significant joint operations

 \Box Applicable $\sqrt{N/A}$

5. Interests in structured entities not included in the scope of consolidated financial statements

Descriptions of structured entities not included in the scope of consolidated financial statements: $\Box Applicable \sqrt{N/A}$

6. Others

 \Box Applicable $\sqrt{N/A}$

X. Risks Related to Financial Instruments

 $\sqrt{\text{Applicable }} \square N/A$

As the goal of risk management, the Company intends to strike a balance between risks and returns, minimize the negative impact of risks on the Company's operating performance, and maximize the 158/185

interests of shareholders and other equity investors. Based on this risk management goal, the Company's basic risk management strategy is to identify and analyze the its exposure to various risks, establish an appropriate maximum tolerance to risk, implement risk management, and monitor regularly and effectively these exposures to ensure the risks are monitored at a certain level.

The Company is exposed to various risks associated with financial instruments in its daily routines, primarily including credit risk, liquidity risk and market risk. The management has reviewed and approved policies to manage these risks, summarized as below.

(I) Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

- 1. Management of credit risk
- (1) Evaluation of credit risk

The Company assesses at each balance sheet date whether the credit risk of the underlying financial instruments has increased significantly since initial recognition. In determining whether the credit risk has increased significantly since initial recognition, the Company considers reasonable and supportable information that is available without undue cost or effort, including quantitative and qualitative analysis based on historical data, ranking of external credit risks and forward-looking information. The Company compares the risk of a default occurring on a financial instrument as at the balance sheet date with the risk of a default occurring on the financial instrument as at the date of initial recognition based on individual financial instrument or financial instruments portfolio with similar credit risk characteristic, to determine the change of the risk of a default occurring on a financial instrument over the expected life.

The Company considers that the credit risk of financial instruments has increased significantly when one or more of the following quantitative and qualitative criteria are met:

- 1) The quantitative criterion primarily refers to a certain percentage of increase in the probability of default over the remaining life of the financial instruments as of the balance sheet date when comparing with that at initial recognition of the financial instruments;
- 2) The qualitative criteria include, inter alia, adverse material changes in business or financial conditions that are expected to cause a significant decrease in the debtor's ability to meet its debt obligations, and an actual or expected significant adverse change in the technological, market, economic, or legal environment of the debtor that results in a significant decrease in the debtor's ability to meet its debt obligations.
 - (2) Definition of defaulted or credit-impaired assets

A financial asset is defined as defaulted when the financial instrument meets one or more conditions stated as below, and the criteria of defining defaulted asset is consistent with the that of defining credit-impaired asset:

- 1) significant financial difficulty of the debtor;
- 2) a breach of contract terms with binding force by the debtor;
- 3) it is becoming probable that the borrower will enter bankruptcy or other financial reorganization;

or/and

- 4) the creditor of the debtor, for economic or contractual reasons relating to the debtor's financial difficulty, has granted to the debtor a concession that the creditor would not otherwise consider.
 - 2. Measurement of expected credit loss ("ECL")

Key parameters to measure ECL include the probability of default, loss given default and the exposure at default. The Company established models of the probability of default, loss given default and the exposure at default on the basis of qualitative analysis on historical statistical data (such as counterparty ranking, guarantee methods, collateral category, and repayment way) and forward-looking information.

- 3. Details of reconciliation of the opening balance and the closing balance of provision for impairment of financial instruments can refer to the Notes VII 5, VII. 6 and VII. 8 of Section X Financial Report in this report.
 - 4. Credit risk exposure and credit risk concentration

The Company's credit risk is primarily from currency funds and receivables. In order to control the risks associated with aforementioned items, the Company has taken the following measures.

(1) Currency funds

The credit risk of the Company is limited because the Company has deposited bank deposits and other monetary funds in banks with high credit ratings.

(2) Receivables

The Company continually evaluates the creditworthiness of its customers with deals on credit, and selects to deal with approved and creditworthy customers subject to the results of the credit assessment with monitoring the balance of its receivables, so as to ensure that the Company is not exposed to significant risk of bad debt.

No collaterals are required since the Company only deals with third parties that are approved and creditworthy. The concentrated credit risks are managed by customers. As of June 30, 2021, the Company was exposed to certain concentration of credit risks, as the Company's accounts receivable from top 5 customers have accounted for 55.61% of the total balance of accounts receivable (December 31, 2020: 49.92%). The Company held no collaterals or other credit ranking measures for the balance of accounts receivable.

The maximum exposure to the Company is the carrying amount of each financial asset in the balance sheet.

(II) Liquidity Risk

Liquidity risk refer to the risk that the Company is in shortage of funds in performing obligations that are settled by delivering cash or another financial asset. Liquidity risk may derive from the inability to sell financial assets at fair value as soon as possible, or from the other party's inability to repay its contractual debt, or from debt that matures early or from the inability to generate expected cash flows.

In order to control this risk, the Company balances the continuity and flexibility of financing by using various financing measures such as notes settlement and bank loans comprehensively and adopting

both long-term and short-term financing methods to optimize the financing structure. The Company has received credit facilities from a number of commercial banks to satisfy its working capital requirements and capital expenditures.

Financial liabilities classified by remaining duration

	Closing balance							
Item	Carrying amount	Undiscounted contract amount	Within 1 year	1-3 years	Over 3 years			
Bank borrowings	200,000,000.00	206,774,520.55	206,774,520.55					
Notes payable	63,672,739.08	63,672,739.08	63,672,739.08					
Accounts payable	347,238,059.11	347,238,059.11	347,238,059.11					
Other payables	73,609,323.68	73,609,323.68	73,609,323.68					
Sub-total	684,520,121.87	691,294,642.42	691,294,642.42					

(Continued)

	Closing amount for the prior year						
Item	Carrying amount	Undiscounted contract amount	Within 1 year	1-3 years	Over 3 years		
Bank borrowings	299,280,435.09	306,965,009.72	306,965,009.72				
Notes payable	64,580,000.00	64,580,000.00	64,580,000.00				
Accounts payable	515,832,031.27	515,832,031.27	515,832,031.27				
Other payables	75,546,323.32	75,546,323.32	75,546,323.32				
Sub-total	955,238,789.68	962,923,364.31	962,923,364.31				

(III) Market Risk

Market risk refers to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk mainly includes interest rate risk and currency risk.

1. Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Interest-bearing financial instruments with fixed interest rates expose the Company to fair value interest rate risk, and interest-bearing financial

instruments with floating interest rates expose the company to cash flow interest rate risk. The Company determines the ratio of fixed-rate and floating-rate financial instruments based on the market environment, and maintains an appropriate portfolio of financial instruments through regular review and monitoring.

2. Foreign currency risks

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the currency risk is primarily associated with the Company's monetary assets and liabilities dominated in foreign currencies. Since the Company mainly operates in Mainland China with its principal activities denominated in RMB, the Company's exposure to the currency risk due to changes in market is not material.

The closing balance of the Company's monetary assets and liabilities dominated in foreign currencies is seen in Note VII 82 of Section X Financial Report in this report.

XI. Disclosure of Fair Value

1. Closing balance of the fair value of assets and liabilities measured at fair value

 $\sqrt{\text{Applicable}} \square N/A$

Item	Closing balance of fair value					
Item	Level 1	Level 2	Level 3	Total		
I. Continuous fair value						
measurement						
(I) Held-for-trading						
financial assets						
1. Financial assets at fair						
value through profit or loss						
(1) Investments in debt						
instruments						
(2) Investments in equity						
instruments						
(3) Derivative financial						
assets						
2. Financial assets, at fair						
value through profit or loss						
(1) Investments in debt						
instruments						
(2) Investments in equity						
instruments						
(II) Other debt investments						
(III) Other investments in			20,580,000.00	20,580,000.00		
equity instruments						
(IV) Investment properties						
1. A land use right that is						
used to be leased out.						

	ı		
2. A building that is leased			
out.			
3. A land use right held for			
transfer upon capital			
appreciation.			
(V) Biological assets			
1. Consumable biological			
assets			
2. Bearer biological assets			
Receivable financing		5,263,729.60	5,263,729.60
Total assets continuously		25,843,729.60	25,843,729.60
measured at fair value			
(VI) Held-for-trading			
financial liabilities			
1. Financial liabilities at			
fair value through profit or			
loss			
Including: Issued tradable			
bonds			
Derivative financial			
liabilities			
Others			
2. Financial liabilities			
designated as at fair value			
through profit or loss			
Total liabilities			
continuously measured at			
fair value			
II. Non-continuous fair			
value measurement			
(I) Held-for-sale assets			
Total assets not			
continuously measured at			
fair value			_
Total liabilities not		 	
continuously measured at			
fair value		 	

2. Basis for determining the market price of continuous and non-continuous level 1 fair value measurement items

 \Box Applicable $\sqrt{N/A}$

3. Valuation techniques and qualitative and quantitative information of key parameters adopted for continuous and non-continuous level 2 fair value measurement items

 \Box Applicable $\sqrt{N/A}$

4. Valuation techniques and qualitative and quantitative information of key parameters adopted for continuous and non-continuous level 3 fair value measurement items

√Applicable □N/A

- 1. For the held notes receivable, the par value is used to determine their fair value.
- 2. The fair value of other equity instrument investments of the Company is determined according to the actual capital contribution.

5. Reconciliation between opening and closing carrying amounts and sensitivity analysis of unobservable parameters for continuous level 3 fair value measurement items

 \Box Applicable $\sqrt{N/A}$

6. In case of transfers among levels for the current period, explain the transfer reasons and policies for determining transfer time point for continuous fair value measurement items

 \Box Applicable $\sqrt{N/A}$

7. Changes in valuation techniques for the current period and reasons for changes

 \Box Applicable $\sqrt{N/A}$

8. Fair value of financial assets and liabilities not measured at fair value

 \Box Applicable $\sqrt{N/A}$

9. Others

 \Box Applicable $\sqrt{N/A}$

XII. Related Party and Related Party Transactions

1. Parent company of the Company

 \Box Applicable $\sqrt{N/A}$

2. Subsidiaries of the Company

For details of the subsidiaries of the Company, please see the notes.

 $\sqrt{\text{Applicable }} \square N/A$

The details of the subsidiaries of the Company are set out in Note IX of Section X in this report.

3. Joint ventures and associates of the Company

For details of the significant joint ventures or associates of the Company, please see the notes. $\Box Applicable \sqrt{N/A}$

The details of other joint ventures or associates having related party transactions and balances with the Company in the current period or prior periods are as follows: $\Box Applicable \sqrt{N/A}$

4. Other related parties of the Company

Name of other related parties	Relationship between other related parties and	
	the Company	
Zhejiang Leqing Rural Commercial Bank Co., Ltd.	Others	
Huzhou Beauty Town Technology Incubation Park	Others	
Co., Ltd.		
Xiongke Culture Media (Hangzhou) Co., Ltd.	Others	
Beijing Mitangpai Cosmetics Co., Ltd. [Note 1]	Others	
Metis Information Technology (Guangzhou) Co., Ltd.	Others	
Cosmetics Industry (Huzhou) Investment	Others	
Development Co., Ltd.		
Zhuhai Healthlong Biotechnology Co., Ltd.	Others	
Shaoqing City Keqiao District Qingteng Culture	Others	

Investment Co., Ltd.	
Parisezhan HK Limited	Others
EURL PHARMATICA	Others
SARL ORTUS	Others
S.A.S AREDIS	Others
YOKIPLUS Co., Ltd.	Others
Shanghai YOKIPLUS Brand Management Co., Ltd.	Others
Pan Xiang	Others

Other descriptions

[Note 1] Beijing Mitangpai Cosmetics Co., Ltd. was revoked in August 2020.

[Note 2] Zhuhai Healthlong Biotechnology Co., Ltd. was a minority shareholder of Shanghai Healthlong Company. In April 2021, the Company increased the capital contribution to Zhuhai Healthlong Biotechnology Co., Ltd. in the form of 52% of equity held by it in Shanghai Healthlong Company. After the increase in capital contribution completes, Shanghai Healthlong Company becomes a wholly-owned subsidiary of Zhuhai Healthlong Biotechnology Co., Ltd., and the Company holds 10.00% of equity in Zhuhai Healthlong Biotechnology Co., Ltd. and has the right to appoint one director to Zhuhai Healthlong Biotechnology Co., Ltd..

5. Related party transactions

(1). Sales and purchase of goods, rendering and receipt of services

Table of purchase of goods/ receipt of services $\sqrt{\text{Applicable}} \square N/A$

Unit: RMB0'000 Currency: RMB

Related parties	Details of related party	Amount for the current	Amount for the prior	
Related parties	transactions	period	period	
Zhuhai Healthlong	Purchase of goods	2 456 11		
Biotechnology Co., Ltd.		2,456.11		
EURL PHARMATICA	Purchase of goods		2,991.63	
SARL ORTUS	Purchase of goods		959.72	
S.A.S AREDIS	Purchase of goods		117.16	
Metis Information	Advertising and			
Technology (Guangzhou)	communication service		117.50	
Co., Ltd.	fee			
Xiongke Culture Media	Video production		13.93	
(Hangzhou) Co., Ltd.	service		13.93	

Table of sales of goods/ rendering of services

Unit: RMB0'000 Currency: RMB

Related parties	Details of related party transactions	Amount for the current period	Amount for the prior period
Shanghai YOKIPLUS Brand Management Co., Ltd.	Sales of goods	3,485.85	2,425.55
YOKIPLUS Co., Ltd.	Sales of goods	91.16	239.92
Shaoqing City Keqiao District Qingteng Culture Investment Co., Ltd.	Sales of goods	2.62	
Zhejiang Leqing Rural Commercial Bank Co., Ltd.	Sales of goods	1.41	

 $[\]sqrt{\text{Applicable }} \square N/A$

Cosmetics Industry (Huzhou) Investment Development Co., Ltd.	Sales of goods	0.30	
Parisezhan HK Limited	Sales of goods		106.78
Beijing Mitangpai Cosmetics Co., Ltd.	Sales of goods		224.95

Descriptions of related party transactions with respect to the sales and purchase of goods, rendering and receipt of services

□Applicable √N/A

(2). Related entrusted management/contracting and entrusting management/outsourcing

Table of the entrusted management/contracting of the Company:

□Applicable √N/A

Descriptions of related trusteeship/outsourcing

 $\Box Applicable \ \ \sqrt{N/A}$

Table of the entrusting management/outsourcing of the Company:

 \Box Applicable $\sqrt{N/A}$

Descriptions of related management/outsourcing

 \Box Applicable $\sqrt{N/A}$

(3). Related leases

The Company as the lessor:

□Applicable √N/A

The Company as the lessee:

 \checkmark Applicable $\square N/A$

Unit: RMB0'000 Currency: RMB

Name of lessors	Category of leased	Lease fees recognized in the	Lease fees recognized in the
Traine of lessors	assets	current period	prior period
Huzhou Beauty	Workshop		
Town Technology		48.40	50.64
Incubation Park		46.40	30.04
Co., Ltd.			
Shanghai	Office premises		
YOKIPLUS Brand		23.49	
Management Co.,		23.49	
Ltd.			

Descriptions of related leases

□Applicable √N/A

(4). Related guarantees

The Company as the guarantor

 \Box Applicable $\sqrt{N/A}$

The Company as the guaranteed party

 $\Box Applicable \ \ \sqrt{N/A}$

Descriptions of guarantees with related parties

□Applicable √N/A

(5). Lending funds of related parties

 $\Box Applicable \quad \sqrt{N/A}$

(6). Asset transfer and debt restructuring between related parties

□Applicable √N/A

(7). Compensation for key management

√ Applicable □N/A

Unit: RMB0'000 Currency: RMB

Item	Amount for the current period	Amount for the prior period
Compensation for key management	491.60	493.10

(8). Other related party transactions

 $\sqrt{\text{Applicable}} \square N/A$

The Company and its subsidiaries open bank accounts in Zhejiang Leqing Rural Commercial Bank Co., Ltd. and collect deposit interest according to market interest rates.

(1) Deposit with the related-party banks

		Un	nt: RMB0′000
Related party	Descriptions of related-party transaction	Closing balance	Opening balance
Zhejiang Leqing Rural Commercial Bank Co., Ltd.	Bank deposit	14,929.61	14,390.77

(2) Collection of interest from related parties

1		Un	it: RMB0'000
Related party	Descriptions of related-party transaction	Current amount	Prior amount
Zhejiang Leqing Rural Commercial Bank Co., Ltd.	Interest income	317.84	286.55

6. Amounts due from / to related parties

(1). Amounts due from related parties

 $\sqrt{\text{Applicable } \square N/A}$

		Closing balance		Opening balance	
Item	Related parties	Gross carrying	Provision for	Gross carrying	Provision for bad
		amount	bad debts	amount	debts
Account			_	_	
receivable					
	Shanghai				
	YOKIPLUS				
	Brand	1,183,869.84	59,193.49		
	Management Co.,				
	Ltd.				
Sub-total		1,183,869.84	59,193.49		

Prepayments					
	Zhuhai Healthlong Biotechnology Co., Ltd.			21,432,452.28	
	Huzhou Beauty Town Technology Incubation Park Co., Ltd.	43,000.00		44,000.00	
	Shanghai YOKIPLUS Brand Management Co., Ltd.			39,150.95	
Sub-total		43,000.00		21,515,603.23	
Other receivables		,		,	
	EURL PHARMATICA [Note]	12,001,399.00	600,069.95	24,167,639.75	1,208,381.99
	Huzhou Beauty Town Technology Incubation Park Co., Ltd.	133,568.20	61,820.46	132,568.20	61,770.46
	Pan Xiang	75,000.00	22,500.00	75,000.00	·
Sub-total		12,209,967.20	684,390.41	24,375,207.95	1,292,652.45

[Note] The amounts in the line of EURL PHARMATICA are combined amounts of EURL PHARMATICA, PARISEZHAN HK LIMITED, SARL ORTUS and S.A.S AREDIS, which are controlled by the same person.

(2). Amount due to related parties

 \checkmark Applicable $\square N/A$

			Unit: Yuan Currency: RMB
Item	Related parties	Gross carrying amount	Gross carrying amount at the
	_	at the end of the period	beginning of the period
Accounts payable			
	Metis Information		99,718.88
	Technology		
	(Guangzhou) Co., Ltd.		
	S.A.S AREDIS		263,358.19
Sub-total			363,077.07
Contract liabilities			
	Shanghai YOKIPLUS		34,200.00
	Brand Management		
	Co., Ltd.		
Sub-total			34,200.00

7. Commitments of related parties

 \Box Applicable $\sqrt{N/A}$

8. Others

□Applicable √N/A

XIII. Share-based Payment

1. Overview of shared-based payment

√Applicable □N/A

	Unit: Share Currency: RMB
Total amount of each type of equity instruments	N/A
granted by the Company in the current period	
Total amount of each type of equity instruments of	293,265.00
the Company exercised in the current period	
Total amount of each type of equity instruments of	
the Company lapsed in the current period	
Range of exercise prices and remaining contractual	N/A
life of share options outstanding of the Company at	
the closing of the period	
Range of exercise prices and remaining contractual	The grant price of the restricted shares granted is
life of other equity instruments outstanding of the	RMB 17.95 per share, and the term is 60 months
Company at the closing of the period.	from the grant date.

Other descriptions

On July 12, 2018, in accordance with the Proposal on the Restricted Share Incentive Plan of the Company in 2018 (Draft) and Its Summary reviewed and approved by the first extraordinary general meeting of the Company in 2018, and pursuant to the incentive plan, the Company proposed to grant no more than 1,467,200 shares of restricted shares to the grantees, of which 1,201,100 shares were granted for the first time, and 266,100 shares were reserved. The restricted shares were initially granted on July 12, 2018 to 32 persons including senior managers, middle managers and core backbones of the Company (excluding independent directors, supervisors and shareholders who individually or jointly hold more than 5% of the Company's shares, or the de facto controllers and their respective spouse, parents, children) at the price of RMB 17.95/share. The source of the underlying shares involved in this incentive plan is A-share common stock directionally by the Company to grantees. The effective period of this incentive plan is from the date when the registration of grant of the restricted shares is completed to the date when all the restricted shares granted to the grantees are vested or repurchased and cancelled, but subject to 60 months at the longest. The restricted shares granted will be vested in three installments within the next 36 months after the expiration of 12 months from the initially granted restricted shares at 30%, 30% and 40%. Performance vesting conditions for the first release period: based on the operating income and net profit in 2017, the growth rate of operating income and net profit in 2018 shall not be less than 30.8% and 30.1%, respectively; performance vesting conditions for the second release period: based on the operating income and net profit in 2017, the growth rate of operating income and net profit in 2019 shall not be less than 74.24% and 71.21%, respectively; performance vesting conditions for the third release period: based on the operating income and net profit in 2017, the growth rate of operating income and net profit in 2020 shall not be less than 132.61% and 131.99%, respectively.

On July 12, 2018, the 22nd meeting of the first board of directors of the Company reviewed and approved the *Proposal on the Initial Grant of Restricted Shares to Grantees*, determining the date July 12, 2018 as the initial grant date. In the actual subscription process, some grantees voluntarily gave up the subscription, and the Company actually granted 1,096,200 restricted shares.

On December 12, 2018, the 3rd meeting of the second board of directors of the Company reviewed and approved the *Proposal on the Grant of Reserved Restricted Shares to Grantees*, determining the date December 12, 2018 as the grant date of reserved restricted shares. In the actual subscription process, all the grantees completed the subscription, and the Company actually granted 266,100 restricted shares.

On December 30, 2019, the 10th meeting of the second board of directors of the Company reviewed and approved the *Proposal on the Satisfaction of Vesting Conditions for the First Release Period of the Initially Granted Restricted Shares and the Granted Reserved Portion under the 2018 Restricted Share Incentive Plan*, 369,500 restricted shares held by the grantees who meet the vesting conditions for the first release period were vested and circulated on January 6, 2020.

In accordance with the *Proposal on Repurchase and Cancellation of Restricted Shares That Have Been Granted but Have Not Vested by Unqualified Grantees* reviewed and approved by the 4th meeting of the second board of directors in 2019 and the first extraordinary general meeting of shareholders in 2019 and the *Proposal on Repurchase and Cancellation of Some Restricted Shares under Share*

Incentive Plan reviewed and approved by the 8th meeting of the second board of directors in 2019, the Company repurchased and cancelled 92,740 restricted shares and paid RMB 1,657,699.80 as repurchase payments because some grantees left the office or failed to meet all vesting conditions of restricted shares upon appraisal of performance for that period.

On July 6, 2020, in accordance with the *Proposal on Adjusting the 2020 Performance Appraisal Index at the Company Level in the 2018 Restricted Share Incentive Plan and Related Documents* reviewed and approved by the second extraordinary general meeting of shareholders of the Company in 2020, the Company revised the performance appraisal appraisal index for the third release period in original incentive plan as the following: based on the operating income in 2017, and the growth rate of operating income in 2020 shall not be less than 110.22% and based on net profit in 2017, the growth rate of net profit in 2020 shall not be less than 131.99%.

On August 24, 2020, in accordance with the *Proposal on Repurchase of Cancelled Restricted Shares under Share Incentive Plan* reviewed and approved by the 15th and 16th meetings of the second board of directors in 2020, and the 3rd extraordinary general meeting of shareholders in 2020, the Company repurchased and cancelled 152,635 restricted shares and paid RMB 2,584,110.55 as the repurchase payment because some grantees left the office or failed to meet all vesting conditions of restricted shares upon appraisal of performance for that period.

The Company's various equity instruments exercised for the current period were based on the *Proposal on the Satisfaction of Vesting Conditions for the Second Release Period of the Initially Granted Restricted Shares and the Granted Reserved Portion under the 2018 Restricted Share Incentive Plan* reviewed and approved by the 18th meeting of the second board of directors on January 5, 2021, and accordingly 293,265 restricted shares held by the grantees who meet the Vesting Conditions for the second release period were vested and circulated on January 14, 2021.

2. Equity-settled share-based payment

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Method of determining the fair value of equity	Determined based on the share price on the grant	
instruments on the grant date	date and grant price of restricted shares	
Basis for determination of number of exercisable	Estimated based on performance conditions of	
equity instruments	the release periods	
Reasons for significant differences between	N/A	
estimates in the current period and those in the prior		
period		
Accumulated amount of equity-settled share-based	34,211,501.90	
payment included in the capital reserve		
Total expense recognized for the current period	2,262,118.91	
arising from equity-settled share-based payments.		

Other descriptions

None

3. Cash-settled share-based payment

 \Box Applicable $\sqrt{N/A}$

4. Modifications to and termination of share-based payment

 \Box Applicable $\sqrt{N/A}$

5. Others

 \Box Applicable $\sqrt{N/A}$

XIV. Commitments and Contingencies

1. Significant commitments

 $\sqrt{\text{Applicable}} \square N/A$

Significant commitments to outsiders as of the balance sheet data, and their nature and amount

On May 13, 2021, through being reviewed and approved by the 2020 annual general meeting of shareholders of the Company, the Company intends to apply for publicly issuing not more than RMB 803,500,000 A-share convertible corporate bonds, and the proceeds from issuance of convertible

corporate bonds net of the issuance expenses will be used for the following projects:

Project	Total investments (RMB 0'000)	Proceeds to be invested
Huzhou production base expansion construction project (phase I)	43,752.54	33,850.00
Longwu R&D center construction project	21,774.45	19,450.00
Information system upgrade construction project	11,239.50	9,050.00
Replenishment of working capital	18,000.00	18,000.00
Total	94,766.49	80,350.00

2. Contingencies

(1). Significant contingencies as of the balance sheet date

□Applicable √N/A

(2). Please also make explanations thereof if the Company has no significant contingency to be disclosed:

□Applicable √N/A

3. Others

□Applicable √N/A

XV. Events After the Balance Sheet Date

1. Significant non-adjustment events

 \Box Applicable $\sqrt{N/A}$

2. Profit distribution

 \Box Applicable $\sqrt{N/A}$

3. Sales returns

 \Box Applicable $\sqrt{N/A}$

4. Descriptions of other events after the balance sheet date

 \Box Applicable $\sqrt{N/A}$

XVI. Other significant events

- 1. Corrections of previous accounting errors
- (1). Retrospective restatement

 \Box Applicable $\sqrt{N/A}$

(2). Prospective application

 \Box Applicable $\sqrt{N/A}$

2. Debt restructuring

 \Box Applicable $\sqrt{N/A}$

3. Replacement of assets

(1). Exchange of non-monetary assets

 \Box Applicable $\sqrt{N/A}$

(2). Replacement of other assets

 \Box Applicable $\sqrt{N/A}$

4. Annuity plan

 \Box Applicable $\sqrt{N/A}$

5. Discontinued operations

 \Box Applicable $\sqrt{N/A}$

6. Segment information

(1). Determination basis and accounting policies of reporting segments

√ Applicable □N/A

The Company does not have diversified operations or cross-regional operations, so there is no reporting segment. The Company's main business income and costs classified by brand are as follows:

From January to June 2021

Brand	Main business income Main business costs		Gross profit	
Proya	1,487,120,837.44	508,232,715.85	978,888,121.59	
Other brands	424,159,627.47	182,705,819.33	241,453,808.14	
Sub-total	1,911,280,464.91	690,938,535.18	1,220,341,929.73	

From January to June 2020

Brand	Main business income	Main business costs	Gross profit	
Proya	1,131,438,646.00	393,086,772.23	738,351,873.77	
Other brands	250,696,466.85	159,861,764.58	90,834,702.27	
Sub-total	1,382,135,112.85	552,948,536.81	829,186,576.04	

(2). Financial information of reporting segments

 \Box Applicable $\sqrt{N/A}$

(3). If the Company has no reporting segment or is unable to disclose total assets and liabilities of each reporting segments, please give the reason therefor

 \Box Applicable $\sqrt{N/A}$

(4). Other descriptions

 \Box Applicable $\sqrt{N/A}$

7. Other significant transactions and events affecting the investors' decisions

 \Box Applicable $\sqrt{N/A}$

8. Others

□Applicable √N/A

XVII. Notes to Key Items in the Financial Statements of the Parent Company

1. Accounts receivable

(1). Disclosure by aging

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Aging	Gross carrying amount at the end of the period
Within 1 year	
Including: Subdivision within 1 year	
Sub-total within 1 year	473,628,112.49
1-2 years	44,732,356.05
2-3 years	12,435,009.76
Over 3 years	346,836.70
3-4 years	
4-5 years	
Above 5 years	
Total	531,142,315.00

(2). Disclosure by categories based on methods of determination of provision for bad debts

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

		Closing balance			(Opening balanc	e			
Category	Gross carrying	g amount	Provision for	bad debts	Carrying	Gross carrying	g amount	Provision for	bad debts	Carrying
	Amount	Proportion (%)	Amount	Proportion (%)	amount	Amount	Proportion (%)	Amount	Proportion (%)	amount
Provision for										
bad debts										
made										
individually										
Including:										
Provision for										
bad debts										
made by										
portfolio:										
Including:										
Aging portfolio	531,142,315.00	100.00	43,665,454.02	8.22	487,476,860.98	617,474,114.36	100.00	52,436,703.21	8.49	565,037,411.15
Total	531,142,315.00	/	43,665,454.02	/	487,476,860.98	617,474,114.36	/	52,436,703.21	/	565,037,411.15

Provision for bad debts made individually:

 \Box Applicable $\sqrt{N/A}$

Provision for bad debts made by portfolio:

 $\sqrt{\text{Applicable }} \square N/A$

Items of portfolio provision: aging portfolio

Unit: Yuan Currency: RMB

Name	Closing balance				
Name	Accounts receivable	Provision for bad debts	Proportion (%)		
Within 1 year	473,628,112.49	23,681,405.62	5.00		
1-2 years	44,732,356.05	13,419,706.82	30.00		
2-3 years	12,435,009.76	6,217,504.88	50.00		
Over 3 years	346,836.70	346,836.70	100.00		
Total	531,142,315.00	43,665,454.02	8.22		

Standards of provision for bad debts made by portfolio and descriptions thereof:

 $\Box Applicable \quad \sqrt{N/A}$

If the provision for bad debts is made in accordance with the general model of expected credit losses, please refer to other receivables disclosure:

 \Box Applicable $\sqrt{N/A}$

(3). Provision for bad debts

 $\sqrt{\text{Applicable } \square N/A}$

Unit: Yuan Currency: RMB						
		C	Changes for the current period			
Cotogory	Opening		Recovery		Other	Closing
Category	balance	Provision	or	Removal/write-off		balance
			reversal		changes	
Provision	52,436,703.21	-8,771,177.49		71.70		43,665,454.02
for bad						
debts						
made by						
portfolio						
Total	52,436,703.21	-8,771,177.49		71.70		43,665,454.02

Significant recovery or reversal of bad debt provision for the current period:

 \Box Applicable $\sqrt{N/A}$

(4). Accounts receivable actually written off for the current period

 $\sqrt{\text{Applicable } \square N/A}$

	Unit: Yuan	Currency: RMB
Item	Write-off amount	
Accounts receivable actually written off		71.70

Descriptions of significant accounts receivable that are written off:

□Applicable √N/A

Descriptions of write-off of accounts receivable:

 \Box Applicable $\sqrt{N/A}$

(5). Top five closing balances of accounts receivable categorized by debtor

		Unit: Yu	an Currency: RMB
Unit	Gross carrying amount	Proportion to the balance of accounts receivable (%)	Provision for bad debts
Hangzhou Proya Trade Co., Ltd.	257,333,981.88	48.45	12,866,699.09
Huzhou Youzilai Trade Co., Ltd.	84,766,828.65	15.96	10,021,930.53
Zhejiang Meili Valley E-commerce Co., Ltd.	64,862,788.89	12.21	3,243,139.44
Hangzhou Proya Business Management Co., Ltd.	44,351,306.05	8.35	4,435,130.61
Ningbo TIMAGE Cosmetics Co., Ltd.	24,017,820.47	4.52	1,200,891.02
Sub-total	475,332,725.94	89.49	31,767,790.69

(6). Accounts receivable derecognized due to the transfer of financial assets

 \Box Applicable $\sqrt{N/A}$

(7). Assets and liabilities generated by the transfer of accounts receivable and continuing involvement therein

□Applicable √N/A

Other descriptions:

□Applicable √N/A

2. Other receivables

Line items

 $\sqrt{\text{Applicable } \square N/A}$

Unit: Yuan Currency: RMB

Item	Closing balance	Opening balance	
Interest receivable			
Dividends receivable			
Other receivables	233,121,481.53	236,585,409.48	
Total	233,121,481.53	236,585,409.48	

Other descriptions:

□Applicable √N/A

Interest receivable

(1). Classification of interest receivable

 \Box Applicable $\sqrt{N/A}$

(2). Significant overdue interest

□Applicable √N/A

(3). Provision for bad debts

□Applicable √N/A

Other descriptions:

□Applicable √N/A

Dividends receivable

(1). Dividends receivable

□Applicable √ N/A

(2). Significant dividends receivable aged more than 1 year

 \Box Applicable $\sqrt{N/A}$

(3). Provision for bad debts

□Applicable √N/A

Other descriptions:

□Applicable √N/A

Other receivables

(1). Disclosure by aging

 $\sqrt{\text{Applicable } \square N/A}$

Unit: Yuan Currency: RMB Gross carrying amount at the end of the Aging period Within 1 year Including: Subdivisions within 1 year Sub-total within 1 year 100,446,944.93 1-2 years 183,038,555.89 2-3 years 35,777,727.67 Over 3 years 123,559,056.72 3-4 years 4-5 years Above 5 years 442,822,285.21 Total

(2). Classification of other receivables by nature

 $\sqrt{\text{Applicable } \square N/A}$

Unit: Yuan Currency: RMB

Nature	Gross carrying amount at the	Gross carrying amount at the	
Nature	end of the period	beginning of the period	
Borrowings	423,287,910.34	402,005,709.08	
Security deposit	17,784,706.72	5,100,314.72	
Revolving funds	591,388.00	932,910.70	
Others	1,158,280.15	4,924.76	
Total	442,822,285.21	408,043,859.26	

(3). Provision for bad debts

 $\sqrt{\text{Applicable } \square N/A}$

	Stage I	Stage II	Stage III	
Provision for bad debts	Future 12-month ECL	Lifetime ECL (without credit impairment)	Lifetime ECL (with credit impairment)	Total
Balance as of January 1, 2021	8,005,556.84	2,792,224.42	160,660,668.52	171,458,449.78
In the current				
period, balance as at January 1, 2021				
transferred to Stage II	-7,875,997.27	7,875,997.27		
transferred to Stage III		-13,879.80	13,879.80	
transferred back to Stage II				
transferred back to Stage I				
Current provision	1,585,733.49	36,601,641.74	54,978.67	38,242,353.90
Current reversal				

Current removal				
Current write-off				
Other changes				
Balance as of June	1,715,293.06	47,255,983.63	160,729,526.99	209,700,803.68
30, 2021				

Descriptions of the significant changes in the gross carrying amount of other receivables for which the changes in loss allowance occur for the current period:

□Applicable √N/A

Provision for bad debts in the current period and the basis for assessing whether the credit risk of financial instruments has increased significantly:

□Applicable √N/A

(4). Provision for bad debts

 $\sqrt{\text{Applicable } \square N/A}$

debts made

Current changes Opening Recovery Closing Category Other balance Provision Removal/write-off balance or changes reversal 160,573,168.52 160,573,168.52 **Provisions** for bad

individually

Provisions 10,885,281.26 38,242,353.90 49,127,635.16 for bad debts by portfolio

Total 171,458,449.78 38,242,353.90 209,700,803.68

Significant recovery or reversal of provision for bad debts for the current period:

 \Box Applicable $\sqrt{N/A}$

(5). Other receivables actually written off for the current period

□Applicable √N/A

Descriptions of significant other receivables that are written off:

 $\Box Applicable \ \ \sqrt{N/A}$

(6). Top five closing balances of other receivables categorized by debtors

 $\sqrt{\text{Applicable } \square \text{N/A}}$

Unit: Yuan Currency: RMB

Entity	Nature	Closing balance	Aging	Proportion to total closing balance of other receivables (%)	Closing balance of provision for bad debts
Hapsode (Hangzhou) Cosmetics Co., Ltd.	Borrowings	249,730,591.44	[Note 1]	56.40	159,856,503.49

	•				
Hongkong	Borrowings	142,545,790.44	[Note 2]	32.19	41,432,595.43
Xinghuo					
Industry					
Limited					
Ningbo	Borrowings	16,304,983.36	[Note 3]	3.68	4,661,849.17
TIMAGE					
Cosmetics Co.,					
Ltd.					
People's	Security	13,493,392.00	Within 1	3.05	674,669.60
Government of	deposit		year		
Taixi Town,					
Wuxing					
District,					
Huzhou City					
Ningbo Keshi	Borrowings	5,170,833.38	Within 1	1.17	258,541.67
Trade Co., Ltd.			year		
Total	/	427,245,590.62	/	96.49	206,884,159.36

[Note 1] Within 1 year: RMB 66,096,979.69, 1-2 years: RMB 24,476,318.83, 2-3 years: RMB 35,731,461.67, and over 3 years: RMB 123,425,831.25.

[Note 2] Within 1 year: RMB 5,324,566.81, and 1-2 years: RMB 137,221,223.63. [Note 3] Within 1 year: RMB RMB 918,583.36 and 1-2 years: RMB 15,386,400.

(7). Receivables involving government grants

□Applicable √N/A

(8). Other receivables derecognized due to the transfer of financial assets

□Applicable √N/A

(9). Assets and liabilities generated by the transfer of other receivables and continuing involvement therein

□Applicable √N/A

Other descriptions: \Box Applicable $\sqrt{N/A}$

3. Long-term equity investments

 $\sqrt{\text{Applicable }} \square N/A$

	(Closing balance	e	Opening balance		
Item	Gross carrying	Provision for	Carrying	Gross carrying	Provision for	Carrying
	amount	impairment	amount	amount	impairment	amount
Investment	230,062,149.4	42,500,000.0	187,562,149.4	337,957,327.2	42,500,000.0	295,457,327.2
s in	1	0	1	4	0	4
subsidiarie						
S						
Investment	191,110,955.1		191,110,955.1	51,915,628.82		51,915,628.82
s in	8		8			
associates						
and joint						
ventures						
Total	421,173,104.5	42,500,000.0	378,673,104.5	389,872,956.0	42,500,000.0	347,372,956.0
Total	9	0	9	6	0	6

(1) Investments in subsidiaries

 $\sqrt{\text{Applicable}} \square N/A$

	1			1	1	T
Investee	Opening balance	Current increase	Current decrease	Closing balance	Current provision for impairme nt	Closing balance of provision for impairment
Hangzhou Proya Trade Co., Ltd.	30,875,097.6	65,593.30		30,940,690.9		
HANNA COSMETICS CO., LTD.	2,094,048.00			2,094,048.00		
Zhejiang Meili Valley E-commerce Co., Ltd.	16,383,777.5 1	476,445.98		16,860,223.4 9		
Leqing Laiya Trading Co., Ltd.	1,000,000.00			1,000,000.00		
Hapsode (Hangzhou) Cosmetics Co., Ltd.	42,500,000.0			42,500,000.0		42,500,000. 00
Mijing Siyu (Hangzhou) Cosmetics Co., Ltd.	18,000,000.0			18,000,000.0		
Huzhou Youzilai Trade Co., LTd.	5,568,795.63	21,727.80		5,590,523.43		
Huzhou Niuke Technology Co., Ltd.	3,500,000.00			3,500,000.00		
Hangzhou Proya Business Management Co., Ltd.	5,000,000.00			5,000,000.00		
Huzhou Y.N.M. Cosmetics Co., Ltd.	20,308,163.0			20,308,163.0		
Shanghai Zhongwen Electronic Commerce Co., Ltd.	5,400,000.00			5,400,000.00		
Y.N.M. Cosmetics Co., Ltd.	5,046,455.61			5,046,455.61		
Hongkong	24,736,491.0			24,736,491.0		

** 11	0				ı	
Keshi	0			0		
Trading						
Limited						
Hongkong	10,185,924.0			10,185,924.0		
Xinghuo	0			0		
Industry	o .			o o		
Limited						
	15,002,200,0			15.002.200.0		
Ningbo	15,902,200.0			15,902,200.0		
TIMAGE	0			0		
Cosmetics						
Co., Ltd.						
Ningbo Keshi	520,000.00			520,000.00		
Trading Co.,	,			ŕ		
Ltd.						
Zhejiang	10,000,000.0			10,000,000.0		
Biyouti	0			0		
Cosmetics						
Co., Ltd.						
Ningbo Proya	4,186,374.85	991,055.09		5,177,429.94		
Enterprise						
Consulting						
Management						
Co., Ltd.						
	1 000 000 00			1 000 000 00		
Hangzhou	1,000,000.00			1,000,000.00		
Yizhuo						
Culture						
Media Co.,						
Ltd.						
Hangzhou	2,000,000.00			2,000,000.00		
Oumisi Trade						
Co., Ltd.						
Guangzhou	1,000,000.00			1,000,000.00		
Qianxi	1,000,000.00			1,000,000.00		
Network						
Technology						
Co., Ltd.						
Zhejiang	550,000.00	550,000.00		1,100,000.00		
Qingya						
Culture and						
Art						
Communicati						
on Co., Ltd.	1 200 000 00			1 200 000 00		
Huzhou	1,200,000.00			1,200,000.00		
Poyun						
E-commerce						
Co., Ltd.						
Shanghai	110,500,000.		110,500,000.			
Healthlong	00		00			
Biochemical						
Technology						
Co., Ltd.	500.000.00			500.000.00		
Hangzhou	500,000.00			500,000.00		
Weiluoke						
Cosmetics						
Co., Ltd.						
BOYA (Hong						
\8	i	i		l .	1	1

Kong) Investment Management					
Co., Limited					
Xuzhou		500,000.00		500,000.00	
Proya					
Information					
Technology					
Co., Ltd.					
Proya					
(Hainan)					
Cosmetics					
Co., Ltd.					
Total	337,957,327.	2,604,822.	110,500,000.	230,062,149.	42,500,000.
Total	24	17	00	41	00

Unit: Yuan Currency: RMB

(2) Investments in associates and joint ventures

 $\checkmark Applicable \; \Box N/A$

Other descriptions:

C	Other descr	riptions:									
				Cı	arrent increa	se or decrea	ise				
Investor	Opening balance	Additional investment	Decrea -sed invest ment	Investme -nt gain or loss under equity method	Adjust- ment in other compre hensive income	Other equity changes	Declared cash dividend -s or profits	Provision for impairment	Others	Closing balanc-e	Closing balance of provision for impairment
I. Joint ventures											
Huzhou Panrui Industrial Investment Partnership (LP)	3,306,630 .57			-5,579.6 3						3,301,05 0.94	
Sub-total	3,306,630 .57			-5,579.6 3						3,301,05 0.94	
II. Associates											
Xiongke Culture Media (Hangzhou) Co., Ltd.	2,985,511			-53,464. 43						2,932,04 6.92	
Jiaxing Woyong Investment Partnership (LP)	45,623,48 6.90	28,206,800. 00		-24,953. 93						73,805,3 32.97	
Zhuhai Healthlong Biotechnolo -gy Co., Ltd.		110,500,00		-2,349,2 63.38						108,150, 736.62	
Beijing Xiushi Culture Developme- nt Co., Ltd.		3,000,000.0		-78,212. 27						2,921,78 7.73	
Sub-total	48,608,99 8.25	141,706,80 0.00		-2,505,8 94.01						187,809, 904.24	
Total	51,915,62 8.82	141,706,80 0.00		-2,511,4 73.64						191,110, 955.18	

 \Box Applicable $\sqrt{N/A}$

4. Revenue and cost of revenue

(1). Descriptions of revenue and cost of revenue

 $\sqrt{\text{Applicable }} \square N/A$

Unit: Yuan Currency: RMB

Itam	Amount for the	current period	Amount for the prior period		
Item	Revenue	Cost	Revenue	Cost	
Main operations	879,711,296.91	450,100,842.12	776,212,301.93	358,574,648.35	
Other operations	17,039,716.68	6,487,404.50	16,841,498.35	6,231,905.61	
Total	896,751,013.59	456,588,246.62	793,053,800.28	364,806,553.96	

(2). Descriptions of revenue generated from contacts

□Applicable √N/A

(3). Descriptions of performance obligations

□Applicable √ N/A

(4). Descriptions of allocation to remaining performance obligations

□Applicable √N/A

Other descriptions:

None

5. Investment income

 $\sqrt{\text{Applicable } \square N/A}$

Unit: Yuan Currency: RMB Amount for the current Item Amount for the prior period period Long-term equity investments accounted for using the cost method -2,511,473.64 -270,798.84 Income from long-term investment accounted for using the equity method Income from disposal of long-term equity investments Investment income from held-for-trading financial assets during the holding period Dividend income from other equity investment instruments during the holding period Interest income from debt investment during the holding period Interest income from other investments during the holding period Investment income from disposal of held-for-trading financial assets Investment income from disposal of other investments in equity instruments Investment income from disposal of debt investments

Investment income from disposal of other debt investments		
Income from wealth management		2,266,301.37
products		
Total	-2,511,473.64	1,995,502.53

Other descriptions:

None

6. Others

 $\Box Applicable \quad \sqrt{N/A}$

XVIII. Supplementary Information

1. Breakdown of non-recurring profit or loss for the current period

 \checkmark Applicable $\square N/A$

Item	Amount	Note
Gains or losses from disposal of non-current	-1,416.28	
assets	=,:10.20	
Unauthorized examination and approval, or		
lack of official approval documents, or tax		
revenue return and abatement		
Government grants recognized in profit or	9,370,319.81	
loss for the current period (excluding		
government grants that are closely related to		
the Company's business operations and		
gained at a fixed amount or quantity		
according to national uniform standards)		
Capital occupation fees charged to the		
non-financial enterprises and included in		
profit or loss for the current period		
Gains when the investment cost of acquiring		
a subsidiary, an associate and a joint venture		
is less than the fair value of the identifiable		
net assets of the investee		
Gains or losses from exchange of		
non-monetary assets		
Gains or losses from entrusting others with		
investment or asset management		
Asset impairment provision made resulting		
from force majeure such as natural disasters		
Gains or losses from debt restructuring		
Enterprise restructuring fees, such as staffing		
expenses and integration fees		
Gains or losses that exceeds the fair value in		
transaction with unfair price		
Current net gains or losses of subsidiaries		
established by business combination		
involving enterprises under common control		
from the beginning of the period to the		
combination date		
Gains or losses on contingencies that have no		
relation with the normal operation of the		
Company		

Gains or losses from change in fair value by held-for trading financial assets and liabilities, derivative financial assets,	-3,545.22	
held-for-trading financial liabilities and		
derivative financial liabilities, and		
investment income from disposal of		
held-for-trading financial assets, derivative financial assets, held-for-trading financial		
liabilities, derivative financial liabilities and		
other debt investments, excluding the		
effective hedging businesses related with		
normal operations of the Company		
Reversal of impairment provision of		
accounts receivable and contract assets that		
have undergone impairment test alone		
Gains or losses from outward entrusted		
loaning		
Gains or losses from changes in the fair		
values of investment properties that are		
subsequently measured using the fair value		
model Impact of a one-time adjustment on current		
profit and loss according to the requirements		
of tax and accounting laws and regulations		
Custody fees of entrusted operation		
Other non-operating income and expenses		
besides the above items	521,323.29	
Other items that conform to the definition of		
non-recurring profit or loss		
Effect of income tax	-2,222,932.24	
Effect of minority equity	-1,842,828.78	
Total	5,820,920.58	

Provide explanations for classifying non-recurring profit and loss items defined in the *Explanatory Announcement No. 1 for Public Company Information Disclosures – Non-recurring Profits and Losses*, and for classifying non-recurring profit and loss items listed in the *Explanatory Announcement No. 1 for Public Company Information Disclosures – Non-recurring Profits and Losses* as recurring profit and loss item.

□Applicable √N/A

2. Return on net assets and earnings per share

 $\checkmark Applicable \; \Box N/A$

	Weighted average	Earnings	per share
Profit for the reporting period	return on equity (%)	Basic EPS	Diluted EPS
Net loss attributable to the	9.10	1.13	1.12
Company's ordinary			
shareholders			
Net profit attributable to the	8.86	1.10	1.10
parent company's shareholders,			
excluding non-recurring profit			
or loss			

3. Differences arising from accounting standard of the PRC and the International Accounting Standards

 \Box Applicable $\sqrt{N/A}$

4. Others

 \Box Applicable $\sqrt{N/A}$

Board Chairman: HOU Juncheng

Date of Submission Approved by the Board: August 24, 2021

Revised information

 $\Box Applicable \ \sqrt{N/A}$